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Rheumatoid arthritis (RA) is a chronic systemic disease, characterized by 
inflammation of the joints that may lead to structural damage. Patients with RA 
typically present with pain, swelling and morning stiffness of the small joints of the 
hands and feet. Besides the joints, many other organs can be involved which might 
be notable by systemic symptoms such as fatigue and weight loss.1-3 Subsequently, 
RA results in significant morbidity with functional and work disability and systemic 
complications, resulting in high socio-economic costs.4-6 With a prevalence of 0.5-
1% in developed countries, RA is among the most common rheumatic diseases. It 
is three times more prevalent in women than in men and its incidence increases 
with age.6 
Although the pathogenesis of RA is not fully elucidated, it is known that there is 
a complex interplay between genetic susceptibility, environmental factors and an 
abnormal (auto) immune response with involvement of both the innate and the 
adaptive immune system. The results is thickening of the synovial layer of joints 
with infiltration of fibroblast-like and macrophage-like synoviocytes, macrophages, 
T cells and B cells. Synovitis is perpetuated by positive feedback loops eventually 
leading to cartilage degradation and bone erosions and eventually to systemic 
disorders.6,7
The two most important autoantibodies involved in RA are rheumatoid factor 
(RF) and anti-citrullinated protein antibodies (ACPA). RF is a polyclonal antibody 
directed against the Fc portion of immunoglobulin G and is the first autoantibody 
that was described in RA. RF is present in about 60% of early RA patients, nonetheless 
RF is also frequently observed in other rheumatic diseases and in patients with 
chronic infections.8-11 ACPA are directed against proteins or peptides containing 
citrulline, which is an uncharged amino acid generated by a post-translational 
modification of the positively charged amino acid arginine by peptidyl arginine 
deiminases.12 ACPA are present in 50-60% of early RA patients and in 60-90% of 
patients with long-standing disease and are observed in only 1% of the general 
population which makes them highly specific for RA.13-15 Both ACPA and RF can 
be present years before disease onset and together with the observed strong 
association between ACPA and RA, this suggests that ACPA have a pathogenic role 
in RA although the underlying mechanism remains unclear.16-18 Both ACPA and RF 
are associated with relevant outcomes such as radiographic progression and are 




in approximately one third of RA patients both these autoantibodies are lacking.21 
Therefore, research is focused on exploring other, novel autoantibodies to also 
identify these patients. 
Besides autoantibodies, genetic risk factors are important for the development of 
RA. More than 50% of the risk of RA is attributable to genetic risk factors, both 
in ACPA-positive and ACPA-negative RA.22 The HLA class II molecules account for 
about 11-37% of the total genetic effect, and are therefore considered the major 
genetic risk factor of development of RA, especially in ACPA-positive patients.23,24 
Several other genetic risk factors have been identified which are different between 
ACPA-positive and ACPA-negative RA.25,26 Finally, several environmental factors 
have been described which affect susceptibility for RA, such as smoking, diet and 
socioeconomic status.27 Of these factors, smoking appears to be the most important 
environmental risk factor, especially in ACPA-positive patients carrying HLA SE 
alleles.28,29
Classification of RA
The diagnosis of RA is made by the rheumatologist, based on clinical, laboratory 
and imaging observations. Diagnosing RA is basically pattern recognition. Since 
there is neither an exact or simple definition of RA, nor a diagnostic test, this 
presumably results in a heterogeneous group of RA patients. To compare findings 
of studies of RA patients, it is important to identify a relatively homogenous group 
of RA patients; therefore classification criteria have been developed. 
In current studies both the 1987 ACR criteria and the 2010 ACR/EULAR classification 
criteria for RA are used; a comparison of both criteria is shown in Table 1.1.20,30 The 
1987 ACR criteria were derived to increase specificity compared to the previously 
used 1958 criteria, thus to improve differentiation of patients with established RA 
from patients with other rheumatic diseases.30 Although the 1987 criteria indeed 
have shown to be specific in classifying established RA, identification of patients 
with early RA is lacking.31 Nowadays, it is clear that early identification and 
treatment of RA patients is important to improve clinical outcomes and prevent 
joint damage progression.32-34 There might even be an early phase in the disease 
in which the disease is more susceptible to treatment, presumably because of 
not fully matured underlying disease processes.35 With the knowledge that early 




To facilitate the identification of early RA patients which was needed for these 
studies, the 2010 ACR/EULAR criteria have been developed.20 The major difference 
between the 2010 criteria and the previous 1987 criteria, is that the 2010 criteria 
focused on features in early arthritis that associated with persistent and/or erosive 
disease, and therefore acute phase reactants and ACPA were added. Rheumatoid 
nodules and the presence of radiographic erosions, which were included in the 
1987 criteria, were not included anymore in the 2010 criteria because these are 
both characteristics of established disease. However, to prevent that patients with 
inactive disease are misclassified as having no RA, the presence of erosions typical 
of RA can be used as prima facie evidence of RA, precluding the need of fulfilling 
the criteria.36 
Table 1.1 Comparison of classification criteria for RA
1987 ACR criteria 2010 ACR/EULAR criteria
Target population: patients with at least 1 joint with 
clinical synovitis, not better explained by another disease
points
1. Morning stiffness ≥1 hour Joint involvement*
2. Arthritis of ≥3 joint areas# 1 large joint 0
3. Arthritis of hand joints 2-10 large joints 1
4. Symmetric arthritis 1-3 small joints 2
5. Rheumatoid nodules 4-10 small joints 3
6. Serum RF >10 joints (at least 1 small joint) 5
7. Radiographic changes Serology
Negative RF and negative ACPA 0
Low-positive RF or low-positive ACPA 2
High-positive RF or high-positive ACPA 3
Acute-phase reactants
Normal CRP and normal ESR 0




≥4 out of 7 criteria must be present 
for classification of RA. Criteria 
1-4 must have been present for ≥6 
weeks.
#Left or right PIP, MCP, wrist, elbow, 
knee, ankle and MTP
≥6 out of 10 points needed for classification of RA. 
*refers to any swollen or tender joint on examination
Large joints: shoulders, elbows, hips, knees, ankles.




Several studies have indeed shown that the 2010 criteria are fulfilled earlier in 
time than the 1987 criteria at the expense of a slight decrease in specificity.37 When 
using these classification criteria, it is important to realize that the phenotype 
of RA patients at disease presentation and during the disease course is different 
between both criteria sets.38 
Patients with arthritis who do not fulfil RA classification criteria and who do not 
have another diagnosis explaining their symptoms are referred to as patients 
with undifferentiated arthritis (UA), and therefore the diagnosis ‘UA’ is made per 
exclusionem. 
Treatment of RA
In the last decades, the treatment of RA has improved tremendously. Whereas 
treatment consisted initially of non-steroidal anti-inflammatory drugs and delayed 
treatment with disease-modifying antirheumatic drugs (DMARDs), nowadays the 
treatment armamentarium has increased and in addition patients are treated 
earlier, directly after diagnosis with RA. Another improvement in the treatment of 
RA was the incorporation of disease activity scores (DAS) to monitor the disease, 
which has contributed to improved patient outcomes.39 
According to current guidelines, treatment should be aimed at reaching 
sustained remission or low disease activity.40 Methotrexate in combination with 
glucocorticoids as bridging therapy is recommended as initial treatment strategy. 
When this treatment failed, another conventional DMARD should be considered. 
Use of a biological DMARD is recommended when patients failed on two or more 
conventional DMARDs. The ultimate treatment goal is achievement of sustained 
remission which is increasingly observed over the past years.41 Some of the 
patients in sustained remission can even successfully taper and stop all DMARD 
therapy; these patients are considered to be in a sustained DMARD-free status. 
This outcome is also relevant from a patient perspective, since this status is 
characterized by normalization of functional status and lower levels of fatigue, 
pain and morning stiffness.42 It is currently considered the best possible outcome 
of RA. Only a few factors are known to be associated with a sustained DMARD-
free status, which are short symptom duration at disease presentation and the 
absence of autoantibodies.9,43 The biological processes underlying extinguishment 




Stages of RA development 
Since it has become clear that early treatment of RA is needed to improve 
patient outcomes, research has focused on the earliest stages of disease, even 
before arthritis has developed. It is ascertained that RA has a preclinical disease 
period since autoantibodies, such as ACPA and RF, can be present years before 
the onset of disease and there is data indicating that the ACPA immune response 
matures during this preclinical phase.17,18,44-48 Furthermore, markers of systemic 
inflammation can be increased in the preclinical disease phase.49,50 To facilitate 
comparison between studies in these early disease phases, a EULAR study group 
described different phases before the development of RA which are genetic risk 
factors, environmental risk factors, systemic autoimmunity associated with RA, 
symptoms without clinical arthritis, unclassified arthritis and RA (Figure 1.1).51 
These phases can be used in a combinatorial manner, thus patients can be in two 
phases at the same time. Furthermore, the different phases do not occur in all 
patients who will develop RA and also do not occur necessarily in the same order. 
Importantly, patients with pre-RA can only be identified retrospectively, once it is 
known that patients have progressed to RA as the majority of patients with certain 
risk factors will never develop RA. 
Figure 1.1 Different phases of RA development
The phase in which clinical synovitis can be identified is that of UA. Of the patients 
with UA, about half will achieve spontaneous remission, whereas RA develops 
in one-third.52 This disease state is of special interest because when risk factors 
for progression to RA are known, patients with RA can be identified even earlier. 
This has been studied before and a prediction model with high discriminative 
ability has been developed and validated which includes several clinical features, 
autoantibodies and C-reactive protein.53,54 However, this prediction model was 
developed in patients with UA according to the 1987 criteria, while characteristics 




addition, when using the 2010 criteria, accurate predictors of progression for 
ACPA-negative UA patients are lacking. 
Besides early identification of UA patients, the aim is currently to identify patients 
with imminent RA even earlier, in the phase of Clinically Suspect Arthralgia 
(CSA). Patients with CSA have recent-onset arthralgia that is considered at risk of 
RA based on the clinical expertise of the rheumatologist.56 Identification of CSA 
patients who will develop RA is challenging as the majority of patients will never 
develop RA. Several factors have been associated with development of arthritis 
in patients with CSA, such as the presence of autoantibodies and subclinical 
joint inflammation detected by magnetic resonance imaging (MRI), but this has 
not resulted yet in a validated prediction model which can be used in clinical 
practice.57,58 Perhaps other biomarkers than autoantibodies and imaging markers 
are needed for accurate risk stratification. 
In addition to predicting which patients with CSA or UA will progress to RA, 
it is important to prevent this progression since the majority of RA patients 
have persistent disease and require life-long treatment. Whether therapeutic 
intervention in the phase of CSA or UA is helpful in preventing RA development is 
still incompletely clarified and is subject of current research.59 
Heterogeneity of RA
Most likely, RA can be considered as a syndrome consisting of different disease 
entities which are all characterized by chronic synovial inflammation, but differ 
in underlying pathophysiology and disease outcome. Currently, the most common 
used subdivision is that into ACPA-positive and ACPA-negative RA. These two 
subsets have different disease courses and the etiology is different regarding 
both genetic and environmental risk factors. But even ACPA-positive and ACPA-
negative RA might be differentiated further into subgroups. The pathogenesis and 
risk factors of ACPA-negative RA are much less understood than of ACPA-positive 
RA, but presumably ACPA-negative RA is more heterogeneous than ACPA-positive 
RA. The assumption that ACPA-negative RA consists of subgroups is supported 
by the observation that part of the ACPA-negative RA patients have a destructive 
disease, while others have not.60 Previously, it was studied whether ACPA-negative 
RA patients could be subdivided into clinically distinguishable sub phenotypes 




sub phenotypes are observed when other factors than clinical ones are assessed. 
Deciphering the syndrome of RA into subgroups is not only important to get more 
pathogenic insight into the disease but it might also eventually improve patient 
outcomes by personalizing treatment. 
Aim and outline of this thesis
In general this thesis has three main aims:
1. To improve identification of early RA patients
2. To investigate clinical and imaging features in relation to the autoantibody
response
3. To improve the understanding of mechanisms underlying a sustained DMARD-
free status
This thesis contains three parts.
In Part I, the association between several biomarkers and the development of RA 
was studied. Early treatment initiation of RA patients is important because it is 
associated with improved outcomes. Therefore, it is important to perform research 
in the preclinical phase of RA. In Chapter 2, it is reviewed what is currently known 
about the phase of pre-clinical RA. The relevance of serological and imaging markers 
for predicting progression to arthritis and their potential value in prognostication 
is discussed. Both autoantibody-positive and autoantibody-negative RA patients 
should be identified early in the disease process, because early treatment is 
beneficiary in both disease subsets.34,35 In Chapter 3, it was studied whether the 2010 
ACR/EULAR criteria performed equally well in early classification of autoantibody-
positive and autoantibody-negative RA. Although the 2010 criteria were 
developed for early classification of RA patients, in daily practice it may 
sometimes be used in the diagnostic process. In the 2010 criteria the presence 
of ACPA and RF are included, but one third of RA patients are negative for both of 
these autoantibodies, and therefore require more than 10 involved joints to fulfil 
classification criteria. The past years several novel autoantibodies have been 
identified, such as anti-carbamylated protein antibodies and anti-acetylated 
peptide antibodies.62,63 The additional value of these autoantibodies for the early 
identification of RA remains unclear. In Chapter 4, it is discussed whether 
information on novel autoantibodies might contribute to the earlier identification 
of RA. As an example, the additional value of anti-CarP antibodies was studied. 




value of imaging biomarkers for improving early identification of RA patients is 
subject of several studies. Traditionally, radiographs are frequently used in the 
diagnostic process for detecting structural damage, including erosions and joint 
space narrowing. Recently it was recommended to use MRI for this purpose 
because MRI is more sensitive in detecting erosions than radiographs.64 In Chapter 
5 we studied several characteristics of MRI-detected erosions in RA patients. The 
specificity of MRI-detected erosions for RA was determined by comparing RA 
patients with patients with other types of arthritis and with healthy controls. A 
subsequent and clinically relevant question is whether MRI-detected erosions in 
patients presenting with UA are valuable in predicting the progression to RA; this 
was studied in Chapter 6. 
In Part II, the association between clinical and imaging features and the 
autoantibody response was investigated. An advantage of MRI over conventional 
radiographs is that MRI can visualize inflammatory soft tissue changes, such as 
synovitis and tenosynovitis. In addition, bone marrow edema (BME) can be depicted 
which are lesions due to replacement of bone marrow fat by an inflammatory 
cell infiltrate, reflecting osteitis. The presence of BME is associated with erosive 
progression.65 Since autoantibodies are also a strong predictor of erosive 
progression of which the underlying mechanism is unclear, we investigated the 
association between autoantibodies and MRI-detected BME in Chapter 7. Next, 
the association between clinical features and the ACPA response was studied. 
Several studies have shown that RA patients with a disease onset at older age have 
different disease characteristics than patients presenting at younger age, possibly 
indicating the presence of different disease subsets. In Chapter 8, the association 
between the presence of three different autoantibodies (ACPA, RF and anti-CarP 
antibodies) and several clinical parameters and age of onset of RA was studied in 
five different early arthritis cohorts with the ultimate aim to identify subgroups 
of RA patients. Besides mere presence of ACPA, also several characteristics of the 
ACPA immune response were studied in relation to age. 
In Part III, the focus was on the long-term outcome of RA patients. To this 
end, the achievement of a sustained DMARD-free status was studied. Only a 
minority of patients is able to achieve this outcome and biological processes 
underlying extinguishment of disease are unclear. Previously, it was suggested 
that autoantibodies act as a driving force for persistent inflammation in RA 
and therefore, that disappearance of autoantibodies is associated with the 




the association between disappearance of ACPA and RF and sustained remission 
has not been extensively studied before and was studied in Chapter 9. To this 
end, anti-CCP2 IgG and IgM and RF IgM levels were measured at diagnosis of 
RA and around the time of achievement of sustained DMARD-free remission. If 
autoantibodies are underlying achievement of remission, these might disappear 
when patients are clinically cured. The fact that only a minority of patients is able 
to achieve a sustained DMARD-free status, supports the presumption that RA is 
a heterogenous disease. Besides clinical characteristics and autoantibodies, other 
serological biomarkers might help in differentiating RA in subgroups. In Chapter 
10, twelve proteins were measured at disease onset, and it was assessed whether 
the presence of these proteins contributes to the identification of subgroups of RA 
patients, for which sustained DMARD-free remission is an achievable outcome. 
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Abstract
Early initiation of treatment in patients with inflammatory arthritis at risk of 
persistence and/or erosive progression is important because it is associated 
with a reduced rate of progression of joint damage and functional disability. It 
has been proposed that a window of opportunity exists, during which disease 
processes are less matured and disease modification can be more effective. The 
phase of arthralgia preceding clinical arthritis is likely to be an important part of 
this window of opportunity, during which treatment might prevent progression 
to clinical arthritis. Several proof-of-concept trials in individuals with arthralgia 
are now evaluating this hypothesis. Central to such trials is the ability to identify 
groups at high risk of rheumatoid arthritis (RA) in whom preventive treatment 
can be tested. This review describes the relevance of adequate prediction making, 
as well as the accuracy of different types of predictors (including imaging and 
serological markers) with their value in predicting the progression of arthralgia to 
arthritis. Despite promising results, studies have been performed in heterogeneous 
patient populations and most findings have not been validated in independent 
studies. Future observational or preventive studies should be conducted with 
homogeneous patient groups (e.g., patients fulfilling the European League Against 
Rheumatism criteria for arthralgia at risk of RA) in order to increase interstudy 
comparability and to allow result validation.
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The relevance of adequate prediction making
Research into the earliest phases of rheumatoid arthritis (RA) is important because 
early treatment is associated with better outcomes. To facilitate this research the 
European League Against Rheumatism (EULAR) study group of risk factors for 
RA has defined several stages of RA development: genetic risk factors for RA, 
environmental risk factors for RA, systemic autoimmunity associated with RA, 
symptoms without clinical arthritis and unclassified arthritis (UA).1 These stages 
are based on the presumed order in which different risk factors exert their 
effects. Individuals in the first three stages are generally asymptomatic. Over 
time symptoms may develop - initially often in the absence of clinically evident 
arthritis. In patients with established RA, the different phases may be identified 
retrospectively. However, it is clinically important to be able to predict with 
accuracy and confidence the future development of RA during its prearthritis 
stages. During recent years the phase of arthralgia has gained increasing interest 
as the risk of progression to RA is (in most cases) likely to be higher in symptomatic 
than in asymptomatic ‘at risk’ individuals. In addition, this is the way individuals 
typically present to medical care.
The phase of arthralgia is likely to be an important part of the so-called window 
of opportunity. Studies in patients with classified RA have revealed that an earlier 
start of treatment is associated with better outcomes.2,3 Because at presentation 
with clinical arthritis most patients will have a chronic disease, it is hypothesised 
that the period preceding clinical arthritis might be important. Within this 
prearthritis phase, disease processes might be less matured, making patients more 
susceptible to disease-modifying antirheumatic drugs (DMARDs). A review of 
murine studies suggested that DMARD initiation (e.g., methotrexate and abatacept) 
prior to clinical arthritis was effective.4 Several ongoing proof-of-concept trials in 
individuals with arthralgia are evaluating the hypothesis that DMARD initiation 
can prevent progression to clinically evident arthritis. Results of two randomised 
controlled trials have been published; the first included 83 patients with anti-
citrullinated protein antibodies (ACPA)-positive and/or rheumatoid factor (RF)-
positive arthralgia who were treated with dexamethasone or placebo, and the 
second included 82 patients with ACPA-positive and RF-positive arthralgia with 
C-reactive protein (CRP) levels ≥3 mg/L and/or subclinical synovitis on ultrasound
(US) or magnetic resonance imaging (MRI) of the hands, who were treated with
a single infusion of rituximab or placebo.5,6 Although a decrease in ACPA levels
and a delay in arthritis onset were reported, neither intervention prevented the
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development of RA. This failure to prevent RA development may indicate that (1) 
the hypothesis is false (i.e., that the disease is not more modifiable in its arthralgia 
phase compared with its arthritis phase), or (2) the wrong drugs were tested, or (3) 
the studies included too few patients with a high risk of progression to RA, making 
it less easy to observe a preventive effect.
The importance of including patients with a high risk of progression to RA was 
illustrated in a recent post-hoc analysis of data from the Probable Rheumatoid 
Arthritis: Methotrexate versus Placebo Treatment (PROMPT) trial, in which patients 
with UA were treated with methotrexate with the aim of preventing progression 
to RA.7 The risk of progression to RA was ~30%, and without further stratification, 
methotrexate did not modify this risk. However when only patients with a high 
(>80%) 1-year predicted risk of progression to RA were evaluated, methotrexate 
was highly effective in preventing RA development. In addition, methotrexate 
was also associated with DMARD-free remission in this high-risk group (36% vs. 
0% in the placebo group). Although these post-hoc analyses were based on small 
sample sizes, these data demonstrate the relevance of including patients with a 
sufficiently high risk in preventive trials. The results of ongoing proof-of-concept 
trials in arthralgia are awaited over the next decade.
Not all of the ongoing preventive trials have fulfilment of the 2010 classification 
criteria for RA as primary outcome. This is supported by the fact that the presence 
of persistent clinical arthritis or a clinical diagnosis of RA is an outcome that fits 
with daily clinical practice.
Before implementing potential positive findings of preventive trials in daily 
rheumatological practice, we need to know which patients with arthralgia would 
otherwise develop RA and should be offered treatment, and conversely which 
patients should be reassured that disease progression is unlikely (Figure 2.1).
Figure 2.1 Adequate risk prediction is crucial for the design of informative preventive trials and for 
implementation of positive trial results
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Types of predictors
Optimally performing biomarkers are often causally related to the underlying 
biological process. Examples include the combination of increased free thyroxine 
(FT4) and decreased serum thyrotropin (TSH) levels, which are pathognomonic 
for hyperthyroidism, and the urinary human chorionic gonadotropin (HCG)-
based pregnancy test, which is seldom negative in pregnant women and high 
HCG levels are rarely present in settings other than pregnancy. Predictors can 
also be bystanders, markers that are side products of the biological process but 
characteristic of the disease. Other predictors are phenotypic in nature (Figure 
2.2). RA has a complex aetiopathology and its development is not easily reflected 
by a single marker. The presence of ACPA within RA is strongly predictive of 
erosive progression and may be causally related to the development of bone 
erosions, but its role in the development of RA is unclear and its presence is not 1:1 
related to disease development. Furthermore, it has become clear that in addition 
to RF and ACPA, several other autoantibodies are present in RA.8-10 These different 
sets of autoantibodies do not seem to relate to specific (sub)phenotypes of RA and 
may thus be considered as bystanders, although very useful in the diagnostic 
process.11 In the absence of pathognomonic markers, multiple biomarkers should 
be combined to predict which patients with arthralgia will progress to RA.
Figure 2.2 Predictors of rheumatoid arthritis development belong to different categories
A predictor of disease might directly reflect the underlying biological process, it can be a biological 
bystander of disease, or it might have no relation at all with the underlying biology and is a phenotypic 
marker.
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Differentiating arthralgia suspicious for progression 
to RA from other arthralgias
Before reviewing the accuracy of different types of predictors, appreciation of 
the population studied is important. Arthralgia is a non-specific symptom and the 
biological nature of joint pain is diverse. Consequently, the risk to progress to RA is 
different for patients with arthralgia in different settings.
Musculoskeletal (MSK) symptoms are very prevalent in primary care.12 Primary 
care data from the Netherlands suggest an annual incidence of non-traumatic MSK 
symptoms of ~300/1000.13-15 In other words, almost one-third of the population visits 
the general practitioner (GP) at least once a year with an MSK symptom. The vast 
majority of these patients have explanations for their joint symptoms other than 
the beginning of a systemic inflammatory arthritis, and inflammatory arthritis is 
considered by GPs in only a minority of patients (Figure 2.3). A separate Dutch GP 
study recorded an incidence of suspected arthritis of ~3/1000/year; most patients 
had a monoarthritis, and 60% had self-limiting symptoms.16 A small proportion of 
patients had suspected oligoarthritis or polyarthritis, and symptom persistence 
was more common in this group. These data support the notion that GPs are able 
to differentiate inflammatory from non-inflammatory cases of MSK symptoms and 
that the incidence of suspected inflammatory arthritis in primary care is low.
A similar observation has been made in secondary care. Most patients with 
arthralgia referred to rheumatologists have a diagnosis other than (imminent) RA. 
In addition, of patients presenting with arthralgia of uncertain cause, the large 
majority are not considered to be at risk of RA by their rheumatologists. A recent 
study revealed that only 7% of these patients with arthralgia were identified as 
clinically suspicious for progression to RA (clinically suspect arthralgia, CSA).17 
Importantly, for patients with CSA, the odds for progression to RA were 55 times 
larger than the odds for patients with unexplained arthralgia. The rheumatologists’ 
clinical expertise had a high accuracy (93%), sensitivity (80%) and specificity 
(93%) for future RA. Although these data support the use of the rheumatologist’s 
clinical experience in identifying patients with arthralgia who are at risk of RA, 
a drawback is that this approach is subjective. This is a particular problem for 
research studies, where homogeneous groups of patients should be included. A 
EULAR task force has recently explicated this clinical expertise in clinical items 
that are measurable.18 The resulting EULAR definition of arthralgia suspicious for 
progression to RA consists of seven clinical items and can be used in patients with 
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arthralgia in whom imminent RA is considered the most likely explanation for 
the symptoms (Figure 2.4). The definition was validated in the rheumatological 
practices of 18 European rheumatologists (area under the curve: 0.92) with clinical 
expertise as the reference. The first longitudinal study of patients with CSA showed 
that the definition had a high sensitivity and served to further harmonise patients, 
as patients with arthralgia who were identified as CSA by their rheumatologist but 
had <3 clinical items indeed had a lower risk of progression to RA.19
Figure 2.3 Clinical expertise of GPs and rheumatologists in differentiating patients with arthralgia
This figure is constructed based on the following references: The clinical expertise of GPs and 
rheumatologists is effective in differentiating patients with arthralgia; of all patients with MSK symptoms 
visiting their GPs (~300/1000/year),13–15 only a small subset is suspected for arthritis (~3/1000/year).16 Of 
all patients with any MSK symptoms visiting secondary care (~8/1000/year),53 only 7% were identified 
as CSA.17 The incidence of any MSK symptom in secondary care is higher than the incidence of patients 
with suspected arthritis in primary care, as GPs also refer patients with MSK symptoms in whom they 
did not suspect arthritis to be present. 74% of patients with CSA had a positive EULAR definition.19 CSA, 
clinically suspect arthralgia; EULAR, European League Against Rheumatism; GP, general practitioner; 
MSK, musculoskeletal symptoms; RA, rheumatoid arthritis.
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Figure 2.4 EULAR-defined characteristics describing arthralgia at risk for RA
The reported AUC, sensitivity and specificity were calculated within newly presenting patients with CSA 
in outpatient clinics of European expert rheumatologists (who were part of the task force who defined 
arthralgia at risk for RA) with clinical expertise as reference.18 A sensitive definition requires the presence 
of at least three items and a specific definition requires the presence of at least four items. AUC, area under 
the curve; EULAR, European League Against Rheumatism; MCP, metacarpophalangeal; RA, rheumatoid 
arthritis; sens, sensitivity; spec, specificity; UA, undifferentiated arthritis.
Altogether, patients with arthralgia in secondary care who are considered as CSA 
and fulfil the EULAR definition of arthralgia represent a very small proportion 
of all individuals suffering from joint pain (Figure 2.3). An optimised selection of 
patients with arthralgia will result in an increased risk of RA in the population, 
and - as a result of Bayes’ theorem - this will also result in higher post-test chances 
when performing additional tests, such as laboratory or imaging tests, in this 
subset of patients with arthralgia.
Search strategy 
The accuracy of different types of laboratory or imaging markers for predicting 
RA development is reviewed below. With the assistance of a medical librarian, 
we searched in the medical literature databases PubMed, Embase (Ovid version), 
Web of Science and Cochrane Library up to June 2017. Central terms in our 
search strategy were arthralgia, arthritis, autoantibodies, serological markers and 
imaging. In total 145 references on autoantibodies, 117 on serological markers and 
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310 on imaging markers were extracted. Reference lists of the identified articles 
were hand-searched for additional articles. From the total list of references, we 
selected the studies on patients with arthralgia with a longitudinal cohort design.
The predictive accuracy of autoantibody testing in 
arthralgia 
Nested case-control studies have shown that autoantibodies can be present years 
before the disease becomes manifest.20,21 Such studies use blood samples collected 
historically from patients known at the time of the study to have RA. Since, for 
patients presenting with arthralgia, it is relevant to know absolute risks for 
development of arthritis, this review focused on longitudinal studies. Most cohort 
studies that investigated the presence of autoantibodies have studied seropositive 
(ACPA and/or RF) patients in clinically ill-defined groups; one cohort study 
evaluated patients with CSA (Table 2.1). In agreement with previous nested case-
control studies, several longitudinal cohort studies have shown that the presence 
of ACPA associated with the development of clinical arthritis.22–26 The value of the 
level of ACPA (within ACPA-positive patients) in predicting arthritis development 
is unclear. While two studies, reporting on the same cohort, found an association 
between ACPA level and arthritis development,22,23 two other studies did not.26,27 
Although these three cohorts selected ACPA-positive patients with arthralgia using 
different inclusion criteria (seropositive arthralgia, CSA or ACPA-positive persons 
with non-specific MSK symptoms) in different settings (primary and/or secondary 
care), the contrasting results are not yet explained. In addition to ACPA level, other 
ACPA characteristics have also been studied. The number of epitopes recognised 
by ACPA was associated with arthritis development in several studies in ACPA-
positive patients with arthralgia.28–30 In addition, a decrease in galactosylation and 
an increase in core fucosylation of serum ACPA IgG1, indicating a change towards 
a more inflammatory phenotype of these autoantibodies, have been observed 
prior to the onset of RA.31
The value of RF in the preclinical phase of RA has also been studied.22-24,26,32 Two 
studies, on the same cohort, performed stratified analyses and observed that 
within ACPA-positive patients, the additive presence of RF associated with arthritis 
development.22,23 These studies did not contain ACPA-negative patients; hence, 
no information could be provided on the single presence of RF. Two studies, on 
the same cohort, did contain an RF-negative group and showed in univariable 
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analyses that the presence of RF conferred a higher risk of arthritis; however, 
after adjusting for the concomitant presence of ACPA, this association was lost.24,26 
Therefore it remains to be determined if the single presence of RF in arthralgia is a 
true predictor, although one study suggested that high levels of RF are a predictor 
in contrast to low levels of RF.26
Finally the presence of anti-carbamylated protein (anti-CarP) antibodies in the 
preclinical phase of RA was studied. One study in autoantibody-positive individuals 
observed an association between anti-CarP antibodies and the development of 
arthritis,33 whereas another study in patients with CSA did not observe an additive 
value of anti-CarP antibodies when ACPA and RF status is known.26
In conclusion, the presence of ACPA is associated with arthritis development 
while this is less clear for RF and anti-CarP antibodies. A disadvantage of most 
current studies is that patients are selected based on autoantibodies; thus, there 
is no autoantibody-negative reference group. In addition, as inclusion of patients 
in these cohorts was driven largely by ACPA positivity, these patients would not 
necessarily have been defined as CSA and would not necessarily have fulfilled the 
EULAR definition of arthralgia. Furthermore as noted above, some of the available 
data are based on analyses of the same patient cohorts (studies in Table 2.1 reported 
on six cohorts). Finally, in clinical practice where patients present with arthralgia, 
it is important to estimate absolute risks for progression to arthritis, but many 
studies did not provide these risks. Studies that did determine positive predictive 
values (PPVs) observed that the PPV of ACPA (independent of RF) ranged between 
16% and 50%.22,26 This broad range can be explained by differences in patient 
settings, since PPVs are dependent on the prior risks of arthritis development, 
which varied in the different settings that were studied.
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The predictive accuracy of non-antibody serological 
markers in arthralgia
Various acute phase reactants, cytokines, chemokines and other systemic 
markers have been studied in the preclinical phase of RA (Table 2.2). Results of 
studies evaluating CRP and erythrocyte sedimentation rate (ESR) are conflicting. 
Some studies have identified an association between CRP or ESR and arthritis 
development,24,31 while others have not.22,27,30,34-36 The only study showing an 
association between CRP level at study entry and development of arthritis included 
patients with CSA and did not select on the presence of autoantibodies.24 Studies 
that showed no predictive value of CRP were mostly conducted in autoantibody-
positive arthralgia.22,27,30,34-36 This could imply that CRP has a predictive value in 
autoantibody-negative patients in particular; further studies are needed to clarify 
this.
Other serological markers have been assessed. In one study, differences were 
observed in the lipid profile of patients with and without progression to arthritis. 
After correction for ACPA, a lower apolipoprotein A1 level was associated with 
arthritis development.37 Another study evaluated 14-3-3η and showed that the PPV 
of 14-3-3η for arthritis development was 86%. However, when corrected for ACPA 
and RF, 14-3-3η did not predict onset of arthritis.38 Other serological biomarkers 
showed trends towards higher levels in patients with progression to arthritis.34,36 
None of these markers was evaluated in other studies.
In conclusion, most results on serological markers of inflammation have not been 
validated in independent studies. Only CRP has been studied in several cohorts of 
patients with seropositive arthralgia and was shown to be of limited value.
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ACPA, anti-citrullinated protein antibodies; apo, apolipoprotein; AUC, area under curve; BCR, B cell 
receptor; CD, cluster of differentiation; CI, confidence interval; EPSTI, epithelial stromal interaction; 
ESR, erythrocyte sedimentation rate; GM-CSF, granulocyte macrophage colony-stimulating factor; HDLc, 
high-density lipoprotein cholesterol; HR, hazard ratio; (hs)CRP, (high sensitivity) C-reactive protein; IFN, 
interferon; IFI6, interferon alpha-inducible protein 6; IFI44L, interferon-induced protein 44 like; IFIT1, 
interferon induced protein with tetratricopeptide repeats 1; IL, interleukin; IQR, interquartile range; LDLc, 
low-density lipoprotein cholesterol; MCP-1, monocyte chemoattractant protein-1; MIG, monokine induced 
by gamma interferon; MIP, macrophage inflammatory protein; MRI, magnetic resonance imaging; MXA, 
myxovirus resistance protein A; NK cells, natural killer cells; NP, not provided; OAS3, 2’−5’-oligoadenylate 
synthetase 3; OR, odds ratio; PB, peripheral blood; PBMC, peripheral blood mononuclear cell; PCT, 
procalcitonin; PPV, positive predictive value; RA, rheumatoid arthritis; RANTES, regulated on activation, 
normal T cell expressed and secreted; RF, rheumatoid factor; RR, relative risk; RSAD2, radical s-adenosyl 
methionine domain containing 2; SPLA2, secretory phospholipase A2; TNFα, tumor necrosis factor α; Treg, 
regulatory T cell; US, ultrasound.
The predictive accuracy of imaging markers 
detecting subclinical inflammation in arthralgia
Different imaging modalities (US, MRI, positron emission tomography and 
scintigraphy) have been used to study the presence of local subclinical 
inflammation24,27,29,32,35,39-46; most studies focused on US (Table 2.3) or MRI (Table 
2.4).
Studies assessing the value of US have provided inconsistent results; some 
studies did not observe significant associations between US abnormalities and 
arthritis development,27,43,44 while others did.35,45,46 The studies that did not observe 
an association either included patients with seropositive arthralgia, ACPA-
positive persons with non-specific MSK symptoms or patients with new-onset 
inflammatory arthralgia; studies that did observe an association included patients 
with arthralgia based on clinical characteristics, and differences in results might 
be partly explained by differences in patient selection. Furthermore, US protocols, 
joint regions assessed and US features reported on differed across the studies. It 
is also important to note that none of the studies have used a healthy reference 
population to define thresholds at which US findings should be classified as 
abnormal. Since a previous study has shown that US lesions (greyscale synovial 
effusion or synovitis with or without power Doppler signal) are also present in the 
majority (88%) of healthy volunteers, it might be important to correct for normal, 
physiological findings when defining a positive US.47 Finally, few studies have 
evaluated the predictive value of US abnormalities in relation to the presence of 
other predictors; therefore, the additive value of US abnormalities to regularly 
used biomarkers is unknown. Despite these shortcomings, the data obtained 
suggest that of the different US features, power Doppler signal might have the 
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highest predictive value for the development of arthritis.45,46
Studies on the predictive value of MRI have been performed. Studies within 
autoantibody-positive non-specified arthralgia did not observe associations 
between MRI features at the knee (bone marrow edema (BME) or synovitis) and 
progression to clinical arthritis.29,39 A small MRI study evaluating synovitis and BME 
in small joints of 28 patients with ACPA-positive arthralgia was also negative.40 
However, larger studies in 150 patients with CSA revealed that MRI-detected 
inflammation was associated with progression to arthritis, independent of ACPA, 
CRP and clinical factors.24,41 Interestingly, in multivariable analyses, the effect size 
of MRI-detected inflammation was almost equal to that of ACPA (HR 5.1 for MRI 
and 6.4 for ACPA). MRI-detected tenosynovitis had a higher accuracy than synovitis 
or BME.24 Altogether subclinical inflammation identified by MRI is a predictor for 
RA development, when measured in small hand and feet joints, but not in knee 
joints (which may not be the location where synovitis begins in RA). As with US, 
age-matched symptom-free controls to define thresholds at which MRI features 
should be viewed as abnormal are lacking in most MRI-based studies. This may 
have affected the results as it has been recently shown that the predictive accuracy 
and specificity of a positive MRI increased when this was taken into account.48 
Finally only one MRI study provided PPVs and observed that an abnormal MRI 
result (in patients with CSA) was associated with a risk for arthritis development 
during the next year of 31%.24
In conclusion, imaging studies in arthralgia have been conducted in different 
patient populations, evaluating different joints and different inflammatory 
features. None of the studies were independently replicated and none compared 
MRI and US in the same patients with arthralgia. Further studies using similar 
protocols in homogeneous patient groups are warranted.
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Markers characterising immune cell dysfunction
It has been suggested that immune system dysregulation is an early feature of RA 
frequently preceding the onset of arthritis. Several markers have been studied. 
The number of regulatory T cells (Tregs) in the peripheral blood appeared not to be 
indicative of RA development in patients with seropositive arthralgia.30 In contrast, 
others showed that reduced naïve T cells and Tregs and increased inflammation-
related cells were predictive of progression to arthritis in ACPA-positive persons 
with non-specific MSK symptoms.49 Seropositive patients who developed arthritis 
had a significantly decreased number of peripheral CD8+ T cells and memory B 
cells compared with non-converters.50 B cell subtypes have been studied; patients 
with seropositive arthralgia with a low B cell score, measured as expression of 
CD19, CD20, CD79α and CD79β, had an increased risk of arthritis if there was also 
a high type I interferon signature.51 B cell receptor (BCR) clones, defined as BCR 
clones expanded beyond 0.5% of the total repertoire, have also been studied in the 
peripheral blood of 71 seropositive individuals at risk of RA and were associated 
with an enhanced risk of arthritis.52
Unfortunately, most of the abovementioned studies did not address whether the 
novel markers added to the predictive utility of regularly used biomarkers and 
validation was lacking. In addition, most of the studied markers are not high-
throughput available in daily clinical practice.
Conclusion
The processes causing arthralgia to progress to clinically evident RA are 
insufficiently understood. Most studied predictors are not pathognomonic for 
this transition or for RA, and the predictive accuracy of most markers has not 
been validated in different studies. Only ACPA positivity has been observed to 
associate with RA development across multiple studies. In addition none of the 
predictors studied, including ACPA, was sufficiently predictive on its own, and the 
vast majority of studies did not combine different types of predictors. The few 
studies that did combine different markers (e.g., imaging and ACPA) revealed 
that combinations were also insufficient for adequate risk stratification in many 
patients (as PPVs were <80%).24 Therefore more research is needed to obtain 
adequate risk stratification in patients with arthralgia.
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Ideally, future studies should be performed in homogeneous patient groups, for 
example, patients fulfilling the EULAR definition of arthralgia at risk for RA. In this 
way, patients with comparable prior risks for RA will be selected, and validation of 
findings in different cohorts will be possible. Results of these future studies should 
provide data to support the development of robust algorithms to differentiate 
patients with arthralgia likely to progress to RA from those unlikely to do so. 
Importantly the variables within these algorithms and their weightings may well 
be different for algorithms designed for use in different contexts, for example, 
primary and secondary care.
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Abstract
Objectives 
The 2010 ACR/EULAR criteria were derived to classify rheumatoid arthritis (RA) 
earlier in time. Previous studies indeed observed that the 2010 criteria were 
fulfilled earlier than the 1987 criteria. This study determined whether the 2010 
criteria perform equally in early classification of autoantibody-positive and 
autoantibody-negative RA. 
Methods
From the total Leiden EAC (n=3448) and ESPOIR (n=813) RA patients who fulfilled 
the 1987 RA criteria at 1 year but not at presentation were selected (n=463 and 
n=53, respectively), as these patients were classified with delay with the 1987 
criteria. These RA patients were studied on fulfilling the 2010 criteria at baseline 
(as 2010 positivity indicated that these RA patients were earlier identified) and 
these analyses were stratified for patients with and without anti-citrullinated 
protein antibodies (ACPA) and rheumatoid factor (RF). Analyses were repeated 
for disease-modifying antirheumatic drug (DMARD) start within the first year as 
reference for RA (instead of fulfilling the 1987 criteria). 
Results
In the EAC, 75% of the selected RA patients did already fulfil the 2010 criteria at 
baseline. In ESPOIR this was 57%, indeed demonstrating early classification with 
the 2010 criteria. Among the selected autoantibody-positive RA patients of the EAC, 
93% was already identified at baseline with the 2010 criteria. Within autoantibody-
negative RA this was 51% (p<0.001), indicating that 49% of autoantibody-negative 
RA patients were not early classified with the 2010 criteria. Similarly, within 
autoantibody-positive RA patients in ESPOIR 92% were 2010 positive at baseline, 
whereas this was only 25% within autoantibody-negative RA (p<0.001), indicating 
that 75% of autoantibody-negative RA patients were not early classified with the 
2010 criteria. Similar results were obtained when DMARD start was the reference 
for RA. 
Conclusions
The 2010 criteria perform well in the early identification of autoantibody-positive 
RA, but autoantibody-negative RA patients are still frequently missed with these 
criteria. This implies that other diagnostics are required for ACPA-negative 
patients.
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Introduction
Previously, the 1987 ACR criteria were used to classify patients as rheumatoid 
arthritis (RA).1 Because these criteria had a low sensitivity to classify RA in an 
early stage, the 2010 ACR/EULAR criteria have been developed.2 Several studies 
have indeed shown that the 2010 criteria are fulfilled earlier in time than the 1987 
criteria.3-5 Cader et al. nicely demonstrated that the 2010 criteria allowed earlier 
identification of RA than the 1987 criteria. Van der Linden et al. studied 2258 
patients that did fulfil the 1987 criteria during the first year but not at baseline. A 
total of 68% of these patients did fulfil the 2010 criteria at baseline, thus these data 
also indicated that the 2010 criteria identified RA patients in an earlier phase of 
the disease.
Early identification of RA is relevant as it allows early treatment. Anti-citrullinated 
protein antibody (ACPA)-positive and ACPA-negative RA have different genetic 
and environmental risk factors and are considered as separate disease subsets. 
However, early treatment is associated with a higher chance on achieving disease-
modifying antirheumatic drug (DMARD)-free sustained remission in both subsets.6,7 
Thus both ACPA-positive and ACPA-negative RA patients should be identified early. 
As described above several studies have been published on the performance of the 
2010 criteria in the earlier identification of RA.3-5,8,9 However, it is undetermined 
if the 2010 criteria perform equally well in the earlier identification of ACPA-
positive RA and ACPA-negative RA, with the 1987 criteria as reference. The recent 
findings that ACPA-negative patients with RA according to the 2010 criteria have 
more inflammation than ACPA-positive patients with 2010-RA suggests that the 
2010 criteria may perform differently in the early identification of ACPA-positive 
and ACPA-negative RA.10,11 To investigate this, this study compared the earlier 
identification of RA by the 2010 criteria, in autoantibody-positive patients with 
that in autoantibody-negative patients using data of two early arthritis cohorts.
Materials and methods
Patients 
Patients from two different cohorts were studied.12,13 The Leiden Early Arthritis 
Clinic (EAC) is an inception cohort that started in 1993 and includes patients with 
clinically confirmed arthritis and symptom duration <2 years at presentation at 
the rheumatologist. The patients studied were included between 1993 and 2015. 
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The total EAC comprised 3448 patients with early arthritis; of these patients, 1645 
were not classified as having RA (according to the 1987 criteria) or with other 
diagnoses at baseline (thus these patients had undifferentiated arthritis, UA) 
(Figure 3.1). The remaining 1803 patients had RA according to the 1987 criteria 
(n=751) or other diagnoses (n=1052) and were excluded from further analyses. The 
Evaluation et Suivi de POlyarthrites Indifférenciées Récentes (ESPOIR) is a cohort 
in which patients from 14 regional centers were recruited; it was started in 2002. 
Included were patients with a symptom duration ≤6 months and a high clinical 
suspicion on RA according to the rheumatologist. Patients were aged between 18 
and 70 years and had ≥2 swollen joints for at least 6 weeks. The ESPOIR cohort 
comprised 813 patients with early RA or UA, included between 2002 and 2005. Of 
these patients 234 were classified as having UA and were included in the present 
study. The remaining 579 patients had RA according to the 1987 criteria and were 
excluded from further analyses. Both studies were approved by the local ethical 
committees; all patients signed informed consent.
Figure 3.1 Flowchart of patient selection (patient group indicated in grey was studied) and research 
question
Patients that at the 2-week visit (when results of laboratory tests and radiographs were known) had clear 
diagnoses other than RA were excluded. Also RA patients who fulfilled the 1987 criteria at baseline were 
excluded. Patients that were classified as having UA according to the 1987 criteria were selected. Of these 
patients we selected patients who fulfilled the 1987 criteria after 1 year of follow-up; patients with other 
diagnoses were excluded from further analyses. The selected RA patients were identified with delay with 
the 1987 criteria. Of these patients it was determined whether they already fulfilled the 2010 criteria at 
baseline. RA, rheumatoid arthritis; UA, undifferentiated arthritis.
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Analyses
The 1987 ACR criteria and 2010 ACR/EULAR criteria were applied as described.1,2 
Because up to 2010, the 1987 criteria were the reference for RA, fulfilling these 
criteria <1 year was used as reference for RA. In line with van der Linden et al.,5 
we selected RA patients that fulfilled the 1987 criteria within 1 year but not at 
baseline. These RA patients were identified with delay with the 1987 criteria. Of 
these patients it was determined whether they already fulfilled the 2010 criteria 
at baseline and thus were earlier recognized as having RA with the 2010 criteria. 
These earlier recognized RA patients were studied on the presence of ACPA and 
rheumatoid factor (RF). In subanalyses, DMARD initiation during the first year was 
used as reference for RA. The presence of ACPA and RF was determined with ELISA 
(EAC: RF, in-house ELISA14 and anti-CCP2, eurodiagnostica, the Netherlands, cut-
off value ≥25 U/ml and anti-CCP2, EliA CCP, Phadia, Nieuwegein, the Netherlands, 
cut-off ≥7 U/ml; ESPOIR: RF, Ménarini, France, cut-off value ≥9 U/ml and anti-
CCP2, Diasorin, France, cut-off value ≥50 U/ml). Differences were tested with chi-
square test or Fisher’s exact test as appropriate. P-values <0.05 were considered 
significant. Analyses were performed using SPSS version 23.0 (IBM).
Results
Of the total Leiden-EAC, 1645 patients were diagnosed with UA at baseline 
according to the 1987 criteria (Figure 3.1). Of these RA patients, 483 did fulfil the 
1987 criteria at 1 year. In total, 20 of these 483 patients were excluded from further 
analyses because of missing ACPA or RF, leaving 463 patients to study. Thus during 
the follow-up, 463 patients were diagnosed with RA; however, these patients were 
missed when applying the 1987 criteria at baseline. Within the ESPOIR cohort, 
234 patients out of 813 RA and UA patients in total were diagnosed with UA at 
baseline according to the 1987 criteria. Out of these 234 patients 53 did fulfil the 
1987 criteria at 1 year and thus were initially missed. Baseline characteristics of 
the patients studied are shown in Table 3.1.
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Table 3.1 Baseline characteristics of patients fulfilling the 1987 RA criteria at 1 year but not at 
baseline









Age, mean (SD) 53 (15) 59 (16) 46 (10) 47 (14)
Female, n (%) 181 (70) 128 (62) 20 (80) 23 (82)
Symptom duration, 
median (IQR), weeks
20 (28) 17 (22) 26 (33) 20 (23)
TJC, median (IQR) 7 (11) 9 (13) 3 (3) 6 (7)
SJC, median (IQR) 5 (6) 7 (11) 3 (1) 4 (3)
ESR (mg/l), median (IQR) 25 (32) 29 (34) 16 (20) 15 (23)
CRP (mg/L), median (IQR) 10 (18) 15 (38) 6 (12) 2 (12)
ACPA, anti-citrullinated protein antibodies; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; 
IQR, interquartile range; Leiden EAC, Leiden Early Arthritis Clinic; N, number of patients; RF, rheumatoid 
factor; SD, standard deviation; SJC, swollen joint count; symptom duration, time between symptom onset 
and inclusion in cohort; TJC, tender joint count.
Leiden EAC
When applying the 2010 criteria on the 463 RA patients at baseline, 75% (345/463) 
was identified as RA already at baseline according to the 2010 criteria (Table 3.2). 
In total, 200 patients (43%) were ACPA-positive and 263 patients (57%) were ACPA-
negative. Of all 200 ACPA-positive RA patients missed at baseline with the 1987 
criteria, 94% (188/200) was 2010 criteria positive at baseline. In contrast, only 60% 
(157/263) of the ACPA-negative RA patients was 2010 criteria positive at baseline 
(p<0.001). Similar analyses were performed when considering RF in addition to 
ACPA (Table 3.2). Of the 463 patients missed when applying the 1987 criteria at 
baseline, 258 patients (56%) were autoantibody-positive and 205 patients (44%) 
were autoantibody-negative. Of the 258 autoantibody-positive RA patients, who 
were missed at baseline with the 1987 criteria, 93% (240/258) did fulfil the 2010 
criteria at baseline. In contrast, only 51% (105/205) of the autoantibody-negative 
RA patients was identified at baseline when applying the 2010 criteria (p<0.001).
Finally, to evaluate the frequency with which RA patients were not classified early 
in time with the current sets of criteria, the proportion of RA patients (fulfilling 
the 1987 criteria at 1 year) that was missed by both the 1987 and 2010 criteria at 
baseline was studied. Of the total Leiden-EAC, 1142 patients out of 2396 RA and UA 
patients in total were diagnosed with RA at 1 year according to the 1987 criteria. In 
all, 18 autoantibody-positive RA patients were missed at baseline by both the 1987 
and 2010 criteria, which is 1.6% (18/1142) of the total number of RA patients. This 
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is in contrast to 100 autoantibody-negative RA patients that were missed by both 
criteria at baseline; this comprised 8.8% (100/1142) of the total RA patients.
ESPOIR
Of the 53 RA patients, 57% (30/53) was recognized earlier with the 2010 criteria 
(Table 3.2). In total, 15 patients (28%) were ACPA-positive and 38 patients (73%) 
were ACPA-negative. Of all ACPA-positive RA patients missed at baseline, 100% 
(15/15) was 2010 criteria positive at baseline, but only 39% (15/38) of the ACPA-
negative RA patients was 2010 criteria positive at baseline (p<0.001). When also 
considering RF, 92% (23/25) of the autoantibody-positive RA patients was 2010 
criteria positive at baseline, in contrast to 25% (7/28) of the autoantibody-negative 
RA patients (p<0.001).
Table 3.2 Proportion of antibody-positive and -negative patients earlier classified with the 2010 RA 
criteria (2010-RA baseline positive) 
Leiden EAC ESPOIR

















200 263 463 15 38 53
ACPA+ 
and/or RF+



















258 205 463 25 28 53
Presented are the patients that fulfilled the 1987 RA criteria within 1 year but not at baseline. Of these 
patients the number of patients fulfilling the 2010 RA criteria at baseline is presented, divided into ACPA-
positive and ACPA-negative patients and into autoantibody-positive and autoantibody-negative patients, 
respectively. ACPA: anti-citrullinated protein antibodies; RF: rheumatoid factor. Differences were tested 
with chi-square test or Fisher’s exact test as appropriate.
Subanalyses
To ascertain the validity of our results, the use of DMARDs was also used as outcome 
measure instead of fulfilment of the 1987 RA criteria at 1 year; this revealed similar 
results (Table 3.3).
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Table 3.3 Proportion of autoantibody-positive and -negative patients earlier classified with the 2010 
RA criteria (outcome DMARD use) 
Leiden EAC ESPOIR

















215 421 636 34 101 135
ACPA+ 
and/or RF+



















300 360 660 52 83 135
Instead of fulfilling the 1987 criteria at 1 year as outcome, DMARD initiation was used as outcome measure. 
Total numbers are patients not fulfilling the 1987 criteria at baseline but who are treated with DMARDs 
at 1 year follow-up. Of these patients the number of patients fulfilling the 2010 RA criteria at baseline 
is shown, divided into ACPA-positive and ACPA-negative patients and into autoantibody-positive and 
autoantibody-negative patients, respectively. ACPA, anti-citrullinated protein antibodies; RF, rheumatoid 
factor; DMARDs, disease-modifying antirheumatic drugs. Differences were tested with chi-square test or 
Fisher’s exact test as appropriate.
Discussion
Studying patients from two early arthritis cohorts revealed that the 2010 
criteria identify RA patients earlier than the 1987 criteria, which is in line with 
previous studies.3-5 The present data now adds the information that autoantibody-
positive RA in particular is earlier identified with the 2010 criteria, in contrast to 
autoantibody-negative RA.
This finding is not surprising since the autoantibodies ACPA and RF are heavily 
weighted in the 2010 criteria. Autoantibody-negative patients should have more 
than 10 tender or swollen joints together with abnormal acute phase reactants and 
≥6 weeks symptom duration to be classified with RA. In contrast, autoantibody-
positive patients can already fulfil the 2010 criteria when they only have two 
involved joints if they fulfil the acute phase reactants and symptom duration 
criteria.2 Nordberg recently demonstrated that ACPA-negative patients fulfilling 
the 2010 criteria for RA indeed had more severe inflammation than ACPA-positive 
patients fulfilling these criteria.10 The current data show a consequence of this 
recent finding for the early identification of RA. This finding is a consequence 
of the circularity of the different components of the criteria, and awarding a 
stronger weight on autoantibodies automatically implies that patients without 
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autoantibodies require more of the other components to fulfil the criteria. A 
recent meta-analysis on the 2010 criteria revealed that the 2010 criteria have a 
moderate specificity, especially when the expert opinion was used as reference.15 
Additionally, it has been observed that the long-term outcome of patients fulfilling 
the 2010 criteria is different from that of patients fulfilling the 1987 criteria, 
suggesting that the criteria identify a slightly different set of patients.16 Despite the 
existing literature on the 2010 criteria, the consequence for the early classification 
of ACPA-negative RA in particular has not yet been clearly described.
Although the findings done here are a logic consequence of the composition of the 
2010 criteria, the difference between the “old” versus the “new” classification criteria 
for RA can have consequences, for instance when the criteria are used to select 
patients for trials that are performed in very early phases of RA. When conducting 
clinical trials in early disease stages and fulfilment of the 2010 classification criteria 
is used in the inclusion criteria, autoantibody-positive patients in particular can be 
included in an early phase, in contrast to autoantibody-negative patients, who are 
less often classified as RA in an early phase.8,17 Then future trials will reveal less 
evidence on the effect of treatments in early autoantibody-negative RA.
The 2010 criteria were developed for classification and not for diagnosis, but 
in practice may sometimes be used in the diagnostic process or influence the 
diagnostic process in daily practice. When this happens, ACPA-negative patients 
are possibly more often identified later in time than ACPA-positive patients. This 
is unfortunate as early treatment is observed to be relevant for both subsets of 
RA6,7,18 Thus additional tools are required to also recognize these ACPA-negative 
RA patients early. In total, 10% of all RA patients are not early identified of which 
almost 9% are autoantibody-negative.
The pathogenesis of ACPA-negative RA is less well understood and presumably 
ACPA-negative RA consists of a variety of subgroups with differences in 
etiopathology. This latter view is supported by the finding that part of the ACPA-
negative patients have no joint destruction, whereas others do have a severely 
destructive disease.19 Despite the difficulties with the conception of ACPA-negative 
RA, it is nowadays questionable if ACPA-negative RA patients suffer less than 
ACPA-positive RA patients. Clinically relevant joint damage has become infrequent 
and several studies evaluated other disease outcomes and observed that ACPA-
negative RA patients have at least as much functional disability and similar disease 
activity scores as ACPA-positive patients.10,11,20 In addition, most ACPA-negative RA 
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patients do have a chronic disease course.11 Moreover, it has been shown that early 
DMARD initiation is beneficial in ACPA-negative RA.21 Finally, the recent findings 
that the majority of autoantibody-negative RA patients who do not fulfil the 2010 
criteria do require DMARD therapy over time and have a persistent disease course 
underline the importance to also classify these RA patients early in time.3,22 Based 
on the combination of these findings, we feel that early classification or early 
identification of ACPA-negative RA is relevant.
In this study, fulfilment of the 1987 RA criteria after 1 year follow-up was chosen 
as reference because these criteria perform well in advanced disease. Additionally, 
the 1987 criteria reflect the situation before the introduction of the new 2010 
criteria which makes it a specific reference of RA. In sub-analyses, DMARD use 
during the first year was used as reference for RA and this showed similar findings 
for the performance of the 2010 criteria in the early classification of RA, showing 
robustness of the data.
A potential limitation is that the inclusion criteria of both cohorts were slightly 
different. The EAC is an inception cohort and the only referral center in a region. 
ESPOIR is a nationwide observational cohort of patients with suspected RA that not 
necessarily included all patients with RA in the participating regions. Furthermore, 
in contrast to ESPOIR, the EAC included patients with ≥1 swollen joint (and the RA 
criteria were applied in retrospect). These differences may explain the difference 
in proportion of RA patients who initially presented with UA. Despite these 
differences the trend in the data was similar.
Conclusions
In conclusion, this study showed that autoantibody-positive RA is more often 
early identified with the 2010 criteria than autoantibody-negative RA. This implies 
that other diagnostic methods or other diagnostic tests are required for the early 
identification and early classification of autoantibody-negative RA.
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Does information on novel 
identified autoantibodies 
contribute to predicting 
the progression from 
undifferentiated arthritis to 
rheumatoid arthritis? A study on 
anti-CarP antibodies as example
Arthritis Res Ther. 2018;20(1):94.
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Leendert A. Trouw
Annette H.M. van der Helm-van Mil 




The presence of autoantibodies is considered an important characteristic of 
rheumatoid arthritis (RA); therefore, both anti-citrullinated protein antibodies 
(ACPA) and rheumatoid factor (RF) are included in the 2010 classification 
criteria for RA. However, a considerable number of RA patients lack both these 
autoantibodies. Recently, several novel autoantibodies have been identified but 
their value for the classification of RA patients is unclear. Therefore, we studied 
the value of novel autoantibodies using the presence of anti-carbamylated protein 
(anti-CarP) antibodies as an example for predicting RA development in patients 
with undifferentiated arthritis (UA).
Methods
There were 1352 UA patients included in the Leiden Early Arthritis Clinic cohort 
according to the 1987 criteria. When the 2010 criteria were used, there were 838 
UA patients. Of these, we evaluated whether they fulfilled the 1987 or 2010 criteria 
after 1 year, respectively. Logistic regression analyses were performed with RA 
as outcome and ACPA, RF, and anti-CarP antibodies as predictors. Analyses were 
repeated after stratification for ACPA and RF. 
Results
Thirty-three percent of the 1987-UA patients and 6% of the 2010-UA patients 
progressed to RA during the first year of follow-up. For the 1987-UA patients, anti-
CarP antibodies were associated with progression to RA, an association which 
remained when a correction was made for the presence of ACPA and RF (OR 1.7, 
95% CI 1.2-2.4). After stratification for ACPA and RF, anti-CarP antibodies were 
associated with progression to RA only for ACPA- and RF-negative patients (OR 
2.1, 95% CI 1.3-3.7). For the 2010-UA patients, anti-CarP antibodies were associated 
with progression to RA; however, they were not when a correction was made for 
the presence of ACPA and RF (OR 0.8, 95% CI 0.3-2.1). 
Conclusions
Our finding that anti-CarP antibodies have no additional value when RA is defined 
according to the 2010 criteria might be inherent to the composition of the 2010 
criteria and therefore might also apply to other novel autoantibodies. Potentially 
it would be interesting to evaluate other, non-autoantibody biomarkers.
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Background
Rheumatoid arthritis (RA) is characterized by the presence of autoantibodies, the 
most characteristic among which are anti-citrullinated protein antibodies (ACPA) 
and rheumatoid factor (RF). These are used as diagnostic tools and are included 
in the classification criteria for RA.1 Nonetheless, in approximately one-third 
of early RA patients these autoantibodies are lacking.2 It is important to better 
characterize these patients since early intervention in seronegative RA is also 
important. Therefore, research has focused on identifying novel autoantibodies and 
several have been identified.3-7 Based on this research, two issues have been raised. 
First, stratified analyses are pivotal to prove an additive value of a test. A novel 
autoantibody should predict an outcome in patients negative for both ACPA and RF, 
or in patient groups with a similar presence of ACPA and/or RF (e.g., ACPA+RF+novel 
autoantibody+ vs. ACPA+RF+novel autoantibody- patients). Thus far, studies that 
have evaluated the predictive value of novel autoantibodies are often stratified for 
ACPA but not for RF, leaving the question unanswered if the findings attributed to 
the novel autoantibody were actually driven by the concomitant presence of RF.5,8 A 
second issue is that, although different disease stages of RA have been studied, the 
value of novel autoantibodies in identifying the patients that will develop RA among 
patients presenting with undifferentiated arthritis (UA) is undetermined. Only one 
study evaluated the role of novel autoantibodies (UH-RA.1, UH-RA. 21) in UA patients 
as an early marker of RA development.4 The ultimate aim of this study was to increase 
our understanding on the value of recently identified autoantibodies to predict RA 
development using accurate stratification for ACPA and RF. An interesting novel 
family of autoantibodies are the anti-carbamylated protein (anti-CarP) antibodies 
which target proteins modified by carbamylation. These antibodies are present in 
RA patients and are associated with the severity of radiographic progression.7,9 In 
this study, we investigated the value of the novel anti-CarP antibodies in predicting 
RA development in patients with UA, independent of ACPA and RF.7
Methods
Patients
Between 1993 and 2015, 1352 UA patients (according to the 1987 criteria; 1987-UA) 
were included in the Leiden Early Arthritis Clinic (EAC) cohort. This became 838 
UA patients when the 2010 criteria were used (2010-UA). The EAC is an inception 
cohort that was started in 1993 and includes patients with clinically confirmed 
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arthritis with symptom duration <2 years at presentation to the rheumatologist.10 
Baseline questionnaires, joint counts, and blood samples were collected, and 
radiographs were taken. Two weeks after inclusion, when the results of laboratory 
investigations and radiography were known, patients received their diagnosis. 
Classification criteria were only applied to patients with a clinical diagnosis or 
suspicion of RA, and patients who were not classified according to RA classification 
criteria were documented as having UA.
Anti-CCP2, RF and anti-CarP antibody measurements
Baseline serum samples were tested for ACPA, RF and anti-CarP antibodies. 
IgG antibodies to cyclic citrullinated peptide (CCP) were measured by second 
generation anti-CCP2 enzyme-linked immunosorbent assay (ELISA; Immunoscan 
RA Mark 2, Eurodiagnostica, Arnhem; cut-off 25 U/ml), and anti-CCP2 ELISA (EliA 
CCP, Phadia, Nieuwegein, the Netherlands; cut-off 7 U/ml). IgM RF was determined 
by an in-house ELISA. IgG anti-CarP antibodies were determined as described 
previously in the Leiden EAC.7 As no commercial kit is available for anti-CarP 
antibodies, we used our own in-house anti-CarP assay based on carbamylated fetal 
calf serum and, as a control, nonmodified fetal calf serum as the coating antigens 
in the ELISA. Cut-off for positivity was based on the mean +2 standard deviations 
(SDs) from a set of healthy controls.
Analyses 
Analyses were first performed when RA was classified using the 1987 criteria; 
thereafter, analyses were repeated using the 2010 criteria since autoantibodies 
are more prominent in the 2010 criteria. Fulfilment of the 1987 criteria and 2010 
criteria was evaluated after 1 year of follow-up for the 1987-UA and 2010-UA 
patients, respectively. Logistic regression analyses were performed with ACPA, RF, 
and anti-CarP antibodies as independent variables and RA as outcome, both in the 
total group of UA patients and after stratification for ACPA and RF status.
Results
Baseline characteristics of the 1352 1987-UA and 838 2010-UA patients are shown 
in Table 4.1. Of these UA patients, 33% (441/1352) and 6% (53/838) progressed to RA 
during the first year according to the 1987 and 2010 criteria, respectively. Of the 
1352 1987-UA patients, 257 (19%) were anti-CarP-positive and of the 838 2010-UA 
patients, 77 (9%) were anti-CarP-positive. 
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Table 4.1 Baseline characteristics of the total group of UA patients and the subgroups of patients 
with UA according to the 1987 and the 2010 criteria 
Total group of UA 
patients
Subgroup of 1987-UA 
patients
Subgroup of 2010-UA 
patients
(n=1430) (n=1352) (n=838)
Age (years), mean (SD) 53 (17) 53 (17) 51 (17)
Female, n (%) 882 (62) 837 (62) 494 (59)
Symptom duration (weeks), 
median (IQR)
14 (6-31) 14 (6-31) 12 (5-28)
66-SJC, median (IQR) 3 (1-7) 3 (1-7) 2 (1-4)
68-TJC, median (IQR) 4 (1-10) 4 (1-10) 2 (1-5)
CRP (mg/ml), median (IQR) 8 (3-22) 8 (3-22) 6 (3-19)
ACPA positivity, n (%) 297 (21) 283 (21) 48 (6)
RF positivity, n (%) 374 (26) 359 (27) 68 (8)
anti-CarP positivity, n (%) 271 (19) 257 (19) 77 (9)
Of the total group of UA patients (n=1430), 760 patients have UA both according to the 1987 and 2010 
criteria, 592 patients only have UA according to the 1987 criteria, and 78 patients only have UA according 
to the 2010 criteria. ACPA, anti-citrullinated protein antibodies; anti-CarP, anti-carbamylated protein 
antibodies; CRP, C-reactive protein; IQR, interquartile range; RF, rheumatoid factor; SD, standard 
deviation; SJC, swollen joint count; symptom duration, time between symptom onset and inclusion in 
cohort; TJC, tender joint count; UA, undifferentiated arthritis.
The value of anti-CarP antibodies was first studied in the 1987-UA patients. The 
presence of anti-CarP antibodies at baseline was associated with progression to 
RA (OR 4.2, 95% CI 3.2–5.6), an association which remained when a correction 
was made for the presence of ACPA and RF (OR 1.7, 95% CI 1.2–2.4). There was 
no additional predictive value of anti-CarP antibody levels in anti-CarP-positive 
patients. The association of anti-CarP antibodies with progression to RA was then 
determined within the strata of patients with a similar ACPA and RF status. The 
majority of the UA patients (69%) were ACPA- and RF-negative; 7% (65/929) of 
these ACPA- and RF-negative patients had anti-CarP antibodies (Table 4.2). Within 
this subgroup, the presence of anti-CarP antibodies was statistically significantly 
associated with progression to RA (OR 2.1, 95% CI 1.3–3.7). When absolute risks 
were examined, the pre-test risk for RA development in the ACPA- and RF-negative 
subgroup was 21%, and this increased to 35% when anti-CarP antibodies were 
present (Table 4.2). When exploring the negative predictive value (NPV), the pre-
test risk of not developing RA was 79% which was similar to the NPV of 80%.
Next, the predictive value of anti-CarP antibodies was studied within the 2010-UA 
patients. Here, anti-CarP antibodies at baseline were associated with progression 
to 2010-RA within 1 year (OR 2.9, 95% CI 1.4–5.8). However, when adjustment was 
made for the presence of ACPA and RF, there was no additive predictive value of 
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anti-CarP antibodies (OR 0.8, 95% CI 0.3–2.1). When analyzing groups of patients 
stratified according to the absence of ACPA and RF, the majority of 2010-UA patients 
were ACPA- and RF-negative (90%) and only 6% (49/755) of these patients had anti-
CarP antibodies. Within this subgroup, no predictive value of anti-CarP antibodies 
was observed (Table 4.2). Evaluation of absolute risks in the ACPA- and RF-negative 
subgroup revealed that the pre-test risk of developing RA was 4% and the positive 
predictive value (PPV) was 2% when anti-CarP antibodies were present. Likewise, the 
pre-test risk of not developing RA in this subgroup was similar to the post-test risk 
(NPV) when patients tested negative for anti-CarP antibodies (both 96%, Table 4.2).
Table 4.2 Proportion of 2010-UA and 1987-UA patients progressing to RA within 1 year within groups 
of similar ACPA and RF status 
1987-UA patients (n=1352) 1987-RA no 
1987-RA









ACPA- RF- (n=929) anti-CarP+ 23 42 21/79 2.1 35 80
anti-CarP- 176 688 (1.3-3.7) (25-48) (77-82)
ACPA+ RF- (n=64) anti-CarP+ 16 10 50/50 2.2 62 58
anti-CarP- 16 22 (0.8-6.1) (43-78) (42-72)
ACPA- RF+ (n=140) anti-CarP+ 8 9 39/61 1.4 47 62
anti-CarP- 47 76 (0.5-4.0) (26-69) (53-70)
ACPA+ RF+ (n=219) anti-CarP+ 107 42 71/29 1.2 72 31 
anti-CarP- 48 22 (0.6-2.2) (64-78) (22-43)








ACPA- RF- (n=755) anti-CarP+ 1 48 4/96 0.5 2 96
anti-CarP- 30 676 (0.1-3.5) (0-11) (94-97)
ACPA+ RF- (n=15) anti-CarP+ 1 2 13/87 5.5 33 92
anti-CarP- 1 11 (0.2-129) (6-79) (65-99)
ACPA- RF+ (n=35) anti-CarP+ 0 4 17/83 Undefined 0 81
anti-CarP- 6 25 (0-49) (64-91)
ACPA+ RF+ (n=33) anti-CarP+ 9 12 42/58 1.1 43 58 
anti-CarP- 5 7 (0.2-4.4) (24-63) (32-81)
Patients were stratified according to the presence of different autoantibody combinations (ACPA-RF-, 
ACPA+RF-, ACPA-RF+, and ACPA+RF+); within these groups the predictive value of the presence of anti-
carbamylated protein (anti-CarP) antibodies for progression to rheumatoid arthritis (RA) was determined, 
both within 2010-undifferentiated arthritis (UA) and 1987-UA patients. †Observed risk of RA development 
within ACPA and RF strata (pre-test risks), without information on anti-CarP status. ACPA, anti-citrullinated 
protein antibodies; CI, confidence interval; NPV, negative predictive value; OR, odds ratio; PPV, positive 
predictive value; RF, rheumatoid factor.
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Discussion
This study was performed to increase our understanding of the value of recently 
identified autoantibodies to predict RA development using accurate stratification 
for ACPA and RF. Anti-CarP antibodies were studied as an example. We observed 
that the presence of anti-CarP antibodies was statistically significantly associated 
with the development of RA within ACPA- and RF-negative 1987-UA patients. In 
this group, the risk of developing RA increased from 21% to 35% when anti-CarP 
antibodies were present. However, when RA was defined according to the 2010 
criteria, anti-CarP antibodies were not associated with RA development and the 
presence of these autoantibodies did not increase the risk of RA development 
compared to the pre-test risks.
Although they used different study designs and entire early arthritis populations, 
two previous studies found 2.2% and 0.4% improved classification when adding 
anti-CarP antibodies to ACPA and RF, thus showing little additive benefit.8,11 These 
findings are in line with our data.
Presumably this finding is explained by the fact that ACPA and RF are heavily 
weighted in the 2010 criteria. Consequently, the majority of UA patients are 
ACPA- and RF-negative and these patients can only fulfil the 2010 criteria if they 
develop >10 involved joints but they can fulfil the 1987 criteria over time with 
less extensive disease progression; hence the definition of the outcome matters. 
Additionally, autoantibodies frequently occur together (Figure 4.1), as has been 
shown for several novel autoantibodies.3,5 These two explanations might also 
apply to other novel autoantibodies. Although novel autoantibodies other than 
anti-CarP antibodies were not evaluated here, we anticipate that similar findings 
will be obtained. Importantly, our findings relate to the earlier identification of 
patients with RA; novel autoantibodies can still be useful for other outcomes, such 
as radiographic progression.7
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Figure 4.1 Concomitant presence of anti-citrullinated protein antibodies (ACPA), rheumatoid factor 
(RF), and anti-carbamylated protein (anti-CarP) antibodies in patients with 1987-undifferentiated 
arthritis (UA) and 2010-UA
Depicted are the percentages of the 1352 1987-UA (A) and the 838 2010-UA (B) patients positive for ACPA, 
RF, and/or anti-CarP antibodies.
Conclusion
More research is needed to identify early RA patients among (2010 criteria-
negative) UA patients, but based on the composition of the current classification 
criteria it will be interesting to evaluate other, non-autoantibody biomarkers.
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Magnetic resonance imaging (MRI) is recommended in the diagnostic process of
rheumatoid arthritis (RA), to detect joint damage early. MRI-detected erosions are 
also present in symptom-free controls, especially at older age. It is unclear if RA-
specific MRI-detected erosions can be distinguished from ‘physiological’ erosions 
in symptom-free individuals. This study compared MRI-detected erosions of RA 
patients with healthy controls and with other arthritides.
Methods 
589 newly-presenting early arthritis patients (238 RA, 351 other arthritides) and 
193 symptom-free controls underwent contrast-enhanced 1.5T MRI of unilateral 
metacarpophalangeal and metatarsophalangeal (MTP) joints. Total erosion score 
(according to RAMRIS), number, severity, location of erosions and simultaneous 
presence of MRI-detected inflammation (synovitis and/or bone marrow edema) 
were compared; participants were categorized in three age-groups (<40, 40-59, 
≥60).
Results 
RA patients had statistically significant higher total erosion scores than controls 
but scores of individual persons largely overlapped. Grade ≥2 erosions and MTP5-
erosions were specific for RA (specificity 98-100% and 90-98% for different age-
groups). MTP1-erosions were only specific if aged <40 (specificity 98%) and erosions 
with inflammation if aged <60 (specificity 91-100%). ≥1 of the mentioned erosions 
characteristics were present in 29% of RA patients. Comparing RA patients with 
other arthritides revealed that grade ≥2 erosions and MTP5-erosions remained 
specific for RA (specificity ≥89%) as well as MTP1-erosions if aged <40 (specificity 
93%), in contrast to erosions combined with inflammation (specificity 49-85%).
Conclusions
Total erosion scores of individual persons were largely overlapping. Erosion 
characteristics specific for RA were identified, but were infrequently present. 
Caution is needed not to overestimate the value of MRI-erosions in the diagnostic 
process.
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Rheumatoid arthritis (RA) is characterized by joint inflammation that may 
lead to bone erosions. Traditionally erosions are evaluated using conventional 
radiographs. Recently it has been recommended by the EULAR imaging taskforce 
that magnetic resonance imaging (MRI) is valuable to detect erosions early.1 
Indeed MRI has shown to be more sensitive for structural damage in early RA than 
conventional radiographs.2-9
Radiographic erosions specific for RA are defined in the 2010 ACR/EULAR-criteria10 
as erosions seen in at least three separate joints at the proximal interphalangeal, 
the metacarpophalangeal (MCP), the wrist and metatarsophalangeal (MTP) joints 
(specificity >80%, sensitivity 15-29%).11 However, for MRI-detected erosions a 
definition specific for RA has not yet been derived. Because MRI is more sensitive 
in detecting erosions than radiographic imaging, RA-specific MRI-detected erosions 
need to be characterized. 
Previously it was shown that MRI-detected erosions are also observed in other 
rheumatic diseases and in healthy controls, especially at older age.12-17 Thus, in 
order to prevent false-positive MRI-results, it is important to distinguish RA-
specific erosions from other erosions.
This cross-sectional study compared erosions in MCP and MTP joints as detected 
on MRI (evaluated using the rheumatoid arthritis MRI scoring system (RAMRIS)) 
between early RA patients at the time of diagnosis and symptom-free controls 
for different characteristics: besides the total erosion score, also the number, 
severity and location of erosions and the simultaneous presence of MRI-detected 
inflammation (synovitis and/or bone marrow edema (BME)) were compared. 
Second, RA patients were also cross-sectionally compared to early arthritis 
patients that presented with other diagnoses. Within patients that presented with 
undifferentiated arthritis (UA), erosions were compared between patients that did 
and did not progress to RA during the first year. All analyses were done with the 
ultimate aim to identify features of MRI-detected erosions that are specific for RA.
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598 patients who presented with early arthritis and were included in the Leiden 
Early Arthritis Clinic (EAC) between 2010 and 2014 were studied. The EAC is 
an inception cohort including patients with clinically confirmed arthritis and 
symptom duration <2 years. At baseline questionnaires were administered, joint 
counts and blood samples were collected and MRI was performed.18 Nine patients 
were excluded because no contrast agent was administered. Two weeks after 
inclusion, when results of regular investigations were known (this did not include 
information on MRI-results), the initial diagnosis of the patients was documented 
by the rheumatologists. The clinical diagnosis of RA was verified by fulfilling 
the 1987 or 2010 criteria at baseline.10,19 Of the 589 patients 238 patients had RA. 
The diagnoses of the remaining group with other arthritides (n=351) were UA 
(n=192), reactive arthritis (n=22), (pseudo)gout (n=15), psoriatic arthritis (n=34), 
inflammatory osteoarthritis (OA) (n=35), Lyme arthritis (n=3), paramalignant 
arthritis (n=1), SLE (n=4), other systemic disorder (n=7), MCTD, vasculitis (n=2), 
sarcoidosis (n=3), spondylarthropathy with peripheral arthritis (n=5), RS3PE 
(n=10), and other diagnosis (n=18).
In addition, 193 symptom-free controls were recruited by advertisements in local 
newspapers and websites as previously reported.13 They had no history of RA or 
other inflammatory rheumatic diseases, no joint symptoms during the last month, 
no recent trauma (<1 year prior to MRI) and no arthritis at physical examination.
Both studies were approved by the local medical ethics committee. All patients and 
controls signed informed consent.
MR imaging and scoring
At baseline MRI of the 2nd-5th MCP and 1st-5th MTP joints on the most painful side 
or in case of symmetric symptoms and in healthy controls on the dominant side 
was performed. MR imaging was performed on a MSK Extreme 1.5T extremity MRI 
system (General Electric, Wisconsin, USA). The MRIs of all subjects were made on 
the same scanner. Coronal T1-weighted fast spin-echo (FSE) and contrast-enhanced 
coronal and axial T1-weighted FSE with frequency-selective fat suppression 
were obtained. Further details on the scan protocol are provided in the online 
Supplementary methods. Erosions, BME and synovitis were scored according to 
the RAMRIS method, with the exception that BME was assessed on a contrast-
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enhanced T1-weighted fat-suppressed sequence.20 According to the RAMRIS 
method erosions were defined as sharply marginated bone lesions, with correct 
juxta-articular localization and typical signal characteristics, which are visible in 
two planes with a cortical break seen in at least one plane. All bones were scored 
separately for erosions on a scale 0-10, based on the proportion of eroded bone 
(0: no erosion, 1: 1-10% of bone eroded, 2: 11-20%, etc.). The total erosion score 
was calculated by summing the erosion score in the MCP and MTP joints (range 
0-180). Each MRI was scored by two readers, blinded to any clinical data. Intra-
reader intraclass correlation coefficients (ICCs) and interreader ICCs were ≥0.86 
(see online Supplementary methods).
Erosion characteristics 
The total erosion score (hence a combination of number of erosions and severity), 
number, severity and location of erosions were studied on the person level. The 
presence of concomitant inflammation was studied. This comprised the presence 
of BME in the same bone or the presence of synovitis around the same bone as 
where the erosion was located. These analyses were done on person and on bone 
level. For the total erosion score the mean of two readers was used. When assessing 
number, severity, location and the combination of erosions with inflammation, 
MRI-erosions were considered present when the mean of both readers was ≥1 at a 
specific bone. Grade ≥2 erosions indicate that >10% of the bone is eroded.
Statistical analyses 
First, total erosion scores of RA patients were compared with scores of controls. 
A linear regression analysis adjusted for age and gender was used with the total 
erosion score as outcome and group (RA/healthy control) as independent variable. 
Erosion scores were logtransformed (log10(score+1)) to approximate a normal 
distribution. The reported effect sizes were back-transformed to the normal score 
and indicated how many times the erosion scores of RA patients were higher than 
that of controls. Thereafter, patients were stratified in three age groups (<40, 40-
59, ≥60 years) and frequencies of erosion characteristics were compared between 
groups. Test characteristics were determined. Similar analyses were performed 
comparing RA patients with other arthritides. Finally the diagnostic value of MRI-
detected erosions in UA patients was assessed. SPSS version 23.0 (IBM) was used. 
P-values <0.05 were considered significant.
 85




Baseline characteristics of patients and symptom-free controls are presented in 
Table 5.1.
Table 5.1 Baseline characteristics of RA patients, symptom-free controls and patients with other 
arthritides
RA patients Symptom-free 
controls
Patients with other 
arthritides
(n=238) (n=193) (n=351)
Age in years, mean (SD) 56 (15) 50 (16) 54 (16)
Female, n(%) 159 (67) 136 (70) 204 (58)
Symptom duration in weeks, median (IQR) 15 (8-29) NA 9 (4-26)
66-SJC, median (IQR) 6 (2-11) NA 2 (1-4)
68-TJC, median (IQR) 9 (5-15) NA 3 (2-8)
CRP (mg/ml), median (IQR) 9 (3-21) NA 4 (3-13)
RF positivity, n(%) 147 (64) NA 39 (12)
ACPA positivity, n(%) 123 (52) NA 14 (4)
ACPA, anti-citrullinated protein antibodies; CRP, C-reactive protein; IQR, interquartile range; NA, not 
applicable; RA, rheumatoid arthritis; RF, rheumatoid factor; SD, standard deviation; SJC, 66-swollen joint 
count; TJC, 68-tender joint count.
Some serology data were missing as follows: in RA patients RF n=10, ACPA n=1; in patients with other 
arthritides: RF n=15, ACPA n=12.
At group level RA patients have slightly higher MRI-detected erosion scores 
than symptom-free controls but on the individual level there is large overlap
First the total erosion scores were evaluated. In both the group of RA patients 
and that of symptom-free controls the MRI-erosion score was associated with age 
(Figure 5.1A, Supplementary table 5.1). When comparing the erosion scores of 
RA patients and controls, RA patients had 1.20 (95% CI 1.08-1.33, p<0.001) times 
higher erosion scores than controls, independent of age and gender. This effect 
size indicates that RA patients had in general a 20% higher total erosion score than 
controls. Despite the significant difference there was large overlap of MRI-erosion 
scores between RA patients and controls, as visually no separate clustering of 
groups was observed (Figure 5.1A). Thus total erosion scores could not differentiate 
RA patients from controls on the individual level.
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Figure 5.1 MRI-detected erosions in MCP and MTP joints in relation to age in RA patients and in 
controls (A) and in patients with other arthritides (B); both figures show overlap at the individual 
level
Linear regression analyses were performed with the mean total erosion score as detected by magnetic 
resonance imaging as outcome and group (RA patients and healthy controls (A) or other arthritides (B)), 
age and gender as independent variables. Y-axis is log-transformed. MCP; metacarpophalangeal; MTP; 
metatarsophalangeal. 
Grade ≥2 MRI-erosions are more prevalent in RA patients than in symptom-
free controls
Then other erosion characteristics were studied to search for RA-specific 
characteristics. Because of the association with age, all analyses were stratified 
for age group (<40, 40-59 and ≥60 years). Since the total erosion score is a 
combination of the number of erosions and severity, both characteristics were 
evaluated separately. The median total number of erosions was 1.0 (IQR 0-2.0) for 
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RA patients and 0 (IQR 0-1.0) for symptom-free controls (Mann-Whitney U-test: 
p=0.001). Within the different age groups there were no significant differences in 
the two oldest groups. In the group <40 years, RA patients had more erosions than 
controls (median 0 (IQR 0-1.0) versus 0 (IQR 0-0), p=0.007) though differences were 
too small to identify a number of MRI-detected erosions that was specific for RA. 
To determine whether grade ≥2 erosions were RA-specific, the frequency of grade 
≥2 erosions was considered per joint location (Supplementary table 5.2). This 
revealed that grade ≥2 erosions were almost exclusively present in RA (specificity 
98-100% for different age groups, Table 5.2). However within all age groups they 
were only sporadically observed in RA at disease presentation (sensitivity 5-10%). 
Evaluation on person level showed that 8% of the RA patients had at least one 
grade ≥2 erosion in an MCP and/or MTP joint, while in controls this was only 1% 
(Table 5.3). Thus the presence of grade ≥2 erosions was highly specific for RA, but 
also infrequent in RA at disease presentation.
Table 5.2 Test characteristics of grade ≥2 erosions (a), an erosion in MTP5 (b), an erosion in MTP1 (c) 
and erosions in combination with inflammation (d) for RA
RA patients RA patients vs. healthy 
controls
RA patients vs. patients 
with other arthritides
sensitivity (95% CI) specificity (95% CI) specificity (95% CI)
a Test characteristics grade ≥2 erosion
<40 years 9% (3-24) 100% (93-100) 100% (95-100)
40-59 years 5% (2-12) 99% (94-100) 96% (91-98)
≥60 years 10% (6-17) 98% (90-100) 96% (91-98)
b Test characteristics erosion in MTP5
<40 years 24% (13-41) 98% (90-100) 100% (95-100)
40-59 years 9% (5-17) 90% (82-95) 89% (83-93)
≥60 years 16% (10-24) 92% (82-97) 90% (84-94)
c Test characteristics erosion in MTP1
<40 years 18% (9-34) 98% (90-100) 93% (84-97)
40-59 years 19% (12-28) 86% (77-91) 77% (69-83)
≥60 years 36% (27-45) 63% (50-75) 66% (57-73)
d Test characteristics of erosion in combination with inflammation
<40 years 33% (20-50) 100% (93-100) 85% (75-92)
40-59 years 24% (17-33) 91% (83-95) 69% (61-76)
≥60 years 56% (47-65) 71% (58-82) 49% (41-57)
RA, rheumatoid arthritis; MTP, metatarsophalangeal joint; CI, confidence interval.
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Table 5.3 Frequencies of RA patients and controls with grade ≥2 erosions and with erosions with the 
simultaneous presence of local inflammation in an MCP and/or MTP joint; analyses on person level
Grade ≥2 erosions Erosions with inflammation










RA <40 years (n=33) 14 11 (79%) 3 (21%) 3 (21%) 11 (79%)
40-59 years (n=96) 39 34 (87%) 5 (13%) 16 (41%) 23 (59%)
≥60 years (n=109) 79 68 (86%) 11 (14%) 18 (23%) 61 (77%)
238
Control <40 years (n=51) 9 9 (100%) 0 (0%) 9 (100%) 0 (0%)
40-59 years (n=90) 36 35 (97%) 1 (3%) 28 (78%) 8 (22%)
≥60 years (n=52) 36 35 (97%) 1 (3%) 21 (58%) 15 (42%)
193
The presence of grade ≥2 erosions and erosions with inflammation (BME and/or synovitis) was 
evaluated per MCP and MTP bone according to the Rheumatoid Arthritis Magnetic Resonance Imaging 
Scoring system. Grade ≥2 erosions indicate that >10% of the bone is eroded. The presence of BME and/
or synovitis was defined as a score of ≥1. BME, bone marrow edema; MCP, metacarpophalangeal; MTP, 
metatarsophalangeal; RA, rheumatoid arthritis.
MTP5 and MTP1 are more often affected in RA patients than in symptom-free 
controls 
Then the location (the affected MCP or MTP joint) was assessed (Table 5.4). Both 
in RA patients and controls most erosions were located in the proximal part of the 
MCP and MTP joints: in RA patients 82-95% of the erosions was located proximal in 
the joint and in controls this was 81-100% for the different age groups. As presented 
in Table 5.4, overall the MCP and MTP bones that were frequently affected in RA 
patients were also frequently affected in healthy controls. For instance MCP2 and 
MCP3 were predilection sites for MRI-detected erosions in RA, but also in controls. 
However there were also some differences: erosions in MTP5 were more frequently 
present in RA patients than in controls in most age groups (specificity 90-98% for 
different age groups, Table 5.2). In addition, erosions in MTP1 in the age group <40 
almost exclusively occurred in RA (specificity 98%); the specificity was lower in 
older age groups (specificity 86% if aged 40-59 and 63% if aged ≥60). Examples of 
MRI-detected erosions are shown in Figure 5.2.
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Table 5.4 Location of erosions in bones of the MCP and MTP joints of RA patients and symptom free 
controls, depicted per age category (18-39, 40-59, ≥60 years)
Erosions
<40 years 40-59 years ≥60 years
RA Control RA Control RA Control
n=33 n=51 n=96 n=90 n=109 n=52
MCP 2 proximal 6 6 7 11 23 23
distal 0 0 4 2 9 10
MCP 3 proximal 9 8 15 12 30 23
distal 0 0 0 1 5 4
MCP 4 proximal 3 0 3 2 9 8
distal 0 0 0 0 0 0
MCP 5 proximal 0 2 5 6 20 13
distal 0 0 0 0 1 6
MTP 1 proximal 18 2 19 14 36 37
distal 0 0 2 0 11 6
MTP 2 proximal 0 0 2 0 4 0
distal 3 0 0 1 4 0
MTP 3 proximal 0 0 2 0 6 0
distal 0 0 0 0 2 0
MTP 4 proximal 3 0 3 0 1 0
distal 0 0 0 0 0 0
MTP 5 proximal 24 2 9 10 16 8
distal 0 0 2 0 1 2 
Values are the percentages of persons with an erosion of all persons in that age category. 
The presence of an erosion is defined as an erosion score of at least 1 in that bone. 
MCP, metacarpophalangeal joint; MTP, metatarsophalangeal joint; RA, rheumatoid arthritis.
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Figure 5.2 Examples of erosions in RA patients, patients with other arthritides and symptom-free 
controls
MR images of RA patients (A, D), patients with other arthritides (B, E) and symptom-free controls (C, 
F). Examples of erosion in MCP2 (A-C) and MTP5 are shown (D). Erosions in MCP2 were observed in all 
different groups (A-C), while erosions in MTP5 were mainly observed in RA patients (D). The erosion 
shown in MTP5 (D) is accompanied by the presence of bone marrow edema. Patient B was diagnosed 
with gout. Person C was aged 48 years. Coronal (A1, B1, C1, D1, E1, F1) and axial (A2, B2, C2, D2, E2, F2) 
images are shown. MRI sequences included coronal T1-weighted fast spin-echo (FSE) sequences and axial 
T1-weighted FSE sequences with fat suppression after contrast enhancement. MCP, metacarpophalangeal 
joint; MRI, magnetic resonance imaging; MTP, metatarsophalangeal joint; RA, rheumatoid arthritis.
Erosions with the simultaneous presence of BME and/or synovitis are more 
frequent in RA patients than in symptom-free controls
Then we questioned whether the combined presence of erosions with surrounding 
inflammation was specific for RA. At bone level, in RA patients 33% (95/285) of 
the total number of MCP and MTP bones with erosions only had erosions without 
synovitis and/or BME while in controls this was 77% (105/136, Table 5.5). Similarly, 
when analysed on person level, 16% of the RA patients only had erosions without 
inflammation and 40% had at least one erosion with inflammation in that same 
joint while in controls this was 30% and 12%, respectively (Table 5.3). When 
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analysing the different age groups it appeared that within the age group <40 years, 
the simultaneous presence of erosions with inflammation was exclusively observed 
in RA patients (specificity 100%). In the age group 40-59 years the specificity was 
91% and it was lower in persons aged ≥60 (specificity 71%) since in this age group 
erosions with inflammation were also observed in healthy controls (Table 5.2). 
Thus the presence of erosions with inflammation was specific for RA, but only if 
aged <60.
Altogether, the presence of grade ≥2 erosions and MTP5-erosions were specific 
for RA in all age groups, erosions with inflammation were specific for RA if aged 
<60 and MTP1-erosions if aged <40. Although these erosion characteristics were 
highly specific for RA only 29% of all RA patients had ≥1 erosion(s) with ≥1 of these 
characteristics.
Table 5.5 Frequencies of erosions in combination with inflammation in MCP and MTP bones of 
symptom free controls and RA patients; analysis on bone level




















RA <40 years 594 7 (32%) 7 (32%) 4 (18%) 4 (18%) 572
40-59 years 1728 28 (39%) 10 (14%) 12 (17%) 21 (30%) 1657
≥60 years 1962 60 (31%) 12 (6%) 65 (34%) 55 (29%) 1770
4284 3999
Control <40 years 918 10 (100%) 0 (0%) 0 (0%) 0 (0%) 908
40-59 years 1620 45 (83%) 2 (4%) 5 (9%) 2 (4%) 1566
≥60 years 936 50 (69%) 7 (10%) 9 (13%) 6 (8%) 864
3474 3338
Values are the number of MCP and MTP bones with erosions and without erosions. MCP and MTP bones 
with erosions are divided in subgroups of erosions without BME and synovitis and with BME and/or 
synovitis. Erosions, BME and synovitis were defined as a score of ≥1 according to the Rheumatoid Arthritis 
Magnetic Resonance Imaging Scoring system. BME, bone marrow edema; MCP, metacarpophalangeal; 
MTP, metatarsophalangeal; RA, rheumatoid arthritis.
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Erosions in MTP5 and grade ≥2 erosions in all age groups and erosions in 
MTP1 if aged <40 remain specific for RA when compared to patients with other 
arthritides
Thus far, different erosion characteristics were compared between RA patients 
and controls revealing some RA-specific characteristics. The next question is 
whether these characteristics are truly RA-specific or are also present in other 
arthritides. Therefore, all analyses were repeated with patients with other 
arthritides as reference group. The total erosion scores of both patient groups were 
not significantly different (beta 0.92 95% CI 0.84-1.01, Figure 5.1B). Comparison of 
the different erosion characteristics showed that the presence of grade ≥2 erosions 
was RA-specific in all age groups (specificity 100% if aged <40 and 96% if aged 40-
59 and ≥60, Table 5.2, Supplementary table 5.3). Also MTP5-erosions were highly 
specific for RA in all age groups (specificity 100% if aged <40, 89% if aged 40-59 
and 90% if aged ≥60, Table 5.2, Supplementary table 5.4). The specificity of MTP1- 
erosions was 93% in patients aged <40 but at higher age specificity decreased to 
66%. Erosions with inflammation were less specific for RA (specificity 49-85% 
within different age groups) as these were also present in other arthritides. Thus, 
erosions with inflammation were not RA-specific, but MTP5-erosions and grade ≥2 
erosions were specific in all age groups and MTP1-erosions in patients aged <40. 
21% of RA patients had ≥1 erosion(s) with these characteristics (sensitivity 21%). 
Additionally, of all patients with erosions with one of these three finally identified 
features, 53% fulfilled criteria for RA (PPV 53%) and of all patients without such 
erosions, criteria were not fulfilled in 62% (NPV 62%).
MRI-detected erosions do not contribute to the identification of UA patients 
that will progress to RA 
Finally, the value of MRI-detected erosions was evaluated within UA patients. Of the 
UA patients, 15% (28/192) fulfilled criteria for RA after one year. Of these patients 
11% had an RA-specific erosion at baseline, whereas 9% of the non-convertors had 
an RA-specific erosion (OR 1.3 95% CI 0.3-4.8).
Discussion
Radiographic erosions specific for RA have been defined as the presence of ≥3 
radiographic erosions on MCP, PIP, wrist or MTP joints and their presence is 
considered sufficiently specific to classify RA.11 MRI is a sensitive imaging modality 
that depicts cortical defects and therefore is suitable to detect erosive damage. 
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Thus far it was unknown which MRI-detected erosions on hand and foot joints 
are specific for RA. This large cross-sectional MRI-study showed that on the group 
level, RA patients had higher MRI-detected erosion scores in MCP and MTP joints 
than controls, but also that there was large overlap on the individual level. Several 
erosion characteristics were studied in detail; this was done within three age 
strata as the total MRI-erosion score was associated with age. Compared to controls 
from the general population, four characteristics were identified as RA-specific: 
grade ≥2 erosions, MTP5-erosions, MTP1-erosions if aged <40 and erosions with 
local inflammation if aged <60. At least one of these characteristics is present in 
29% of RA patients.
Subsequently RA patients were compared to early arthritis patients with other 
diagnoses, because studies comparing established cases and healthy controls will 
reveal the maximal contrast. Differences are often smaller when more clinically 
relevant patient groups are studied.21,22 Indeed we observed that some erosion 
characteristics that were specific for RA when compared to controls were not 
specific when RA was compared with other arthritides. This was most prominent 
for the combined presence of erosions with inflammation. Nonetheless, some 
characteristics (grade ≥2 erosions, MTP5-erosions, MTP1-erosions in persons aged 
<40) were RA-specific in both settings. 21% of RA patients had ≥1 erosion(s) with 
≥1 of these characteristics.
Although some erosion characteristics were identified as RA-specific, an important 
overlap between early RA patients and controls was observed. It has been 
recommended that novel imaging modalities, such as MRI, can be used to detect 
erosions early.1 The present data show that if all MRI-detected erosions (according 
to RAMRIS) would be considered as characteristic for RA or disease, this would 
yield many false-positive results.
We used the RAMRIS-definition of erosions that basically evaluated the volume of 
the erosion in relation to the assessed bone. Others showed that small lesions on 
high-resolution peripheral quantitative computed tomography were not entirely 
specific for RA and suggested that lesions >1.9 mm in diameter were highly 
specific.23,24 It remains to be determined if a phenotypic definition of MRI-erosions, 
for instance one that includes a description of the size of the cortical break, will be 
more discriminative; this is subject of further studies and is also considered within 
an ongoing EULAR taskforce.
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Some of the findings on MRI-detected erosions are in line with previous findings 
on radiographic erosions. Radiographic erosions have been shown to occur 
more frequently at disease onset with higher age.25-31 MTP5 has been shown as 
a predilection site for RA-related erosions as well.32-34 We observed that the large 
majority of erosions (both in RA and in the other groups studied) were located in the 
proximal bone of the joint which is completely in line with previous findings.23,33,35
Erosive lesions in symptom-free controls have also been reported in other 
studies.12 The nature of these lesions is unclear. Because of the association with age, 
degenerative subchondral bone cysts may be one of the explanations. In addition 
a very recent study, evaluating bone microstructure of MCP joints using high-
resolution tomography and microCT, demonstrated that the number of so called 
cortical microchannels (linking the synovial and bone marrow compartments) 
was higher in RA patients than in healthy controls and was associated with 
erosions and with age.36 It is intriguing to speculate that these channels have a 
causal role in erosion development, both in RA and controls. Another possibility 
is that mechanical strains are involved in erosion development, since erosions 
were frequently located in the foot (49% of the erosions in RA patients and 38% 
in symptom-free controls). However, a pathophysiological explanation for the 
findings done in symptom-free persons is beyond the scope of this study.
The location of erosions within the bone was not studied here. This information 
could not be discerned using RAMRIS as this method evaluates the volume of the 
erosive lesion per bone. However, previous studies have shown that the majority 
of erosive MRI-lesions in MCP joints occurred adjacent to the radial collateral 
ligaments, both in RA patients and in healthy controls.37,38 Similar observations 
were done in a study in RA patients and healthy controls on the location of erosions 
as detected on CT.23 The location of erosions in the symptom-free controls that were 
studied here has been reported previously,13 and showed that also in these persons 
erosions were present adjacent to the collateral ligaments and were not situated 
centrally in the bone. Because of these previous reports, showing no difference 
in location of erosions within the bone between RA patients and controls, we 
anticipated that this characteristic will not result in further discrimination of RA-
specific erosions from other erosions.
Cross-sectional analyses revealed that of all patients with an erosion that was 
identified as characteristic for RA 53% actually had RA (PPV). Likewise, 62% of 
all patients without such erosions did not have RA (NPV), whereas 38% did fulfil 
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criteria for RA. These data illustrate that the absence or presence of RA-specific 
erosions at disease presentation are of moderate value to identify patients that 
fulfil criteria for RA at the same point in time.
Longitudinal analysis within UA patients suggested that the presence of RA-specific 
erosions was also not predictive for the development of RA. However, this analysis 
was of limited power. Additionally, other outcomes, such as the start of disease-
modifying antirheumatic drugs (DMARDs), should be studied, since DMARD 
treatment might hamper progression to RA. Finally, it was not possible to study 
the different RA-specific erosion features separately due to the limited number of 
patients. Further studies are warranted.
We studied an early RA-population. 36% of the patients was RF-negative and 
48% were ACPA-negative which is comparable to other early RA cohorts.39,40 Our 
population is somewhat different from RA patients included in clinical trials where 
generally a selection of RA patients is included.
A limitation of this study is that it was cross-sectional in nature and that imaging 
follow-up was not studied. Sensitivity of readers could have been a problem and 
could be equally present in the three groups. The presence of serial MRI-data 
facilitates the differentiation of erosions from vascular channels and entheseal 
attachments, as these should not change during follow-up. Erosions in contrast 
could progress over time, although this progression may also have been hampered 
by up-to-date treatment strategies. Serial MRIs were not made but would have been 
beneficial to evaluate if some erosions were falsely identified as such. However if 
MRI will be used for early identification of patients in clinical practice, single MRI-
measurements will be made.
In conclusion, MRI-detected erosions (according to the RAMRIS definition) in MCP 
and MTP joints are not confined to RA, but also present in other arthritides and in 
symptom-free persons from the general population. On the individual level there 
was a large overlap. Some erosion characteristics were identified as specific for 
RA (grade ≥2 erosions, MTP5-erosions, and MTP1-erosions if aged <40), though 
these occurred in a minority (21%) of the patients. Longitudinal MR-imaging may 
improve specificity; however this was not tested in this study. The present data 
imply that if single measurements with novel imaging modalities such as MRI are 
used for the early detection of structural damage in clinical practice, the risk of 
false-positive findings should be considered.
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Supplementary material
Supplementary methods are available at the website of Annals of the Rheumatic 
Diseases.
Supplementary table 5.1 Median and mean values of the total erosion score in MCP and MTP joints
RA Symptom-free control Other arthritides
Median (IQR) 1.0 (0.4-2.5) 0.5 (0-1.5) 1.0 (0-2.0)
<40 years 0.5 (0-1.3) 0 (0-0.5) 0 (0-0.9)
40-59 years 0.5 (0-1.4) 0.5 (0-1.0) 1 (0-2.0)
≥60 years 2.0 (1.0-3.5) 1.5 (0.5-2.5) 1.5 (0.5-3.0)
Mean (SD) 1.8 (2.4) 0.9 (1.2) 1.3 (1.5)
<40 years 1.0 (1.2) 0.3 (0.5) 0.4 (0.6)
40-59 years 1.2 (1.8) 0.8 (1.0) 1.2 (1.3)
≥60 years 2.5 (2.9) 1.7 (1.5) 1.9 (1.8)
Presented are the median and mean total erosion scores in MCP en MTP joints for RA patients, symptom-
free controls and patients with other arthritides, within different age groups. IQR, interquartile range; 
MCP, metacarpophalangeal; MTP, metatarsophalangeal; RA, rheumatoid arthritis; SD, standard deviation. 
Supplementary table 5.2 Frequencies of erosions with score ≥2 in the MCP and MTP joints of RA 
patients and symptom free controls, depicted per age category (18-39, 40-59, ≥60 years)
Erosions
<40 years 40-59 years ≥60 years
RA Control RA Control RA Control
n=33 n=51 n=96 n=90 n=109 n=52
MCP 2 proximal 0 0 0 0 3 0
distal 0 0 0 0 0 0
MCP 3 proximal 3 0 2 1 3 2
distal 0 0 0 0 0 0
MCP 4 proximal 0 0 0 0 0 0
distal 0 0 0 0 0 0
MCP 5 proximal 0 0 0 0 0 0
distal 0 0 0 0 0 0
MTP 1 proximal 0 0 0 0 3 0
distal 0 0 0 0 1 0
MTP 2 proximal 0 0 1 0 0 0
distal 0 0 0 0 1 0
MTP 3 proximal 0 0 2 0 1 0
distal 0 0 0 0 0 0
MTP 4 proximal 0 0 0 0 0 0
distal 0 0 0 0 0 0
MTP 5 proximal 6 0 1 0 3 0
distal 0 0 1 0 1  0
Values are the percentages of persons with an erosion score of at least 2 of all persons in that age category. 
MCP, metacarpophalangeal joint; MTP, metatarsophalangeal joint; RA, rheumatoid arthritis.
100 
PART I | CHAPTER 5
5
Supplementary table 5.3 Frequencies of RA patients and patients with other arthritides with grade 
≥2 erosions and with erosions with the simultaneous presence of local inflammation in an MCP and/
or MTP joint; analyses on person level
Grade ≥2 erosions Erosions with inflammation










RA <40 years (n=33) 14 11 (79%) 3 (21%) 3 (21%) 11 (79%)
40-59 years (n=96) 39 34 (87%) 5 (13%) 16 (41%) 23 (59%)




<40 years (n=68) 17 17 (100%) 0 (0%) 7 (41%) 10 (59%)
40-59 years (n=146) 74 68 (92%) 6 (8%) 29 (39%) 45 (61%)
≥60 years (n=137) 99 93 (94%) 6 (6%) 29 (29%) 70 (71%)
351
The presence of grade ≥2 erosions and erosions with inflammation (BME and/or synovitis) was evaluated 
per MCP and MTP bone according to the Rheumatoid Arthritis Magnetic Resonance Imaging Scoring system. 
Grade ≥2 indicate that >10% of the bone is eroded. The presence of BME and/or synovitis was defined 
as a score of ≥1. BME, bone marrow edema; MCP, metacarpophalangeal; MTP, metatarsophalangeal; RA, 
rheumatoid arthritis.
Supplementary table 5.4 Location of erosions in bones of the MCP and MTP joints of RA patients and 
patients with other arthritides, depicted per age category (18-39, 40-59, ≥60 years)
Erosions










n=38 n=63 n=112 n=130 n=134 n=112
MCP 2 proximal 5 2 10 6 22 26
distal 0 0 4 2 9 8
MCP 3 proximal 8 8 16 22 31 26
distal 0 2 0 0 4 5
MCP 4 proximal 5 0 3 4 8 6
distal 3 0 0 0 0 4
MCP 5 proximal 0 2 5 5 18 14
distal 0 2 1 0 2 1
MTP 1 proximal 16 8 21 22 36 34
distal 0 6 2 2 10 9
MTP 2 proximal 0 2 2 2 3 3
distal 3 0 0 1 4 1
MTP 3 proximal 0 0 2 1 4 1
distal 0 0 0 2 1 1
MTP 4 proximal 3 0 3 2 1 0
distal 0 0 0 0 0 1
MTP 5 proximal 21 0 11 10 15 10
distal 0 0 2 0 1 0
Values are the percentages of patients with an erosion of all patients in that age category. The presence of 
an erosion is defined as an erosion score of at least 1 in that bone. MCP, metacarpophalangeal joint; MTP, 
metatarsophalangeal joint; RA, rheumatoid arthritis.
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Evaluation of the predictive 
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undifferentiated arthritis
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Radiographic erosions are a clear hallmark of rheumatoid arthritis (RA). The 
European League Against Rheumatism (EULAR) definition of radiographic erosive 
disease has a high specificity, and its fulfilment alone is sufficient to classify RA.1 
However, the sensitivity of radiography to detect erosions early in the disease is low. 
Other imaging techniques, such as magnetic resonance imaging (MRI), are more 
sensitive to detect erosions than radiography and are therefore recommended 
by a EULAR imaging task force.2 To determine the specificity of MRI-detected 
erosions, we recently compared erosions in the metacarpophalangeal (MCP) and 
metatarsophalangeal (MTP) joints (scored according to the RA MRI Scoring System 
(RAMRIS)3) of patients presenting with RA with those of symptom-free persons 
and patients presenting with arthritides other than RA.4 MRI-detected erosions 
were present in all groups; therefore, the specificity of the presence of any MRI-
detected erosions was low. By evaluating different erosion features, a few features 
were identified as specific for RA; these were severe erosions (grade ≥2, defined 
as >10% of bone eroded), erosions in MTP5 and erosions in MTP1 in persons 
aged <40. A subsequent and clinically relevant question is whether MRI-detected 
erosions in patients presenting with undifferentiated arthritis (UA) are valuable 
in predicting future progression to RA. This was explored to a limited extent in 
our previous study but as the number of patients with UA was limited (n=192), 
the predictive value of the different ‘RA-specific erosions’ could not be studied. In 
addition, the outcome was fulfilment of classification criteria but start of disease-
modifying antirheumatic drugs (DMARDs) was not considered, while DMARD 
treatment might have hampered progression to fulfilment of RA classification 
criteria. Finally, MRI-detected erosions were only evaluated in the MCP and MTP 
joints and not in wrist joints, while erosions in the wrist are prevalent. To evaluate 
the predictive accuracy of MRI-detected erosions more thoroughly, we continued 
with a larger longitudinal study. In order to also include erosions in the wrist, we 
also performed a cross-sectional comparison between patients with early RA and 
patients with other arthritides to search for erosion features of wrist joints which 
are RA specific.
All studied patients were consecutively included in the Leiden Early Arthritis Clinic 
cohort. Inclusion required the presence of clinically confirmed inflammatory 
arthritis and symptom duration less than 2 years.5 At baseline 1.5T MRI of the 2nd-
5th MCP, wrist and 1st-5th MTP joints was performed as described.4 Erosions were 
scored on a scale 0–10 according to the RAMRIS system.3 Wrist erosions specific 
for RA were assessed by performing cross-sectional comparisons of MRI-detected 
erosions in the wrist in 238 patients with RA and 351 patients with other arthritides 
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who were included between 2010 and 2014; the number, location and severity 
of erosions as well as concomitant bone marrow edema (BME) were evaluated. 
Thereafter, the predictive value of MRI-detected erosions in MCP, wrist and MTP 
joints in 286 patients with UA (using the 2010 criteria to classify RA), included 
between 2010 and 2016, was evaluated. The predictive accuracy of the presence of 
any MRI-detected erosions, defined as score ≥1 by both readers, as well as of the 
presence of RA-specific erosions (as defined previously for MCP and MTP joints or 
as studied here for the wrist) was assessed.4
Ninety-four per cent of the 286 2010-UA patients were anti-citrullinated protein 
antibody (ACPA)-negative (Supplementary table 6.1), which is in line with other 
descriptions of the population of 2010-UA patients.6,7 Patients were followed for 
1 year on RA development, defined as fulfilling the 2010 criteria or the start of 
DMARDs because of a clinical diagnosis of RA. The latter was added as ACPA-
negative patients need >10 involved joints to fulfil the 2010 criteria which could 
be hampered by DMARD treatment. One hundred and twenty-eight (45%) patients 
with UA developed the outcome, of which 111 had a clinical diagnosis of RA and 
started DMARDs and 17 fulfilled the 2010 criteria.
First, we searched for MRI-detected wrist erosions that were specific for RA. The 
median total number of erosions in the wrist was 1.0 (IQR 0–3.0) for patients with 
RA and 1.0 (IQR 0–2.0) for patients with other arthritides (Mann-Whitney U test: 
p=0.82). Severe erosions, defined as grade ≥2, were infrequent and present at a 
similar rate in patients with RA and patients with other arthritides (5% and 6%, 
respectively; Supplementary table 6.2). With respect to the location, erosions 
were most frequently observed in the capitate, triquetrum, lunate and scaphoid, 
especially at increasing age of onset; however, the frequency was not different in 
patients with RA and patients with other arthritides (Supplementary table 6.3). 
Finally, the combined presence of erosions with BME within the same bone was 
evaluated. This combination was more prevalent with increasing age of onset, 
but frequencies were comparable in both groups (30% of both patients with 
RA and patients with other arthritides, Supplementary table 6.2). Altogether, no 
RA-specific features of MRI-detected erosions located in the wrist could be 
identified.
Next, the predictive value of MRI-detected erosions was evaluated in patients 
with UA. Any MRI-detected MCP and MTP erosions were present in 49% of the 
286 patients with UA and were not predictive for RA development (OR 1.2, 95% CI 
0.8 to 2.0, PPV 48%, Table 6.1). RA-specific erosions were present in only 7% of the 
2010-
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UA patients and were also not associated with development of RA (OR 0.6, 95% CI 
0.2 to 1.5, PPV 33%). Similar findings were obtained for the individual ‘RA-specific 
erosions’ (Table 6.1). Any MRI-detected wrist erosions were present in 61% of the 
patients with UA and were also not predictive for RA development (OR 1.5, 95% CI 
0.9 to 2.4, PPV 49%). Sensitivity analyses stratified for the outcome (DMARD start or 
only 2010 criteria positive) revealed similar results (data not shown).
This is the largest longitudinal dataset on MRI-detected erosions in hand and foot 
joints in UA to date. In all analyses, MRI-detected erosions were not associated 
with an increased risk on RA. Although MRI is sensitive to detect the presence of 
erosions, the present data suggest that evaluation of MRI-detected erosions in UA 
is not relevant for the early detection of RA.
Table 6.1 Predictive values of MRI-detected erosions within 2010-UA patients for the development 
of RA
Patients with UA with 











Any MRI-detected erosion in 

































Grade ≥2 erosion in MCP and/
or MTP joint




















Erosion in MTP1 and aged 
<40








The prior risk for development of RA and/or DMARD use within 1 year was 45%. Any MRI-detected erosion 
was defined as score ≥1 by both readers according to the RA MRI Scoring System. Any RA-specific erosion 
was defined on MRI as the presence of a grade ≥2 erosion in an MCP and/or MTP joint, an erosion in MTP5 
and/or an erosion in MTP1 in the age group <40 years, as described earlier (Boeters et al. ARD 2018). CI, 
confidence interval; DMARD, disease-modifying antirheumatic drug; NPV, negative predictive value; PPV, 
positive predictive value; RA, rheumatoid arthritis.
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Supplementary material
Supplementary table 6.1 Baseline characteristics of the total group of patients with undifferentiated 
arthritis and the subgroups of patients with and without progression to rheumatoid arthritis
All patients with 
2010-UA
(n=286)
Subgroup of UA 
patients with 
progression to RA 
(n=128)
Subgroup of UA 
patients without 
progression to RA 
(n=158)
Age in years, mean (SD) 55 (16) 58 (16) 52 (15)
Female, n(%) 174 (61) 72 (56) 102 (65)
Symptom duration in weeks, median (IQR) 8 (4-21) 10 (5-25) 7 (3-16)
66-SJC, median (IQR) 2 (1-4) 3 (2-6) 2 (1-3)
68-TJC, median (IQR) 3 (1-7) 5 (2-8) 2 (1-5)
CRP (mg/ml), median (IQR) 4 (3-11) 7 (3-16) 3 (3-6)
RF positivity, n(%) 32 (11) 18 (14) 14 (9)
ACPA positivity, n(%) 24 (8) 20 (16) 4 (3)
Any MRI-detected erosion 152 (53) 71 (55) 81 (51)
Any RA-specific erosion 21 (7) 7 (5) 14 (9)
Grade ≥2 5 (2) 2 (2) 3 (2)
Erosion in MTP5 16 (6) 7 (5) 9 (6)
Erosion in MTP1 and aged <40 2 (1) 0 (0) 2 (1)
Presented are numbers (percentages). Any MRI-detected erosion was defined as score ≥1 by both readers 
according to the Rheumatoid Arthritis MRI Scoring System. Any RA-specific erosion was defined on MRI 
as the presence of a grade ≥2 erosion, an erosion in MTP5 and/or an erosion in MTP1 in the age group 
<40 years, as described earlier (Boeters et al. ARD 2018). ACPA, anti-citrullinated protein antibodies; CRP, 
C-reactive protein; IQR, interquartile range; MRI, magnetic resonance imaging; MTP, metatarsophalangeal 
joint; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, 66-swollen joint count; SD, standard deviation; 
TJC, 68-tender joint count; UA, undifferentiated arthritis; DMARD, disease-modifying antirheumatic drug. 
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Supplementary table 6.2 Frequencies of RA patients and controls with grade ≥2 erosions and with 
erosions with the simultaneous presence of local bone marrow edema in the wrist
Grade ≥2 erosions Erosions with BME











RA <40 years (n=33) 8 7 (87.5%) 1 (12.5%) 6 (75%) 2 (25%)
40-59 years (n=96) 60 57 (95%) 3 (5%) 38 (63%) 22 (37%)
≥60 years (n=109) 91 84 (92%) 7 (8%) 34 (37%) 57 (63%)
238
Other <40 years (n=68) 16 15 (94%) 1 (6%) 11 (69%) 5 (31%)
arthritides 40-59 years (n=146) 95 90 (95%) 5 (5%) 64 (67%) 31 (33%)
≥60 years (n=137) 113 97 (86%) 16 (14%) 53 (47%) 60 (53%)
351
The presence of grade ≥2 erosions and erosions with BME was evaluated per wrist bone according to the 
Rheumatoid Arthritis Magnetic Resonance Imaging Scoring system. Grade ≥2 indicates that >10% of the 
bone is eroded. The presence of BME was defined as a score of ≥1 by both readers. BME, bone marrow 
edema; RA, rheumatoid arthritis.
Supplementary table 6.3 Location of erosions in bones of the wrist of RA patients and patients with 
other arthritides, depicted per age category (18-39, 40-59, ≥60 years)










 n=33 n=68 n=96 n=146 n=109 n=137
basis metacarpal 1 3 3 6 6 23 27
basis metacarpal 2 0 0 2 2 9 7
basis metacarpal 3 3 0 3 2 3 4
basis metacarpal 4 0 0 1 1 6 4
basis metacarpal 5 0 0 1 2 1 1
hamate 6 0 8 10 19 17
capitate 9 6 21 23 36 36
trapezoid 6 6 8 10 12 18
trapezium 3 0 5 9 24 28
pisiform 3 0 4 5 6 4
triquetrum 6 3 16 19 27 27
lunate 0 6 13 21 27 28
scaphoid 0 4 18 16 29 35
distal ulna 3 3 7 11 23 18
distal radius 3 0 5 3 10 9
Values are the percentages of persons with an erosion of all persons in that age category. The presence of 
an erosion is defined as a score of ≥1 in that bone by both readers. RA, rheumatoid arthritis. 
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Clinical and imaging features 
and the ACPA response
PART II

MRI-detected osteitis is not 
associated with the presence 
or level of ACPA alone, but 
with the combined presence 
of ACPA and RF







Leendert A. Trouw 




In rheumatoid arthritis (RA) bone marrow edema (BME, osteitis) and anti-
citrullinated protein antibodies (ACPA) are associated with radiographic 
progression. ACPA have been associated with BME, but it is unknown if this 
association is confined to ACPA and BME. We performed cross-sectional analysis 
of the association of ACPA, rheumatoid factor (RF) and anti-carbamylated protein 
(anti-CarP) antibodies with BME and other types of inflammation (synovitis, 
tenosynovitis) detected by magnetic resonance imaging (MRI). 
Methods
Disease-modifying antirheumatic drug (DMARD)-naïve patients with early 
arthritis (n=589), included in the Leiden Early Arthritis Clinic cohort, underwent 
contrast-enhanced 1.5T MRI of unilateral wrist, metacarpophalangeal and 
metatarsophalangeal joints at baseline. BME, synovitis and tenosynovitis were 
scored by two readers. ACPA, RF and anti-CarP antibodies were determined at 
baseline. 
Results
In univariable analyses ACPA-positive patients had higher BME scores than 
ACPA-negative patients (median 4.5 vs. 2.0, p<0.001), but not more synovitis and 
tenosynovitis. Also RF (median 3.75 vs. 2.0, p<0.001) and anti-CarP antibodies 
(median 3.5 vs. 2.5, p=0.012) were associated with higher BME scores. Because 
the autoantibodies were concomitantly present, analyses were stratified for the 
presence of different autoantibody combinations. ACPA+ RF- anti-CarP- patients 
did not have higher BME scores than ACPA- RF- anti-CarP- patients. However 
ACPA+ RF+ anti-CarP- patients and ACPA+ RF+ anti-CarP+ patients had higher BME 
scores than ACPA- RF- anti-CarP- patients (median 5.0 and 4.5 vs. 2.0, p<0.001 and 
p<0.001). ACPA levels were not associated with BME scores. Analyses within RA 
and UA patients revealed similar results. 
Conclusions
The presence of ACPA alone or ACPA level was not statistically significantly 
associated with BME scores, but the combined presence of ACPA and RF was 
associated with more BME. This suggests an additive role of RF to ACPA in 
mediating osteitis. 
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Background
Rheumatoid arthritis (RA) is characterized by chronic inflammation of the joints 
that may result in progressive structural damage. Magnetic resonance imaging 
(MRI) detects inflammation sensitively.1 Whereas synovitis and tenosynovitis can 
also be evaluated by other imaging modalities, such as ultrasound, MRI is the 
only modality that depicts bone marrow edema (BME). Histopathology studies 
in RA have shown that BME lesions consist of infiltration by leucocytes and an 
increased number of osteoclasts.2-4 Therefore, BME has also been named osteitis. 
These data suggest a link between BME and structural damage in RA. Indeed, the 
importance of BME is supported by several studies showing that BME is a predictor 
of radiographic evidence of progression.5-13 A recent study even showed that the 
persisting presence of BME is associated with an odds ratio of 60 for erosive 
progression at the same location.14
In addition to BME, anti-citrullinated protein antibodies (ACPA) are also a strong 
predictor of radiographic progression.15-23 Up to two-thirds of patients with RA 
harbor ACPA, as has been known for many years.24 However, the underlying 
mechanism linking ACPA with a more severe disease progression with increased 
joint destruction is incompletely elucidated. Recent data suggest that ACPA 
influences bone resorption by directly activating osteoclasts.25 The combination of 
these findings lead us to hypothesize that ACPA are associated with BME.
Other studies, including a small study that we performed previously suggest 
there is association between BME and ACPA.26,27 However, ACPA are often 
simultaneously present with other RA-related autoantibodies such as rheumatoid 
factor (RF) and anti-carbamylated protein (anti-CarP) antibodies (which also have 
been associated with radiographic destruction).28-30 To our knowledge the effects 
of different autoantibodies (either alone or in combination) on BME are unknown. 
Furthermore, the association between different autoantibodies and other types 
of inflammation detected by MRI (synovitis and tenosynovitis) has never been 
thoroughly explored. Therefore, this cross-sectional study aimed to investigate 
the associations of ACPA, RF and anti-CarP antibodies with BME, synovitis and 
tenosynovitis.
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The 589 patients with early arthritis were consecutively included in the Leiden 
Early Arthritis Clinic (EAC) between 2010 and 2014. The EAC is an inception cohort 
that includes patients attending the rheumatologist who present with clinically 
confirmed arthritis and symptom duration of <2 years. Patients were disease-
modifying antirheumatic drug (DMARD)-naïve at inclusion. The cohort started 
in 1993. MRI was performed from 2010 onwards; 598 patients underwent MRI, 
and 9 were excluded from analysis because no contrast agent was administered. 
The median interval between inclusion in the study and MRI was 1.3 weeks. 
Questionnaires were administered, and joint counts and blood samples were 
collected at baseline.31 Baseline serum samples were tested for ACPA (anti-CCP2, 
Eurodiagnostica, Arnhem, the Netherlands, cut-off value ≥7 U/ml), IgM RF (as 
described previously, in-house ELISA32) and IgG anti-CarP antibodies against 
carbamylated fetal calf serum (FCS). Anti-CarP antibodies were determined as 
described previously;28 the cut-off for positivity for anti-CarP antibodies was 
based on the mean plus two times the standard deviation from a set of 204 healthy 
controls. One year after presentation, 183 patients fulfilled the 1987 criteria for 
RA,33 214 had undifferentiated arthritis (UA) and 192 had other forms of arthritis, 
including psoriatic arthritis, reactive arthritis and others (Table 7.1).
Magnetic resonance imaging and scoring 
At baseline, MRI was performed of the metacarpophalangeal (MCP), wrist and 
metatarsophalangeal (MTP) joints on the most painful side or on the dominant side 
in the case of symmetric symptoms. MRI was performed using an MSK Extreme 1.5T 
extremity MRI system. In the wrist and MCP joints a coronal T1-weighted sequence 
was acquired before intravenous injection of contrast agent (gadoteric acid). Post-
contrast, coronal and axial T1-weighted sequences with frequency-selective fat 
saturation were obtained. The forefoot was scanned using a T1-weighted sequence 
and a T2-weighted fat-saturated sequence in the axial plane. The protocol was 
shortened after 371 patients had been imaged.34 For post-contrast imaging of the 
foot in the remaining 218 patients, T1-weighted, fat-saturated sequences were 
obtained in the coronal and axial plane and the T2-weighted sequence was deleted. 
A more detailed description of the scan protocol is provided elsewhere14,35,36 and in 
the online Supplementary methods. 
BME and synovitis were scored semi-quantitatively according to the rheumatoid 
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arthritis MRI scoring system (RAMRIS),37 with the exception that BME was assessed 
on a contrast-enhanced T1-weigthed fat-suppressed sequence. Previous studies 
have shown that T2-weighted fat-saturated sequences and contrast-enhanced T1-
weighted fat-saturated images perform equally well in the depiction of BME,34,38,39 
and according to the European Society of Musculoskeletal Radiology (ESSR), both 
sequences can be used to evaluate BME.40 The T1-sequence was used as it allowed a 
shorter scan time. In addition, tenosynovitis in the wrist and MCP joints was scored 
according to the method proposed by Haavardsholm et al.,41 with tenosynovitis 
assessed for the flexor and extensor tendons of MCP joints 2-5 using the same scale 
of 0-3 as for the wrist. MR images were scored by two readers blinded to any clinical 
data. The mean total scores of both readers for BME, synovitis and tenosynovitis 
were used in further analyses. The intra-reader class correlation coefficients for 
the total inflammation score based on 40 MR images that were scored twice, were 
0.98 and 0.93, respectively. Based on all 598 scans, the interreader class correlation 
coefficient for the total inflammation score was 0.95. 
Sensitivity analyses 
Our primary analyses were performed in all 589 early arthritis patients, as we 
hypothesized that direct association between autoantibodies and MRI-detected 
inflammation, if present, would be independent of the clinical diagnosis. 
However, analyses were repeated in the subgroup of 397 patients classified with 
UA or RA according to the 1987 American College of Rheumatology (ACR) criteria. 
Patients who had UA after one year were included in these analyses because 
misclassification could have occurred due to DMARD treatment during the first 
year that could have hampered progression to fulfilling the 1987 criteria for RA. 
As some of these patients with UA would have progressed to RA without treatment 
(but now remain unclassified), we also studied the patients with UA. 
Statistical analysis 
The t test, multivariable linear regression, and multivariable logistic regression 
were used for analysis as appropriate. In multivariable linear regression analysis, 
the BME scores were log10-transformed (log10(score+1)) to approximate a 
normal distribution. For interpretation, the obtained effect size (beta) was back-
transformed to the normal score. All models were adjusted for age, gender and 
symptom duration. Baseline data on ACPA, RF and anti-CarP antibodies were 
dichotomized (seropositive vs. seronegative). Anti-CarP data were missing for 16 
patients. ACPA and RF status was known for all patients. To determine the effect 
of ACPA levels on BME, baseline ACPA was categorized into three groups within 
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ACPA-positive patients based on the range of ACPA values (low, intermediate, or 
high); the thresholds were: ≥7 U/ml, ≥167 U/ml and ≥327 U/ml. P-values <0.05 were 
considered significant. Analyses were performed using SPSS version 23.0 (IBM). 
Results
Baseline characteristics 
Baseline characteristics of the 589 patients are presented in Table 7.1.
Table 7.1 Baseline characteristics of the total group of early arthritis patients studied and the 
subgroups of patients with RA or UA
Variable All patients with early arthritis 
(n=589) 
Subgroup of patients with RA 
or UA (n=397) 
Age, mean (sd) 54.8 (16) 54.9 (15)
Female, n (%) 363 (62) 253 (64)
Symptom duration, median (IQR), weeks 12.6 (5-27) 12.2 (5-26.2)
TJC, median (IQR) 4 (2-7) 4 (2-6)
SJC, median (IQR) 3 (2-7) 3 (2-7)
CRP (mg/L), median (IQR) 5.7 (3-17) 6 (3-17)
ACPA positivity, n (%) 141 (24) 123 (31)
RF positivity, n (%) 193 (33) 151 (38)
Anti-CarP positivity, n (%) 88 (15) 71 (18)
Total RAMRIS, median (IQR) 12.5 (5.5-24) 13.5 (6-24)
Total BME score, median (IQR) 2.5 (1-6) 2.5 (1-6)
Total synovitis score, median (IQR) 3.5 (1-7.5) 4 (1.5-8)
Total tenosynovitis score, median (IQR) 2 (0-6) 3 (0.5-6)
The diagnoses of the 589 patients with early arthritis were: 183 RA (according to the 1987 RA criteria), 
214 UA, 14 reactive arthritis, 14 gout, 2 pseudogout, 30 psoriatic arthritis, 35 inflammatory osteoarthritis, 
4 Lyme’s arthritis, 1 paramalignant arthritis, 3 systemic lupus erythematosus, 11 other systemic 
disorder, 7 mixed connective tissue disease, vasculitis, 4 sarcoidosis, 9 spondyloarthritis, 8 remitting 
seronegative symmetrical synovitis with pitting edema, and 50 other unspecified conditions. ACPA, anti-
citrullinated protein antibodies; anti-CarP, anti-carbamylated protein antibodies; CRP, C-reactive protein; 
IQR, interquartile range; n, number of patients; RA/UA, subgroup of patients with rheumatoid arthritis 
(according to the 1987 RA criteria) or undifferentiated arthritis; RF, rheumatoid factor; sd, standard 
deviation; SJC, 66-swollen joint count; symptom duration, time between symptom onset and inclusion in 
cohort; TJC, 68-tender joint count. 
ACPA is associated with BME at baseline 
We first evaluated whether patients with ACPA (n=141) or without ACPA (n=448) 
had differences in BME scores (Figure 7.1A). ACPA-positive patients had higher 
BME scores (median=4.5) than ACPA-negative patients (median=2.0, p<0.001). We 
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subsequently questioned whether ACPA is also associated with other types of MRI-
detected inflammation, i.e., synovitis and tenosynovitis. There were no statistically 
significant differences in synovitis or tenosynovitis scores in ACPA-positive and 
ACPA-negative patients (Figure 7.1A). Similar results were obtained for BME when 
only patients with RA and UA were studied (ACPA-positive median=3.5, ACPA-
negative median=2.0, p=0.001) and no statistically significant differences were 
observed for synovitis and tenosynovitis (Supplementary figure 7.1A). Based on 
these data ACPA seemed to be primarily associated with BME.
Figure 7.1 Illustration of the association between anti-citrullinated protein antibodies (ACPA) (A), 
rheumatoid factor (RF) (B) and anti-carbamylated protein antibodies (anti-CarP) (C), and magnetic-
resonance-imaging-detected bone marrow edema (BME), synovitis and tenosynovitis scores in early 
arthritis (n=589)
Horizontal lines represent median. Whiskers show the 10th-90th percentile. Dots represent outliers. 
(A) BME: p≤0.001; synovitis: p=0.084; tenosynovitis: p=0.064. (B) BME: p≤0.001; synovitis: p=0.001; 
tenosynovitis: p=0.004. (C) BME: p≤0.012; synovitis: p=0.021; tenosynovitis: p=0.013. Total score: sum of 
scores in metacarpophalangeal, wrist, and metatarsophalangeal joints. *Significant difference (p<0.05) 
between autoantibody-negative and autoantibody-positive patients.
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RF and anti-CarP antibodies are also associated with BME 
We were also interested in whether RF and anti-CarP antibodies are also 
associated with more severe BME. The BME scores were higher in RF-positive 
patients (median=3.75) compared to RF-negative patients (median=2.0, p<0.001, 
Figure 7.1B). Similarly, BME scores were also higher in anti-CarP-positive than 
in anti-CarP-negative patients (median=3.5 vs. 2.5, p=0.012, Figure 7.1C). Besides 
BME, synovitis and tenosynovitis scores were also higher in RF-positive than in 
RF-negative patients (synovitis: median 4.5 vs. 3.0, p=0.001; tenosynovitis: median 
3.5 vs. 1.5, p=0.004). Synovitis and tenosynovitis scores were also higher in anti-
CarP-positive than in anti-CarP-negative patients (synovitis: median=4.75 vs. 3.5, 
p=0.021; tenosynovitis: median=4.25 vs. 1.5, p=0.013). In patients with RA and 
UA only the BME scores were significantly higher in RF-positive (RF+) or anti-
CarP-positive (anti-CarP+) patients, but synovitis and tenosynovitis scores were 
not statistically significantly different (BME: RF+ median=3.5, RF-negative (RF-) 
median=2.0, p=0.002; anti-CarP+ median=3.5, anti-CarP-negative (anti-CarP-) 
median=2.5, p=0.017, Supplementary figure 7.1B, C).
Patients can concurrently have BME, synovitis, and tenosynovitis. To unravel the 
independent association between RF and BME, synovitis, and tenosynovitis scores, 
multivariable logistic regression analysis was performed with RF as the dependent 
variable and BME, synovitis, and tenosynovitis as independent variables. The 
same was done with anti-CarP antibodies as the dependent variable. In early 
arthritis, only the BME score was independently associated with RF (p<0.001) or 
with anti-CarP antibodies (p=0.003). Similar results were observed in the subgroup 
of patients with RA or UA, in whom only BME was associated with RF (p<0.001) 
or with anti-CarP antibodies (p=0.001). Thus, these multivariable analyses suggest 
that the BME score is independently associated with RF or anti-CarP antibodies, 
in contrast to the synovitis and tenosynovitis scores. Because of this result, and 
because it was observed that there was an association between BME and ACPA, 
subsequent analyses focused on BME.
ACPA and RF are both independently associated with BME 
Patients frequently have a combination of different types of inflammation, and also 
concomitantly have the three autoantibodies. For more insight into the relationship 
between the different autoantibodies and BME, multivariable linear regression 
analysis was performed with BME as the outcome and the three autoantibodies 
as independent variables. Both ACPA and RF were significantly associated with 
BME (ACPA: p=0.015, beta=1.33, indicating that ACPA-positive (ACPA+) patients 
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had 33% higher BME scores than ACPA-negative (ACPA-) patients; RF: p=0.004, 
beta=1.31, indicating that RF+ patients had 31% higher BME scores than RF- 
patients). Additional adjustments for CRP and SJC produced similar results (ACPA: 
p=0.009, beta=1.36; RF: p=0.001, beta=1.36). In a similar analysis in the subgroup of 
patients with RA and UA, there was a trend towards significance for ACPA (p=0.091, 
beta=1.26) and a significant result for RF (RF: p=0.022, beta=1.31). Thus, together 
these data indicated that ACPA and RF are independently associated with BME 
scores.
Combined presence of ACPA and RF is associated with BME 
The multivariable analyses described above did not evaluate different effects for 
combinations of antibodies. Different autoantibody combinations were compared 
for more insight into the effect of individual antibodies and a combination of 
antibodies on BME (Figure 7.2). In the absence of both RF and anti-CarP antibodies, 
ACPA was not associated with BME (ACPA+ RF- anti-CarP- patients vs. ACPA- RF- 
anti-CarP- patients, median 1.0 vs. 2.0, p=0.43). Also the presence of RF or anti-CarP 
antibodies alone was not associated with BME (ACPA- RF+ anti-CarP- patients and 
ACPA- RF- anti-CarP+ patients vs. ACPA- RF- anti-CarP- patients, median 2.5 and 1.5 
vs. 2.0 respectively, p=0.096 and p=0.43). However ACPA+ RF+ anti-CarP- patients 
and ACPA+ RF+ anti-CarP+ patients did have significantly higher BME scores than 
ACPA- RF- anti-CarP- patients (median 5.0 and 4.5 vs. 2.0 respectively, p<0.001 and 
p<0.001). The same analysis in only RA and UA patients showed that ACPA+ RF+ 
anti-CarP- patients and ACPA+ RF+ anti-CarP+ patients had higher BME scores than 
ACPA- RF- anti-CarP- patients (median 4.5 and 4.5 vs. 2.0 respectively, p<0.001 and 
p<0.001, Figure 7.3). Thus only the combined presence of ACPA and RF (with or 
without the presence of anti-CarP antibodies) was associated with higher BME 
scores.
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Figure 7.2 Bone marrow edema (BME) scores in patients with early arthritis (n=589) with different 
combinations of anti-citrullinated protein antibodies (ACPA), rheumatoid factor (RF) and anti-
carbamylated protein antibodies (anti-CarP)
Horizontal lines represent median. Whiskers show the 10th-90th percentile. Dots represent outliers. ACPA+ 
RF+ anti-CarP- patients vs. ACPA- RF- anti-CarP- patients, p<0.001; ACPA+ RF+ anti-CarP+ patients vs. ACPA- 
RF- anti-CarP- patients, p<0.001. ACPA- RF- anti-CarP- patients, n=353; ACPA- RF+ anti-CarP- patients, n=68; 
ACPA+ RF- anti-CarP- patients, n=15; ACPA+ RF+ anti-CarP- patients, n=48; ACPA- RF- anti-CarP+ patients, 
n=11; ACPA- RF+ anti-CarP+ patients, n=3; ACPA+ RF- anti-CarP+ patients, n=5; ACPA+ RF+ anti-CarP+ 
patients, n=69. Total score: sum of BME scores in metacarpophalangeal, wrist, and metatarsophalangeal 
joints. *Significant difference (p<0.05) between subgroups.
ACPA level is not associated with BME 
In general, patients who carry different RA-related autoantibodies also have 
higher levels of ACPA.42 In our present data we also observed higher ACPA levels 
in patients who also carried RF and anti-CarP antibodies (ACPA+ RF- anti-CarP- 
patients median 116 U/ml, ACPA+ RF+ anti-CarP- patients median 155 U/ml, ACPA+ 
RF- anti-CarP+ patients median 92 U/ml, ACPA+ RF+ anti-CarP+ patients median 
257 U/ml, p=0.020). This prompted us to explore whether the combined presence 
of ACPA and RF with higher BME scores could be explained by higher ACPA levels. 
To investigate the association between BME and ACPA levels, ACPA were studied 
as continuous data (Supplementary figure 7.2) and divided into three subgroups. 
The BME scores observed in these ACPA categories were not different (Figure 7.4). 
Similarly, no differences were observed when analyzing the BME scores in relation 
to ACPA levels in patients with RA and UA (Supplementary figure 7.3). These data 
suggest that it is the combined presence of ACPA and RF that is associated with 
BME, rather than ACPA levels.
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Figure 7.3 Bone marrow edema (BME) scores in patients with rheumatoid arthritis (RA) and 
undifferentiated arthritis (UA) (n=397) with different combinations of anti-citrullinated protein 
antibodies (ACPA), rheumatoid factor (RF) and anti-carbamylated protein antibodies (anti-CarP)
Horizontal lines representing median. Whiskers show the 10th-90th percentile. Dots represent outliers. 
ACPA+ RF+ anti-CarP+ patients vs. ACPA- RF- anti-CarP- patients, p<0.001; ACPA+ RF+ anti-CarP- patients 
vs. ACPA- RF- anti-CarP- patients, p<0.001. ACPA-, RF-, anti-CarP- patients, n=217; ACPA- RF+ anti-CarP- 
patients, n=43; ACPA+ RF- anti-CarP- patients, n=14; ACPA+ RF+ anti-CarP- patients, n=42; ACPA- RF- anti-
CarP+ patients, n=6; ACPA- RF+ anti-CarP+ patients, n=1; ACPA+ RF- anti-CarP+ patients, n=3; ACPA+ 
RF+ anti-CarP+ patients, n=61. Total score: sum of BME scores in metacarpophalangeal, wrist, and 
metatarsophalangeal joints. *Significant difference between subgroups (p<0.05).
Figure 7.4 Bone marrow edema (BME) scores in anti-citrullinated protein antibodies (ACPA)-positive 
patients with early arthritis (n=141) with low, intermediate, or high levels of ACPA 
Horizontal lines represent median. Whiskers show the 10th-90th percentile. Dots represent outliers. Baseline 
ACPA is shown categorically as low, intermediate, or high. The groups were as follows: low ≥7 U/ml, 
intermediate ≥167 U/ml and high ≥327 U/ml. Low: n=64; intermediate: n=32; high: n=45. Kruskal-Wallis 
test, p=0.14.
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Combined presence of ACPA, RF and anti-CarP antibodies is associated with 
synovitis and tenosynovitis 
The analyses focused on BME as the different autoantibodies were not associated 
with synovitis or tenosynovitis scores in univariable analyses (for ACPA) or in 
multivariable analyses (for RF and anti-CarP antibodies). However, having observed 
that higher BME scores were primarily associated with the combined presence 
of ACPA and RF (and not with the presence of a single antibody), we reasoned 
that it might also be possible that antibodies were not individually associated with 
synovitis or tenosynovitis scores, but that some combinations of autoantibodies 
were associated with synovitis or tenosynovitis scores. To study this, we finally 
assessed the association between different combinations of autoantibodies and 
synovitis and tenosynovitis (Figure 7.5). ACPA+ RF+ anti-CarP+ patients had higher 
synovitis scores than ACPA- RF- anti-CarP- patients (median 5.0 vs. 3.0, p=0.001). 
For tenosynovitis, ACPA+ RF+ anti-CarP+ patients had higher scores than ACPA-
RF- anti-CarP- patients (median 4.5 vs. 1.0, p<0.001), and ACPA+ RF+ anti-CarP+ 
patients had higher scores than ACPA+ RF+ anti-CarP- patients (median 4.5 vs. 3.5 
p=0.039). Thus, the combined presence of ACPA, RF and anti-CarP antibodies was 
associated with the highest synovitis and tenosynovitis scores.
Figure 7.5 Scores for synovitis detected by magnetic resonance imaging (A) and tenosynovitis (B) 
in patients with early arthritis (n=589) with different combinations of anti-citrullinated protein 
antibodies (ACPA), rheumatoid factor (RF) and anti-carbamylated protein antibodies (anti-CarP)
Horizontal lines represent median. Whiskers show the 10th-90th percentile. Dots represent outliers. 
Synovitis: ACPA+ RF+ anti-CarP+ patients vs. ACPA- RF- anti-CarP- patients, p<0.001. Tenosynovitis: ACPA+ 
RF+ anti-CarP+ patients vs. ACPA- RF- anti-CarP- patients, p<0.001; ACPA+ RF+ anti-CarP+ patients vs. ACPA+ 
RF+ anti-CarP- patients, p=0.039. ACPA- RF- anti-CarP- patients, n=353; ACPA- RF+ anti-CarP- patients, n=69; 
ACPA+ RF- anti-CarP- patients, n=15; ACPA+ RF+ anti-CarP- patients, n=48; ACPA- RF- anti-CarP+ patients, 
n=11; ACPA- RF+ anti-CarP+ patients, n=3; ACPA+ RF- anti-CarP+ patients, n=5; ACPA+ RF+ anti-CarP+ 
patients, n=69. Total score: sum of scores in metacarpophalangeal, wrist, and metatarsophalangeal joints. 
*Significant difference between subgroups (p<0.05).
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Discussion 
The relationship between ACPA and other RA-related autoantibodies and BME 
was subject of this study. We showed that ACPA, RF and anti-CarP antibodies were 
all associated with BME in univariable analyses. However, when the different 
autoantibody combinations were compared, the presence of ACPA alone was 
not associated with BME, but the combined presence of ACPA and RF (with or 
without anti-CarP antibodies) was associated with BME. The level of ACPA was not 
associated with BME, suggesting that this cannot be explained by ACPA levels but 
rather by the combined presence of ACPA and RF.
To our knowledge this is the first study including almost 600 MR images in 
which the relationship between the different autoantibodies and MRI-detected 
inflammation was investigated in detail. Due to this large sample size it was 
possible to evaluate the independent associations between BME and ACPA, RF and 
anti-CarP antibodies. Furthermore, it was possible to investigate the differential 
effects of the autoantibodies on the different types of MRI-detected inflammation. 
On analyses in subgroups of patients with different autoantibody combinations 
the BME scores were mainly increased when both ACPA and RF were present.
Our data suggest a potential interaction between RF and ACPA; however, the 
underlying mechanism by which ACPA and RF could act in concert was not studied. 
Potentially RF could have an immune-enhancing effect by crosslinking immune 
complexes and thereby activate monocytes or macrophages and induce cytokine 
expression. This is supported by a recent study that showed that RF augments TNFα 
production by ACPA immune complexes in vitro.43 Another explanation could be 
that RF has a role in immune complex stabilization. ACPA bind to target antigens 
with low avidity but it could well be that when RF is also involved in the immune 
complex this binding is more stable. Further fundamental studies should be 
performed for more insight into the interaction between these two autoantibodies.
This study investigated local inflammation as observed on MRI. Recently the 
combined effect of ACPA and RF on systemic inflammation was investigated in 
RA, showing that the combined presence of ACPA and RF was associated with 
higher levels of pro-inflammatory cytokines and increased acute phase reactants 
and disease activity.43 We also analyzed the association between the different 
autoantibody combinations and CRP, erythrocyte sedimentation rate (ESR), SJC 
and 28-joint count disease activity score (DAS28) as measures of disease activity 
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in our patients with RA or UA at baseline; no large differences were observed but 
patients positive for all three autoantibodies had the highest disease activity scores 
(Supplementary figure 7.4).
Association between the combined presence of autoantibodies and BME was 
observed. Since BME is associated with erosive progression,5-14 it would be interesting 
to investigate whether combinations of autoantibodies are also associated with 
radiographic progression. The association between ACPA or RF and radiographic 
progression is well-investigated.15-23 However the number of studies investigating 
the combined effect of ACPA and RF is limited. A recent study in two cohorts showed 
no additive effect of RF on radiographic progression in ACPA-positive patients.44 
Another study analyzing high-resolution peripheral quantitative computed 
tomography (CT) images of the MCP joints in patients with RA showed that there 
was an additive effect of ACPA and RF on erosion number and size.45 The read-out 
of these studies (microCT and conventional radiography) was different. It would 
be interesting to further unravel the association between different autoantibody 
combinations and erosive progression in further observational studies.
A limitation of the subgroup analysis is that some autoantibody combinations 
were infrequent and so no definite conclusions can be drawn for these. For 
instance, patients who were ACPA+ RF- anti-CarP- were infrequent. Despite the 
limited power, there was no tendency in the data towards higher BME scores in 
these patients compared to the triple-negative group. This study is not the first 
that did not identify a deleterious effect of the presence of ACPA alone. Two recent 
papers reported on mice that were injected with ACPA, and although ACPA was 
detected in the joint, no signs of inflammation were observed in the synovium.46,47 
Surprisingly, in our data the presence of ACPA alone even had a non-significant 
tendency towards a protective effect against synovitis (in all patients with early 
arthritis patients and in patients with RA or UA). Interestingly, two recent studies 
in humans showed that the presence of ACPA without RF was associated with lower 
disease activity.42,43 In summary, further larger studies are needed to determine the 
role of ACPA single positivity.
Another limitation could be that we used contrast-enhanced T1-weighted images 
to assess BME. Using the RAMRIS method, T2-weighted fat-suppressed sequences, 
or when this sequence is not available, a short tau inversion recovery (STIR) 
sequence, should be used to assess BME. However, it has been demonstrated that 
a contrast-enhanced T1-weighted fat-suppressed sequence performed equally well 
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to depict BME as a T2-weighted fat-suppressed sequence34,38,39 and the evaluation of 
BME on a T1-weighted fat suppressed sequence is also supported by the ESSR.40 In 
this study the contrast-enhanced T1-weighted fat-suppressed sequence was used 
because it allowed a shorter scan time and has a higher signal-to-noise ratio.34,38
A third limitation is that the scan protocol for the foot was changed. When the 
analyses of the different autoantibody combinations and BME scores in patients with 
early arthritis were repeated separately in the patients scanned with or without the 
coronal sequence of the foot, the presence of ACPA alone was not associated with 
higher BME scores, but the combined presence of ACPA and RF was associated with 
higher BME scores (data not shown). This suggests that the change in scan protocol 
for the foot had no major influences on the results of this study.
Finally, our arthritis cohort includes patients with early disease who presented 
with different diagnoses. We hypothesized that direct association between ACPA 
and MRI-detected inflammation would be independent of the clinical diagnosis. 
However, to exclude an effect of this heterogeneity in patient selection on our 
findings we repeated all analyses within the subgroup of patients with RA and UA. 
This produced similar results.
Of note, the differences observed in BME scores were statistically significant but 
the absolute differences were relatively small. The variation in BME scores was 
only partly explained by the autoantibody status. Nonetheless the present study 
does increase our understanding of the relationship between autoantibodies and 
BME, which are both predictors of radiographic progression. The observation that 
ACPA is associated with osteitis, only when RF is present, fuels further laboratory 
studies on the biological relevance of these autoantibodies.
Conclusions 
In conclusion, the presence of ACPA alone and ACPA serum levels were not 
associated with BME scores. However, BME scores were higher when patients were 
seropositive for both ACPA and RF. These results suggest that RF has an additive 
role to ACPA in mediating osteitis.
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Supplementary material
Supplementary methods are available at the website of Arthritis Research and 
Therapy. 
Supplementary figure 7.1A Illustration of association between ACPA (A), RF (B) and anti-CarP 
antibodies (C) and MRI-detected BME, synovitis and tenosynovitis scores in patients with RA and 
UA (n=397)
Horizontal lines represent median. Whiskers show the 10th-90th percentile. Dots represent outliers. (A) 
BME: p=0.001; synovitis: p=0.776; tenosynovitis: p=0.99. (B) BME: p=0.002; synovitis: p=0.19; tenosynovitis: 
p=0.26. (C) BME: p=0.017; synovitis: p=0.085; tenosynovitis: p=0.056. Total score: sum of scores in MCP, 
wrist, and MTP joints. ACPA, anti-citrullinated protein antibodies; anti-CarP, anti-carbamylated protein 
antibodies; BME, bone marrow edema; MRI, magnetic resonance imaging; RF, rheumatoid factor. 
*Significant difference between autoantibody-negative and autoantibody-positive patients (p<0.05).
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Supplementary figure 7.2 Association between ACPA level and BME scores within ACPA-positive 
patients with early arthritis (A) (n=141, r=0.071, p=0.403) and within ACPA-positive patients with RA 
or UA (B) (n=123, r=0.034, p=0.706)
ACPA, anti-citrullinated protein antibodies; BME, bone marrow edema; RA, rheumatoid arthritis; UA, 
undifferentiated arthritis.
Supplementary figure 7.3 BME scores of ACPA-positive patients with RA or UA (n=123) with low, 
intermediate, or high levels of ACPA
Horizontal lines represent median. Whiskers show the 10th-90th percentile. Dots represent outliers. 
Baseline ACPA levels are shown categorically as low, intermediate, or high. The groups were as follows: 
low ≥7 U/ml, intermediate ≥167 U/ml, and high ≥327 U/ml. Low: n=57; intermediate: n=27; high: n=39. 
ACPA, anti-citrullinated protein antibodies; BME, bone marrow edema; RA, rheumatoid arthritis; UA, 
undifferentiated arthritis. Kruskal-Wallis test, p=0.23.
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Supplementary figure 7.4 Association between CRP (A), ESR (B), SJC (C) and DAS28 (D) and different 
autoantibody combinations
Horizontal lines represent median. Whiskers show the 10th-90th percentile. Dots represent outliers. ACPA, 
anti-citrullinated protein antibodies; anti-CarP, anti-carbamylated protein antibodies; CRP, C-reactive 
protein; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; RF, rheumatoid 
factor; SJC, swollen joint count based on 66 joints. *Significant difference between subgroups (p<0.05).
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onset but the composition of 
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Rheumatoid arthritis (RA) consists of two syndromes, one autoantibody-positive 
and one autoantibody-negative. Existing data on the relation between age of onset 
and prevalence of autoantibodies were conflicting. Therefore this multicohort 
study assessed the age of onset in relation to the presence of autoantibodies. The 
association with characteristics of the anti-citrullinated protein antibodies (ACPA) 
response was also explored. 
Methods
The 1987 criteria-positive RA patients included in the Leiden EAC, BARFOT, ESPOIR, 
Umeå and Lund cohorts (n=3321) were studied at presentation for age of onset and 
the presence of ACPA, rheumatoid factor (RF) and anti-carbamylated protein (anti-
CarP) antibodies. Logistic regression analyses were performed; effect sizes were 
summarized in inverse-weighted meta-analyses. Within ACPA-positive RA, ACPA 
level was studied in all cohorts; ACPA isotypes, ACPA fine specificity and ACPA 
avidity index and clinical characteristics were studied in the Leiden EAC. 
Results
From the age of 50 onward, the proportion of ACPA-negative RA patients increased 
with age in the five cohorts. Similar observations were made for RF and anti-CarP 
antibodies. The composition of the ACPA response did not change with increasing 
age of onset with respect to titer, isotype distribution, fine specificity and avidity 
index. With increasing age of onset, RA patients smoked less often, had higher 
acute phase reactants and more often had a sub(acute) symptom onset. 
Conclusions
Data of five cohorts revealed that with older age of onset ACPA-negative RA is 
more frequent than ACPA-positive RA, while characteristics of ACPA-positive RA 
as judged by the composition of the ACPA response appeared not age dependent. 
Further biologic studies are needed to characterize the pathogenesis of ACPA-
negative polyarthritis at older age and to promote personalized treatment 
decisions in ACPA-negative patients in daily practice.
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Background
Rheumatoid arthritis (RA) is a syndrome for which characterization is based on a 
combination of clinical features. Symmetric polyarthritis of hands and feet is a key 
clinical feature and is captured in the 1987 classification criteria.1 It is presumed 
that different biologic pathways can end up in the same clinical phenotype of RA. 
To arrive at personalized medicine, it is relevant to identify such different groups 
of patients. The most commonly used division is that into anti-citrullinated protein 
antibodies (ACPA)-positive RA and ACPA-negative RA, and both subgroups have 
differences in genetic and environmental risk factors.2,3
In addition to ACPA, there is some evidence suggesting that there are different 
characteristics of RA patients presenting at an older age. Several studies have 
shown that RA patients with disease onset at older age have a more equal 
gender distribution, more frequently an acute onset of symptoms4,5 and more 
often experience constitutional symptoms than younger patients at disease 
presentation.4-6 ACPA positivity is more frequent with older age, suggesting that 
ACPA-positive RA may also be more frequent with older age.7 However, within 
autoantibody-positive patients it was recently observed that patients with two or 
three autoantibodies were younger at onset than patients with one autoantibody.8 
In addition, some studies showed lower frequencies of autoantibodies in RA 
patients presenting at older age,9-14 while other studies observed no differences15,16 
or showed a nonsignificant trend toward a higher prevalence of ACPA in RA 
patients presenting at older age.17,18 Altogether, the association between age of 
onset and the distribution of ACPA-positive RA versus ACPA-negative RA remains 
to be established.
If there is an association between age of onset and the presence of autoantibodies, 
this could be explained by different scenarios. There could be an age-related 
effect on the ACPA response itself. Then, in addition to the presence of ACPA, 
characteristics of the ACPA response could also vary with age. This could be a 
conceivable explanation because in the general population the immune system 
changes with ageing. For instance, an increase in proinflammatory cytokines, a 
more active innate immunity and a decline in the function of the adaptive immune 
system has been observed with older age.19 T cell senescence has been described 
and may mediate the development of RA.20 With regard to B cells and antibodies, 
titers of antibodies against nearly all vaccines, including tetanus, decrease with 
age.21 Furthermore there is a defect in isotype switching and limited production of 
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high-affinity antibodies with increasing age, all thought to associate with decreased 
protection by vaccines and increased susceptibility to infections.22 Whether B cell 
senescence has a role in RA development is still unclear.19 Despite these studies on 
the autoantibody response and aging, to our knowledge it is unknown whether age 
influences characteristics of the ACPA response, measured at RA onset.
An alternative explanation could be that some of the patients presenting at older 
age with ‘typical RA’ (e.g., symmetric polyarthritis of small joints) have differences 
in underlying biologic mechanisms compared with younger patients. Although 
biologic studies are needed to verify this hypothesis, detailed phenotypic studies 
can identify subtle differences between patient groups, despite their similarity in 
key clinical characteristics that are required for classification.
As a follow-up on previous studies of ACPA and age of onset as well as on the 
mentioned considerations, this study had three aims. Firstly, to determine the 
association between age of RA onset and the frequency of three autoantibodies 
(ACPA, rheumatoid factor (RF) and anti-carbamylated protein (anti-CarP) 
antibodies). For this purpose a large study on data of five cohorts was performed. 
Secondly, to study whether age at onset was associated with characteristics of the 
ACPA response in ACPA-positive RA patients. Thirdly, to substantiate previously 
reported associations between age at onset and clinical characteristics.4-6
Methods 
Patients 
The association between age at RA onset and prevalence of ACPA and RF was 
studied in all five RA cohorts (Leiden Early Arthritis Clinic (EAC), BARFOT, ESPOIR, 
Umeå, Lund) and anti-CarP antibodies were studied in two cohorts (Leiden EAC, 
BARFOT). The association between age at RA onset and ACPA level was also studied 
in all five cohorts. Other ACPA characteristics were studied in ACPA-positive RA 
patients from the Leiden EAC. RA was defined as fulfilling the 1987 classification 
criteria.1 The 2010 classification criteria were not used because autoantibodies 
are heavily weighted in these criteria, which may induce circularity between the 
parameter that was studied and the reference.
Leiden EAC 
The Leiden EAC is an inception cohort set up in the Leiden University Medical 
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Center (the Netherlands) that started in 1993 and includes patients with clinically 
confirmed arthritis and symptom duration <2 years at presentation to the 
rheumatologist.23 This department is the only referral center in a health care 
population of >400,000 inhabitants. At baseline questionnaires, joint counts and 
blood samples were collected. Information on smoking (present versus none 
and past) was obtained at baseline. The presence of shared epitope alleles was 
determined as described previously.24 The patients studied were included between 
1993 and 2015; a total of 1244 RA patients were consecutively included and studied 
here. The age ranged between 18 and 92 years.
BARFOT 
The BARFOT (Better Anti-Rheumatic Farmaco-Therapy) study is an observational 
study of patients with early RA in Sweden.25 Patients aged 18-93 years were 
included from six rheumatology centers when they were diagnosed with RA and 
had symptom duration <1 year. In this study, 839 patients included between 1993 
and 1999 were enrolled.
ESPOIR 
The Evaluation et Suivi de POlyarthrites Indifférenciées Récentes (ESPOIR) is a 
cohort in which patients from 14 regional centers across France (16 university 
hospital rheumatology departments) were recruited.26 Patients were aged 18-70 
years and had ≥2 swollen joints for >6 weeks and <6 months and a high clinical 
suspicion on RA based on expert assessment. In total, 632 RA patients included 
between 2002 and 2005 were studied here. 
Umeå 
Umeå is an observational inception cohort in which 459 RA patients with symptom 
duration <12 months from four different counties in Sweden were included 
between 1995 and 2010.12 The age ranged between 18 and 83 years.
Lund 
This cohort study recruited patients from primary care units in the area of Lund, 
Sweden, and included patients with RA for <24 months aged 18-78 years.27 Although 
at inclusion RA was defined using the 1958 criteria, these patients also fulfilled the 
1987 criteria.28-30 In total, 183 patients were included between 1985 and 1989; of 
these, 147 were previously evaluated in longitudinal studies31,32 and also studied 
here.
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Serological measurements 
Baseline serum samples were tested for ACPA: Leiden EAC, anti-CCP2 Immunoscan 
RA Mark 2 (Eurodiagnostica, Arnhem), cut-off 25 U/ml, and anti-CCP2 EliA CCP 
(Phadia, Nieuwegein, the Netherlands), cut-off 7 U/ml, were used to determine the 
presence of ACPA, ACPA level was studied in samples tested with the anti-CCP2-
test from Eurodiagnostica; ESPOIR, anti-CCP2 (DiaSorin, France), cut-off 50 U/ml; 
BARFOT and Umeå, anti-CCP2 (Eurodiagnostica, Malmö, Sweden), cut-off 25 U/ml; 
and Lund, anti-CCP2 (Anamar Lund, using commercial kits, Inova Diagnostics, 
San Diego, CA), cut-off 20 U/ml. IgM RF was determined as follows: Leiden EAC, 
in-house ELISA; BARFOT, Serodia RA agglutination test (Fujirebio Inc., Tokyo, 
Japan); ESPOIR: Elisa, Menarini, France; positive >9 UI/ml); Umeå, in-house ELISA; 
and Lund (ELISA, Anamar Lund, using commercial kits, Inova Diagnostics, San 
Diego, CA). IgG anti-CarP antibodies against carbamylated fetal calf serum were 
determined as described previously in the Leiden EAC,33 cut-off for positivity was 
based on the mean +2 SD from a set of 204 healthy controls; and in BARFOT the 
cut-off was based on the 82 controls from the source population.34
ACPA characteristics 
Data on ACPA isotypes, ACPA fine specificity and ACPA avidity were determined as 
described previously35-37 in 157 RA patients included in the Leiden EAC. In short, by 
measuring ACPA isotypes different antibody subclasses can be distinguished which 
all differ in their ability to mediate effector responses.38 ACPA IgG1, IgG2, IgG3, 
IgG4, IgA and IgM were determined using a sandwich ELISA.37 The total number 
of ACPA isotypes in each ACPA-positive patient was used in our analysis. ACPA 
fine specificity was studied to measure an increase or shift in antigen recognition. 
To determine ACPA fine specificity, antibodies against the citrullinated and the 
arginine-containing form of two peptides derived from vimentin (Vim1-16; Vim59-
74), two peptides derived from fibrinogen (Fibα 27-43; Fibβ 36-52) and one peptide 
derived from α-enolase (Eno 5-20) and against citrullinated myelin basic protein 
were determined by in-house ELISA.36 The sum of citrullinated antigens recognized 
by ACPA in each patient was used in our analysis. Finally the avidity of ACPA IgG, 
as a measure of the strength of the ACPA response, was determined with elution 
ELISAs.35 Avidity is presented as the relative avidity index, which was defined as 
the ratio of the amount of residual antibodies bound to the antigen-coated plate 
after NaSCN (1 M) elution to the amount of bound antibodies in the absence of 
NaSCN, expressed as a percentage. 
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Statistical analysis 
To visually inspect the relation between age of onset and presence of autoantibodies, 
the proportion of autoantibody-positive and autoantibody-negative patients was 
plotted for different age groups of each 5 years. If <10 patients were present in 
the older age groups (BARFOT, Lund), age groups were summed. To statistically 
evaluate associations with age of onset, logistic regression analyses were 
performed per cohort with ACPA, RF or anti-CarP antibodies as the dependent 
variable and age of onset as the independent variable. Because descriptive results 
(Figure 8.1, Supplementary figure 8.1, 8.2, 8.3) showed that the proportion of 
autoantibody-positive RA patients decreased after ±50 years of age, a two-phase 
logistic regression analysis with one change point at 50 years was fitted. Odds ratios 
of the different cohorts (obtained from regression analyses) were entered in an 
inverse-weighted meta-analysis. This method weights results with a low standard 
error stronger than results with a higher standard error, thereby preventing over-
representation of less precise data. A random effect model was used. The meta-
analysis was performed separately for age of onset <50.0 years and >50.0 years and 
separately in males and females.
Figure 8.1 Proportion of ACPA-negative RA patients at different ages of RA onset within the different 
age groups at RA onset in the five different cohorts
Number of patients in each age group: Leiden EAC: <25, n=48; 25-29, n=23; 30-34, n=49; 35-39, n=65; 40-44, 
n=86; 45-49, n=121; 50-54, n=125; 55-59, n=144; 60-64, n=153; 65-69, n=122; 70-74, n=131; 75-79, n=92; ≥80, 
n=49; BARFOT: <25, n=16; 25-29, n=25; 30-34, n=42; 35-39, n=40; 40-44, n=45; 45-49, n=66; 50-54, n=92; 55-59, 
n=90; 60-64, n=75; 65-69, n=92; 70-74, n=82; 75-79, n=66; ≥80, n=29; ESPOIR: <25, n=30; 25-29, n=24; 30-34, 
n=45; 35-39, n=52; 40-44, n=65; 45-49, n=78; 50-54, n=107; 55-59, n=109; 60-64, n=73; ≥65, n=49; Umeå: <25, 
n=20; 25-29, n=13; 30-34, n=22; 35-39, n=28; 40-44, n=28; 45-49, n=43; 50-54, n=62; 55-59, n=60; 60-64, n=72; 
65-69, n=48; 70-74, n=32; ≥75, n=31; Lund: <25, n=2; 25-29, n=6; 30-34, n=2; 35-39, n=13; 40-44, n=15; 45-49, 
n=30; 50-54, n=21; 55-59, n=25; 60-64, n=11; ≥65, n=17. ACPA, anti-citrullinated protein antibodies.
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The proportion of ACPA-positive and ACPA-negative RA patients within the 
Leiden EAC was then compared with ACPA probabilities from the general Dutch 
population.7 Within different age categories the risk of being ACPA-positive within 
the Leiden EAC was divided by the risk of being ACPA-positive within the general 
Dutch source population, revealing a risk ratio. The same was done for the risk 
of being ACPA-negative. Risk ratios of ACPA positivity and ACPA negativity were 
plotted for different age categories. 
Data on ACPA characteristics were depicted visually for different age groups of 
each 10 years, and evaluated statistically with linear regression analysis (ACPA 
level, ACPA avidity) and ordinal regression analysis (ACPA isotypes, ACPA fine 
specificity), using Bonferroni correction for multiple testing.
Within the Leiden EAC, the association between age of onset and smoking, SE 
alleles and symptom onset was analyzed with logistic regression analysis, and with 
C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and swollen joint 
count (SJC) with Spearman’s correlation coefficient, using Bonferroni correction 
for multiple testing. Symptom onset was considered sub(acute) when there was 
prompt onset (e.g., <1 week), and not a gradual or intermittent onset. All regression 




Baseline characteristics of all included patients are presented in Table 8.1. The 
majority of the included patients were female and the mean age of onset in the 
different cohorts ranged from 48.9 to 56.7 years. Symptom duration ranged from 
18.3 to 43.3 weeks with the longest symptom duration observed in Lund. Within 
Leiden EAC, BARFOT and ESPOIR about 50% of the included patients were ACPA-
positive, while in Umeå and Lund the percentage of ACPA-positive patients was 
73.9% and 80.3%.
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Table 8.1 Baseline characteristics of patients with rheumatoid arthritis included in the cohorts 
studied
variable Leiden-EAC BARFOT ESPOIR Umeå Lund
Total number of patients 1244 839 632 459 147
Age, mean(sd) 56.6 (15.5) 56.7 (15.4) 48.9 (12.2) 53.9 (14.5) 50.7 (11.5)
Female, n(%) 827 (66.5) 538 (64.1) 484 (76.6) 321 (69.9) 98 (66.7)
Symptom durationa, median (IQR), weeks 18.3 (9-36) 26.1 (17-39) 21.4 (13-33) 28.0 (16-39) 43.3 (28-61)
Smoking at baseline, n(%) 308 (25.9) 227 (27.1) 137 (21.7) 107 (23.9) 39 (30.7)
ACPA+, n(%) 638 (52.8) 418 (55.0) 291 (46.0) 339 (73.9) 114 (80.3)
RF+, n(%) 715 (58.0) 453 (59.6) 344 (54.4) 362 (79.0) 115 (81.0)
anti-CarP+, n(%) 474 (42.3) 280 (34.7) NA NA NA
ESR (mm/h), median (IQR) 31 (16-50) 30 (15-50) 23 (12-41) 22 (12-39) 28 (13-50)
CRP (mg/L), median (IQR) 14 (6-35.5) 19 (7-47.5) 10 (3-26) 10 (8-25) 15 (0-45.5)
SJC, median (IQR) 5 (3-10) 10 (6-14) 7 (4-11) 6 (3-10) 6 (3-10)
TJC, median (IQR) 6 (2-11) 7 (3-12) 8 (4-14) 5 (2-10) 7 (4-11)
aTime between symptom onset and inclusion in cohort.
ACPA, anti-citrullinated protein antibodies; anti-CarP, anti-carbamylated protein antibodies; CRP, 
C-reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquartile range; n, number of patients; 
NA, not available; RF, rheumatoid factor; SD, standard deviation; SJC, swollen joint count based on 66 
joints (Leiden EAC) or on 28 joints (BARFOT, ESPOIR, Umeå) or on 50 joints (Lund); TJC, tender joint count 
based on 68 joints (Leiden EAC) or on 28 joints (BARFOT, ESPOIR, Umeå) or Ritchie index (Lund). 
ACPA prevalence decreased in RA patients with an older age at onset
The proportion of ACPA-positive RA was plotted for all age categories in all five 
cohorts (Figure 8.1). This showed that the proportion of ACPA-positive patients 
seemed to decrease after age of onset of 50 years. Logistic regression analyses with 
a change point at 50 years of age and with adjustment for gender were performed 
for each cohort; odds ratios (ORs) were combined in a meta-analysis. There was 
no association between the age of onset and the presence of ACPA in RA patients 
with an age of onset <50 years (OR 1.01, 95% CI 0.99-1.04). However, age of onset 
>50 years was associated with a lower frequency of ACPA positivity (OR 0.96, 95% 
CI 0.95–0.97; Figure 8.2A). An OR of 0.96 indicates that for a 1-year increase in 
the age of onset, the odds of being ACPA-positive decrease 4%; thus this reflects 
18% per 5-year increase in age. Results were similar when studying ACPA in age 
categories of 5 years instead of continuously (Supplementary figure 8.1). Similar 
results were observed for RF and anti-CarP antibodies (Supplementary figure 8.2, 
Supplementary figure 8.3, Figure 8.2B, C). 
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Figure 8.2 Meta-analysis on the association between age of onset (<50 and >50 years) and the presence 
of ACPA, RF and anti-CarP antibodies
Association between ACPA (A), RF (B) and anti-CarP antibodies (C) with age of onset in the different 
cohorts. The meta-analysis summarizes the effect of age of onset in the different cohorts and is based on 
a random effect model, combining ORs from separate logistic regression analyses of the different cohorts 
with age and gender as independent variables and ACPA, RF or anti-CarP antibodies as outcome. Separate 
meta-analyses were performed for the association between autoantibodies and age <50 years and >50 
years. OR of 0.96 indicates that for a 1-year increase in age, the odds of being ACPA-positive decrease 
4%; this is 18% per 5-year increase in age of RA onset (0.965). ACPA, anti-citrullinated protein antibodies; 
anti-CarP, anti-carbamylated protein antibodies; OR, odds ratio; RF, rheumatoid factor.
Also when analyses were repeated with a change point at 60 years of age, similar 
results were obtained (meta-analysis: p<0.001 for an association between ACPA 
presence and age of onset in patients aged >60 years; and no significant association 
in patients aged <60 years, p=0.88).
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Then we studied the proportion of ACPA-positive and ACPA-negative patients in 
relation to the ACPA prevalence of the Dutch source population (Figure 8.3). This 
showed that, for example, in the age group 18-29 the risk of being ACPA-positive 
was 87 times higher for RA patients compared with individuals from the general 
population. In line with this, the risk of being ACPA-negative was 0.48 times higher 
(meaning 52% lower) for RA patients compared with individuals from the general 
population. The risk ratio for ACPA-negativity increased at older age.
Figure 8.3 Risk of ACPA positivity and ACPA negativity in RA patients compared with individuals 
from the Dutch source population, presented for different age categories
For example, in the age group 18–29 the risk of being ACPA-positive was 87 times higher for RA patients 
than for individuals from the general Dutch population, and the risk of being ACPA-negative was 0.48 times 
higher (meaning 52% lower). The ratio for ACPA negativity increased at older age. ACPA, anti-citrullinated 
protein antibodies; obs, observed; exp, expected. 
ACPA characteristics did not differ for different ages of RA onset 
After having studied the presence of ACPA-positive RA, several characteristics of 
the ACPA response were evaluated within ACPA-positive RA patients. First, ACPA 
level was analyzed in relation to age of onset; no association between ACPA level 
and age of onset was observed (Leiden EAC p=0.49, BARFOT p=0.21, ESPOIR p=0.91, 
Umeå p=0.34, Lund p=0.08; Figure 8.4). Then within the Leiden EAC the number 
of ACPA isotypes was evaluated because isotype class switching can lead to an 
increased diversity of the antibody repertoire. The ordinal regression showed 
p=0.03, and was not significant after correcting for multiple testing (cut-off 
Bonferroni correction p=0.01, Figure 8.5A). No association was observed between 
age at onset and the ACPA fine specificity (which we presented as the number 
of recognized citrullinated antigens by ACPA, p=0.96; Figure 8.5B) and the ACPA 
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avidity index (which measures the overall binding strength of the ACPA response 
to CCP2, p=0.62; Figure 8.5C). These findings together suggest that the analyzed 
ACPA characteristics were comparable within different age categories.
Figure 8.4 ACPA level of ACPA-positive RA at different ages of RA onset; data from five cohorts 
Association between age of onset and ACPA level within RA patients of the Leiden EAC (A), BARFOT (B), 
ESPOIR (C), Umeå (D) and Lund (E) cohorts. In Lund the upper detection limit of the anti-CCP2 test was 
200 U/ml; there were 76 patients with anti-CCP2 level >200 U/ml. Horizontal lines represent median 
values. Each dot represents one patient. ACPA, anti-citrullinated protein antibodies; anti-CCP2, anti-cyclic 
citrullinated peptide 2.
Figure 8.5 Isotypes, fine specificity and avidity index of ACPA-positive RA patients at different ages 
of onset; data from the Leiden EAC
Association between age of onset and ACPA isotypes (A), ACPA fine specificity (B) and ACPA avidity index 
(C) within RA patients of the Leiden EAC. Horizontal lines represent median values. Each dot represents 
one patient. ACPA, anti-citrullinated protein antibodies.
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Several clinical parameters in RA patients at disease onset associated with 
age of onset
The decrease in the relative proportion of ACPA-positive RA patients with increasing 
age of onset was not paralleled by age-related differences in the ACPA response 
itself, which suggests that an age-dependent effect on the ACPA response was not 
the most likely explanation. To further substantiate this, the associations of age with 
smoking and the HLA-SE alleles were determined, because these are the main risk 
factors for ACPA-positive RA. The presence of SE alleles remained constant over 
age of onset (p=0.54), but the proportion of smokers decreased with increasing age 
(p<0.001, Supplementary figure 8.4). Similar to that observed for ACPA, this decrease 
was most prominent for RA patients with an age of onset >50 years.
Another explanation for the higher proportion of ACPA-negative RA at older 
age of onset is that a group of (autoantibody-negative) patients with different 
etiopathology was preferentially present at older age and classified as RA. Because 
some previous studies have reported associations between clinical characteristics 
(male gender, more often acute onset, higher acute phase reactants) and an older 
age of onset,4-6 we aimed to substantiate this in the present data. We evaluated 
whether the association between age and the presence of autoantibodies was 
similar in males and females, showing that the effect was more pronounced in 
males (Supplementary figure 8.5). Furthermore, an older age of onset was associated 
with higher CRP levels (ρ=0.26, p<0.001), higher ESR levels (ρ=0.32, p<0.001) and a 
higher number of swollen joints (ρ=0.10, p=0.001) at first presentation. RA patients 
presenting at older age also more often had (sub)acute onset of symptoms (p=0.003, 
Supplementary figure 8.6). These findings remained significant after Bonferroni 
correction (cut-off p=0.008).
Altogether these data suggest that at older age there is a subgroup of patients who 
fulfil the classification criteria for RA that is more often male, nonsmoking, has 
higher acute phase reactants, more often has (sub)acute symptom onset and is also 
more often ACPA-negative.
Discussion
Previous studies have evaluated differences in relation to the age of onset of RA, 
and have shown that some clinical characteristics were more prevalent at an 
older age of onset. Whether or not the ratio of ACPA-positive and ACPA-negative 
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RA was also different was unresolved until now because different studies have 
yielded contrasting results. This prompted us to perform the present study in 3321 
RA patients from five RA cohorts. The combination of the present data clearly 
showed that the proportion of autoantibody-positive patients (i.e., ACPA, RF and 
anti-CarP antibodies) was lower in RA patients who presented at older age. We also 
studied characteristics of the ACPA response, and within ACPA-positive RA patients 
characteristics of this response did not appear to differ at different ages of onset. 
Hence, our results suggest that the composition of the ACPA response is not different, 
but only the proportion of ACPA-positive RA is lower at older age of onset. In other 
words, the data revealed that ACPA-negative RA was more prevalent at older age.
Some findings within RA patients are different from findings obtained in the general 
population. In the general population, ageing is associated with lower antibody levels 
in response to vaccination.21 In this study there was no association between ACPA level 
and age of onset. In addition, in the population autoantibodies (such as antinuclear 
antibodies, RF and ACPA) are increasingly prevalent at older age,7,39-41 whereas within 
RA patents we observed a higher proportion of ACPA-negative disease at older age. 
This difference also resulted in the observation made in Figure 8.3.
Interestingly, not only the proportion of ACPA-positive RA decreased with an older 
age at onset but also the proportion of RA patients who smoked at disease onset. 
This observation corresponds to the prevalence of present smokers in the general 
population, which decreases around 50 years of age.42 Smoking is a known risk 
factor for ACPA-positive RA43 and it is intriguing to speculate that a decrease in 
smoking patients (compared with nonsmokers) mediates the lower proportion of 
ACPA-positive RA at older age.
The 2010 classification criteria for RA could not be used to classify RA in the present 
study because of circularity between the dependent and independent variables. 
According to the 1987 criteria, RA is mainly classified based on clinical features, 
among which is symmetric polyarthritis of small joints. Our data suggest that 
patients fulfilling the 1987 criteria at older age more often had slight differences 
in other baseline characteristics, because they were more often males, had higher 
acute phase reactants and more often had (sub)acute onset of symptoms. Cluster 
analysis using only clinical characteristics, however, was insufficient to cluster 
patients on the individual level (data not shown). Nonetheless, based on the 
present data we presume that part of the ACPA-negative RA patients presenting 
at older age constitute a subgroup with slight differences in clinical presentation 
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but with more pronounced differences in underlying pathogenic mechanisms. 
Biologic studies are now warranted to further evaluate this hypothesis and to 
identify a distinct subgroup within the seronegative patients.
A potential limitation is that the five cohorts were not completely comparable and 
that two cohorts contained an overall higher percentage of ACPA-positive patients 
than the other cohorts. Probably this can be explained by differences in health care 
systems or settings. When for instance the presence of ACPA (or other characteristics 
of more severe disease) is considered more relevant in the referral process or for 
inclusion in cohorts, this could explain the higher percentage of ACPA-positive 
patients in these cohorts. Nonetheless, here the percentage of ACPA-negative 
patients was also higher at older age of onset. The measurement of ACPA was not 
centralized, which may have led to different misclassification in different cohorts. 
Furthermore, anti-CarP antibodies were determined in only two of the five cohorts. 
We observed that RF and anti-CarP antibodies also decreased with increasing age 
of onset, although less distinctly than ACPA. The different autoantibodies often 
occur in the same patients; therefore another limitation is that we have not studied 
whether the decrease of RF and anti-CarP antibodies was independent of the age-
related decrease of ACPA.
A final limitation is that studies on ACPA fine specificity, ACPA isotypes and ACPA 
avidity index were less powered than those on ACPA level. However, it is known 
that ACPA level is highly associated with ACPA fine specificity and the number of 
ACPA isotypes.44 Because ACPA level was determined in all cohorts and there was no 
tendency toward differences in ACPA level in patients aged >50 years at RA onset, 
this may suggest that ACPA fine specificity and ACPA isotypes would also remain 
stable with increasing age of RA onset. In some cohorts, patients aged >80 appeared 
to have lower ACPA levels, although this age group contained very few patients.
Conclusions 
Characteristics of the ACPA response in ACPA-positive RA patients did not appear 
to be age dependent, while data of five cohorts revealed that with older age of 
onset ACPA-negative RA is more frequent than ACPA-positive RA. Further biologic 
studies are needed to characterize the pathogenesis of ACPA-negative polyarthritis 
at older age and to promote personalized treatment decisions in ACPA-negative 
patients in daily practice.
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Supplementary material
Supplementary figure 8.1 Association between age and ACPA within the Leiden-EAC with age in 
categories of 5 years
Logistic regression analyses were performed with the presence of ACPA as outcome variable and gender 
and age as independent variables. Age was studied as a categorical variable (age groups of 5 years), with 
the age group 50-54 as the reference group. The ORs for ACPA positivity decreased linearly with increasing 
age groups. OR, odds ratio. 
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Supplementary figure 8.2 Proportion of RF-negative RA patients at different ages of RA onset; data 
from five cohorts
Presented are the proportion RF-negative and RF-positive RA patients within the different age groups in 
the five different cohorts. Number of patients in each age group: Leiden EAC: <25, n=49; 25-29, n=23; 30-34, 
n=49; 35-39, n=66; 40-44, n=88; 45-49, n=125; 50-54, n=127; 55-59, n=147; 60-64, n=156; 65-69, n=128; 70-74, 
n=130; 75-79, n=93; ≥80, n=51; BARFOT: <25, n=16; 25-29, n=25; 30-34, n=43; 35-39, n=40; 40-44, n=45; 45-49, 
n=66; 50-54, n=92; 55-59, n=90; 60-64, n=75; 65-69, n=92; 70-74, n=81; 75-79, n=66; ≥80, n=29; ESPOIR: <25, 
n=30; 25-29, n=24; 30-34, n=45; 35-39, n=52; 40-44, n=65; 45-49, n=78; 50-54, n=107; 55-59, n=109; 60-64, 
n=73; ≥65, n=49; Umeå: <25, n=20; 25-29, n=13; 30-34, n=21; 35-39, n=28; 40-44, n=28; 45-49, n=43; 50-54, 
n=62; 55-59, n=60; 60-64, n=72; 65-69, n=48; 70-74, n=32; ≥75, n=31; Lund: <25, n=2; 25-29, n=6; 30-34, n=2; 
35-39, n=13; 40-44, n=15; 45-49, n=30; 50-54, n=21; 55-59, n=25; 60-64, n=11; ≥65, n=17. RA, rheumatoid 
arthritis; RF, rheumatoid factor. 
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Supplementary figure 8.3 Proportion of anti-CarP-negative RA patients at different ages of RA onset; 
data from two cohorts
Presented are the proportion of anti-CarP-negative and anti-CarP-positive RA patients within the different 
age groups in the Leiden EAC and BARFOT cohorts. Number of patients in each age group: Leiden EAC: 
<25, n=43; 25-29, n=23; 30-34, n=44; 35-39, n=62; 40-44, n=79; 45-49, n=111; 50-54, n=112; 55-59, n=135; 60-
64, n=144; 65-69, n=114; 70-74, n=120; 75-79, n=87; ≥80, n=47; BARFOT: <25, n=18; 25-29, n=27; 30-34, n=37; 
35-39, n=41; 40-44, n=43; 45-49, n=62; 50-54, n=96; 55-59, n=88; 60-64, n=80; 65-69, n=103; 70-74, n=88; 75-79, 
n=87; ≥80, n=38. RA, rheumatoid arthritis; anti-CarP, anti-carbamylated protein antibodies.
Supplementary figure 8.4 Proportion of present smokers and presence of SE alleles at different ages 
of onset of RA; data from the Leiden EAC
Presented are the proportion of currently smoking RA patients (n=308) versus not smoking (none and past 
smoking) RA patients (n=880) (A) and the proportion of patients carrying one or two SE alleles (n=467) 
versus no SE alleles (n=272) (B) within different age groups in the Leiden EAC. Number of patients in each 
group: smoking: <25, n=47; 25-29, n=22; 30-34, n=48; 35-39, n=66; 40-44, n=85; 45-49, n=119; 50-54, n=125; 
55-59, n=141; 60-64, n=153; 65-69, n=121; 70-74, n=127; 75-79, n=87; ≥80, n=47; SE alleles: <25, n=28; 25-29, 
n=12; 30-34, n=29; 35-39, n=40; 40-44, n=59; 45-49, n=74; 50-54, n=81; 55-59, n=80; 60-64, n=91; 65-69, n=73; 
70-74, n=75; 75-79, n=61; ≥80, n=36. RA, rheumatoid arthritis; SE, shared epitope.
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Supplementary figure 8.5 Meta-analysis on the association between age of onset and the presence of 
ACPA, RF and anti-CarP antibodies in male and female RA patients
Association between ACPA (A), RF (B) and anti-CarP antibodies (C) with age of onset in the different 
cohorts for males and females separately. The meta-analysis summarizes the effect of age of onset in 
the different cohorts and is based on a random effect model, combining the ORs from separate logistic 
regression analyses of the different cohorts with age as the independent variable and ACPA, RF or anti-
CarP antibodies as outcome. Only the meta-analyses on the association between autoantibodies and age 
>50 years at RA diagnosis are shown. OR of 0.94 indicates that for a 1-year increase in age of onset, the
odds of being ACPA-positive decrease 6%; this is 27% per 5-year increase in age of onset (0.945). ACPA,
anti-citrullinated protein antibodies; anti-CarP, anti-carbamylated protein antibodies; OR, odds ratio; RA,
rheumatoid arthritis; RF, rheumatoid factor. 
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Supplementary figure 8 .6 Association between age of onset and onset of symptoms within RA 
patients of the Leiden EAC. 
(A) Results of logistic regression analyses of age at RA onset in relation to the onset of symptoms. OR of 
1.01 indicates that per 1-year increase in the age of onset, the odds of having (sub)acute onset increase 1%. 
This reflects 12% (1.0110) per 10-year increase in age of onset and 25% (1.0120) per 20-year increase in age 
of onset. (B) Proportion of RA patients with (sub)acute onset of symptoms in three age groups (p=0.003). 
Number of patients per age group: <40, n=181; 40-60, n=466; >60, n=537. CI, confidence interval; OR, odds 
ratio; RA, rheumatoid arthritis.
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Does immunological remission, 
defined as disappearance of 
autoantibodies, occur with 
current treatment strategies? 
A long-term follow-up study in 
rheumatoid arthritis patients 
who achieved sustained 
DMARD-free status








Sustained disease-modifying antirheumatic drug (DMARD)-free status, the 
sustained absence of synovitis after cessation of DMARD therapy, is infrequent 
in autoantibody-positive rheumatoid arthritis (RA), but approximates cure 
(i.e., disappearance of signs and symptoms). It was recently suggested that 
immunological remission, defined as disappearance of anti-citrullinated protein 
antibodies (ACPA) and rheumatoid factor (RF), underlies this outcome. Therefore, 
this long-term observational study determined if autoantibodies disappear in RA 
patients who achieved sustained DMARD-free remission.
Methods 
We studied 95 ACPA-positive and/or RF-positive RA patients who achieved DMARD-
free remission after median 4.8 years and kept this status for the remaining follow-
up (median 4.2 years). Additionally, 21 autoantibody-positive RA patients with a 
late flare, defined as recurrence of clinical synovitis after a DMARD-free status of 
≥1 year, and 45 autoantibody-positive RA patients who were unable to stop DMARD 
therapy (during median 10 years) were studied. Anti-cyclic citrullinated peptide 2 
(anti-CCP2) IgG, IgM and RF IgM levels were measured in 587 samples obtained at 
diagnosis, before and after achieving DMARD-free remission. 
Results 
13% of anti-CCP2 IgG-positive RA patients had seroreverted when achieving 
remission. In RA patients with a flare and persistent disease this was 8% and 6%, 
respectively (p=0.63). For anti-CCP2 IgM and RF IgM, similar results were observed. 
Evaluating the estimated slope of serially measured levels revealed that RF levels 
decreased more in patients with than without remission (p<0.001); the course of 
anti-CCP2 levels was not different (p=0.66).
Conclusions 
Sustained DMARD-free status in autoantibody-positive RA was not paralleled 
by an increased frequency of reversion to autoantibody negativity. This form of 
immunological remission may therefore not be a treatment target in patients with 
classified RA.
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Introduction
Sustained disease-modifying antirheumatic drug (DMARD)-free status is defined 
as sustained absence of synovitis after cessation of all DMARD therapy and is 
increasingly achievable by patients with rheumatoid arthritis (RA).1 This status 
is also characterised by normalisation of functional status and lower levels of 
fatigue, pain and morning stiffness and is currently considered the best possible 
outcome of RA.1 Absence of anti-citrullinated protein antibodies (ACPA) at disease 
presentation is an important predictor of achievement of sustained DMARD-
free remission; however, with current treatment strategies this outcome is also 
observed in 10% of ACPA-positive RA.1-5
The pathophysiological role of ACPA in RA development or progression is not 
exactly known. ACPA can be present years before the onset of joint symptoms 
and disease, indicating that the mere presence of ACPA is not enough to develop 
disease.6,7 Studies in the preclinical phase have shown that the ACPA immune 
response matures once disease onset is approached, as characterised by an increase 
in ACPA level, isotype-usage, avidity and the number of citrullinated epitopes 
recognised by ACPA.8-11 In addition, there are changes in Fc glycosylation before 
RA onset.12 Once RA is established the ACPA immune response does not mature any 
further.13 Besides ACPA, also rheumatoid factor (RF) can be present years before 
disease onset.6,7 Since autoantibodies are considered to have a prominent role in 
seropositive RA and precede symptom development, it is tempting to hypothesise 
that changes in the autoantibody response occur before or at the time when 
clinical disease has been extinguished, as is the case when sustained DMARD-free 
remission is reached. In this light, it was recently suggested that disappearance of 
autoantibodies is a hallmark of immunological remission and might characterise 
patients who are able to achieve drug-free remission.14
However, so far this hypothesis has not been thoroughly investigated. In a few 
studies, seroconversion and seroreversion during follow-up of early arthritis 
and RA patients were investigated. The observations described indicate that both 
are infrequent and not associated with relevant outcomes such as radiographic 
damage, functional status or the disease activity score.15-18 In only one study, the 
association between seroreversion and drug-free remission was analysed and no 
association was observed.19 However, autoantibody levels were only determined 
at disease presentation and at 1 year of follow-up, thus generally years before 
achievement of drug-free remission. In addition, follow-up of patients after the 
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achievement of drug-free remission was limited.19
We aimed to increase the understanding of the long-term course of RA-related 
autoantibodies in patients who had achieved the closest available proxy of cure of 
RA. Therefore, we investigated the association between ACPA and RF seroreversion 
and achievement of sustained DMARD-free remission in a unique population of RA 
patients with available serum samples at the time of remission and with a long 
follow-up duration after achievement of DMARD-free status.
Methods
Patients
Patients were retrieved from the Leiden Early Arthritis Clinic cohort, which is 
an inception cohort that includes patients with clinically confirmed arthritis and 
symptom duration <2 years. At baseline, patients and rheumatologists completed 
questionnaires, joint counts were performed and blood samples were collected. 
Follow-up visits were scheduled and blood samples were taken at 3-4 months, 6-8 
months, 12 months, 18 months, 24 months and yearly thereafter. Between 1993 
and 2014, 3473 patients were consecutively included, of which 1586 patients had 
a clinical diagnosis of RA and also fulfilled 1987 or 2010 RA classification criteria 
during the first year of follow-up.20,21 Of these, 941 patients were ACPA-positive 
and/or RF-positive at baseline.
Treatment strategies changed over time. In general, patients included in 1993-
1995 were initially treated with non-steroidal anti-inflammatory drugs, patients 
included in 1996-1998 with mild DMARDs (hydroxychloroquine or sulphasalazine) 
and patients included ≥1999 were initially treated with methotrexate. When 
this treatment failed, another conventional DMARD was initiated or added. A 
biological DMARD was allowed in patients who failed on ≥2 conventional DMARDs. 
Medication used by all studied patients during the observed follow-up period is 
shown in Table 9.1. Disease activity score (DAS44)-guided treatment became 
common from 2005 onwards with tapering and eventually stopping of treatment 
if DAS44 remained <2.4 and synovitis was absent at clinical joint examination, and 
intensifying treatment in case of DAS44 ≥2.4.
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Table 9.1 Medication use during the total follow-up period; stratified by patient group
DMARD-free sustained 
remission (n=95)




Methotrexate, n(%) 76 (80) 21 (100) 44 (98)
Other conventional DMARDs, n(%) 46 (48) 11 (52) 37 (82)
Sulfasalazine, n(%) 27 (28) 6 (29) 28 (62)
Hydroxychloroquine, n(%) 26 (27) 8 (38) 32 (71)
Leflunomide, n(%) 9 (9) 5 (24) 17 (38)
Azathioprine, n(%) 1 (1) 0 (0) 3 (7)
Cyclosporine, n(%) 0 (0) 1 (5) 0 (0)
Gold, n(%) 2 (2) 0 (0) 1 (2)
Biological DMARD, n(%) 14 (15) 6 (29) 19 (42)
TNF-inhibitor, n(%) 11 (12) 4 (19) 17 (38)
Rituximab, n(%) 1 (1) 1 (5) 2 (4)
Abatacept, n(%) 0 (0) 0 (0) 3 (7)
Tocilizumab, n(%) 2 (2) 1 (5) 3 (7)
Omalizumab, n(%) 0 (0) 0 (0) 1 (2)
Numbers indicate the number of patients who used the indicated medication at any time during follow-
up; therefore, the indicated percentages for the different groups do not add up to 100%. The duration that 
patients used the medication and the number of patients using combination therapy is not indicated here. 
DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; TNF, tumor necrosis factor.
Of the 1586 RA patients, medical files were studied on occurrence of sustained 
DMARD-free remission until April 2017. This outcome was defined as absence of 
synovitis (by physical examination) after cessation of all DMARD therapy (including 
biologics and systemic and intra-articular corticosteroids) for at least 1 year and for 
the remainder of follow-up. Patients who experienced a flare of clinical synovitis 
early or late after DMARD cessation were considered as not in sustained DMARD-
free remission. The date of sustained DMARD-free remission was the date 1 year 
after DMARD cessation. Patients who did not achieve remission were censored at 
the date when medical files were explored or at an earlier date when they were 
lost to follow-up or had died. Ninety-five of 941 ACPA-positive and/or RF-positive 
RA patients achieved sustained DMARD-free remission after a median follow-up 
of 4.8 years (Figure 9.1). After achievement of sustained DMARD-free remission, 
patients were additionally followed for median 4.2 years. Except for 1 patient, all 
patients were included from 1999 onwards.
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Figure 9.1 Flowchart of patient selection
DMARD-free remission was defined as the absence of clinical synovitis for ≥1 year after DMARD 
cessation. Flares were defined as recurrence of synovitis after having achieved DMARD-free remission, 
thus recurrence of synovitis >1 year after DMARD cessation. Sustained DMARD-free remission was 
defined as absence of synovitis after DMARD cessation during the complete follow-up, but at least for 
1 year. As control, 45 autoantibody-positive patients with persistent RA were selected from the group 
of autoantibody-positive RA patients who never achieved DMARD-free remission based on comparable 
inclusion period as patients who achieved sustained remission and based on available serum samples. 
ACPA, anti-citrullinated protein antibodies; DMARD, disease-modifying antirheumatic drug; RA, 
rheumatoid arthritis; RF, rheumatoid factor.
In addition, 21 autoantibody-positive RA patients who experienced a late flare 
were studied. These patients had absence of clinical synovitis for ≥1 year after 
DMARD cessation, thus were initially in DMARD-free remission. However, this 
remission was not sustained since these patients had recurrence of synovitis 
and needed to restart DMARDs during the remainder of follow-up. The median 
duration of being in DMARD-free remission before a flare occurred was 2.2 years. 
As control, 45 autoantibody-positive RA patients who were unable to stop DMARD 
therapy because of persistent swollen joints during follow-up, were evaluated. 
These patients were selected from the group of autoantibody-positive RA patients 
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who never achieved DMARD-free remission based on comparable inclusion period 
and on available serum samples at baseline, 1 year and at 7-8 years follow-up or 
earlier in case patients had a shorter follow-up duration.
Median total follow-up of the studied patients was 10 years and was comparable 
between the studied groups. 
Serological measurements 
Anti-cyclic citrullinated peptide 2 (anti-CCP2) IgG and RF IgM were measured in 
587 serum samples obtained at diagnosis, before and after achieving DMARD-
free remission, using enzyme-linked immunosorbent assays as described 
previously.22,23 In all cases, <5% of controls were autoantibody-positive with the 
cut-offs used. In short, for IgM-RF, human IgG1 was used as the capture antigen 
and bound antibodies were detected with F(ab′)2 fragments of peroxidase-
conjugated antihuman IgM. The cut-off for positivity was 8 IU/mL. For anti-CCP2 
IgG, the anti-CCP2 test (Immunoscan RA Mark 2; Euro-Diagnostica, Arnhem, The 
Netherlands) was used with a cut-off value of 25 units/mL, as described in the 
manufacturer’s instructions. An overview of the measured samples during follow-
up for the different groups is depicted in Figure 9.2. Of each patient, a median of 
three samples was measured. In addition, anti-CCP2 IgM was measured in the first 
and last available serum sample of patients who were positive for anti-CCP2 IgG 
at disease presentation. In brief, microtiter plates were coated with citrullinated 
CCP2. An arginine control was used as control for citrulline specificity of the anti-
CCP antibodies. Plates were incubated for 1 hour at 37°C with serum samples, 50 
µL/well, at a dilution of 1:50. To detect anti-CCP2 IgM, plates were incubated for 
1 hour at 37°C, 50 µL/well, with peroxidase-conjugated anti-human IgM. Pooled 
serum samples of highly positive patients were used in all plates to generate 
standard curves. Autoantibody levels were estimated by interpolation from these 
standard curves and were expressed in arbitrary units per millilitre. Samples were 
considered positive when the signal was higher than the mean +2 SD of serum 
samples of 64 healthy control subjects in total. This resulted in a cut-off value of 
12 AU/mL. In addition, to ascertain that the obtained signal within the anti-CCP2 
IgM ELISA was citrulline-specific, the difference between the signal against the 
citrullinated peptide and the unmodified arginine peptide had to be >0.1 (OD >0.1). 
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Figure 9.2 Overview of samples measured during follow-up of patients who achieved sustained 
DMARD-free remission (A), patients with a late flare (B) and patients with persistent RA (C)
Numbers indicate the number of samples measured within the indicated time periods. In total, 587 samples 
were measured. Of patients who achieved sustained DMARD-free remission, samples were obtained at 
diagnosis, before and at or after achieving remission. DMARD, disease-modifying antirheumatic drug; RA, 
rheumatoid arthritis.
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Statistical analyses 
The difference between the first and last available serum sample was used to 
calculate the proportion of patients with seroreversion. This was performed 
separately for patients positive for anti-CCP2 IgG, anti-CCP2 IgM and RF IgM. 
Differences in seroreversion between the three patient groups were compared 
with the Fisher exact test. To test whether changes in ACPA and/or RF levels during 
follow-up were associated with achievement of sustained DMARD-free remission, 
Cox proportional hazards regression analyses were performed with time till 
achievement of remission as outcome. For these analyses, patients with a late flare 
were combined with patients with persistent RA as one group. Changes in anti-
CCP2 IgG and RF IgM level per year were estimated with linear regression analyses 
for each patient individually. These changes in levels over time were used as 
predictor in Cox proportional hazards regression analyses. Antibody levels below 
the detection limit were imputed with a value of 0.
Several subanalyses were performed to study whether results on seroreverion 
could be ascribed to variation around the cut-off level, whether results were 
different when groups were stratified for autoantibody combinations, whether 
results were different in patients who were treated early, or whether results 
were dependent on the follow-up duration. Finally, for RF a second cut-off for RF 
positivity was used. This was done as the cut-off that is used in clinical practice 
has a specificity of 95% when compared with healthy controls, but a reduced 
specificity when patients with other arthritides were used as reference.24 A cut-off 
of 33 allowed a specificity of 98% relative to patients with other early arthritides 
in our cohort (data not shown) which was then equal to the specificity of ACPA. 
SPSS V.23.0 was used and p-values <0.05 were considered significant.
Results
Patient characteristics 
Baseline characteristics of the studied autoantibody-positive patients are presented 
in Table 9.2 and are similar between the different groups, with the exception that 
patients who achieved sustained DMARD-free remission were less frequently 
ACPA-positive.
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Table 9.2 Baseline characteristics of RA patients who achieved sustained DMARD-free remission, 
who flared after being in DMARD-free remission and of patients with persistent RA
Sustained DMARD-
free remission (n=95)
Late flare after ≥1 





Age in years, mean (SD) 54 (17) 52 (13) 55 (12) 0.63
Female, n (%) 65 (68) 13 (62) 30 (67) 0.85
Symptom duration in weeks, median 
(IQR)
17 (10-35) 20 (8-37) 20 (13-38) 0.56
66-SJC, median (IQR) 5 (3-9) 5 (2-13) 5 (3-8) 0.81
68-TJC, median (IQR) 8 (3-13) 12 (4-15) 5 (4-11) 0.32
Autoantibody status 0.047
anti-CCP2 IgG+ RF IgM-, n(%) 9 (9) 0 (0) 4 (9)
anti-CCP2 IgG- RF IgM+, n(%) 41 (43) 6 (29) 10 (22)
anti-CCP2 IgG+ RF IgM+, n(%) 45 (47) 15 (71) 31 (69)
CRP (mg/L), median (IQR) 11 (3-28) 11 (4-23) 14 (5-40) 0.39
ESR (mm/h), median (IQR) 26 (14-49) 29 (13-44) 29 (20-41) 0.75
Patients with persistent RA were selected from the group of autoantibody-positive RA patients who 
never achieved DMARD-free remission based on comparable inclusion period as patients who achieved 
sustained remission and based on available serum samples. anti-CCP2, anti-cyclic citrullinated peptide 
2; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; IQR, interquartile range; RA, 
rheumatoid arthritis; RF, rheumatoid factor; SD, standard deviation; SJC, 66-swollen joint count; symptom 
duration, time between symptom onset and inclusion in cohort; TJC, 68-tender joint count.
Anti-CCP2 IgG and RF IgM seroreversion were not associated with achievement 
of sustained DMARD-free remission
First, anti-CCP2 IgG levels were serially measured in the three different patient 
groups (Figure 9.3A). Of anti-CCP2 IgG-positive RA patients who achieved sustained 
DMARD-free remission, 13% had reverted to anti-CCP2 IgG negativity around the 
time of remission (Figure 9.4A). However, for RA patients with a late flare or with 
persistent disease, seroreversion was observed in 8% and 6%, respectively, which 
was not significantly different from patients who achieved sustained DMARD-free 
remission (p=0.63).
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Figure 9.3 Anti-CCP2 IgG levels in ACPA-positive RA patients (A) and RF IgM levels in RF-
positive patients (B) during follow-up, stratified for clinical outcome
Dotted lines indicate the cut-off values (25 AU/mL for anti-CCP2 IgG and 8 IU/mL for RF IgM). Values 
below the detection limit were imputed with the value of 0. Number of ACPA and RF-positive patients 
in each group: DMARD-free sustained remission: ACPA+ n=54, RF+ n=86, flare: ACPA+ n=15, RF+ n=21, 
persistent RA: ACPA+ n=35, RF+ n=41. ACPA, anti-citrullinated protein antibodies; anti-CCP2, anti-cyclic 
citrullinated peptide 2; DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; 
RF, rheumatoid factor.
Patients with seroreversion had lower median anti-CCP2 IgG levels at disease 
presentation than patients without seroreversion (42 and 420 AU/mL, 
respectively, p<0.001). Ever use of biological DMARDs was comparable in 
patients with and without seroreversion (33% and 32%, respectively, p=1.00). To 
further analyse the effect of differences in medication use between patients, 
analyses were stratified for medication ever used during follow-up. This 
revealed similar results as in the whole group of patients (Supplementary table 
9.1).
Similar results were observed for RF IgM (Figures 9.3B and 9.4B). RF-positive 
patients who achieved sustained DMARD-free remission had seroreversion in 
20%, whereas this occurred in 6% and 15% of patients with a late flare and with 
persistent disease, respectively (p=0.44, Figure 9.4B). RF IgM levels were lower in 
patients with seroreversion than in patients who remained positive for RF IgM (19 
and 53 IU/mL, respectively, p=0.003). Thus, ACPA or RF seropositive RA 
patients who achieved sustained DMARD-free remission did not become more 
frequently seronegative than patients who did not achieve remission.
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Figure 9.4 Reversion to anti-CCP2 IgG (A) and RF IgM (B, C) seronegativity in autoantibody-positive 
RA patients who achieved sustained DMARD-free remission, who had a late flare and in patients 
with persistent RA
Analyses were performed in patients positive for anti-CCP2 IgG (A) or positive for RF IgM (B, C). For the 
analyses presented in (A) and (B) the cut-offs used were determined by the manufacturer and are similar 
to those used in clinical practice. For RF, also a cut-off of 33 was used to define positivity. This cut-off 
resulted in a specificity of 98% relative to patients with other early arthritides and was then comparable 
to the ACPA test (C). Seroreversion was defined as shifting from seropositive at baseline to seronegative 
in the last available serum sample; for patients who achieved sustained DMARD-free remission the last 
sample was measured at the time of remission. Number of patients in each group: sustained DMARD-
free remission: ACPA+ n=47, RF+ cut-off 8 n=71, RF+ cut-off 33 n=44, late flare: ACPA+ n=12, RF+ cut-off 8 
n=16, RF+ cut-off 33 n=13, persistent RA: ACPA+ n=35, RF+ cut-off 8 n=41, RF+ cut-off 33 n=25. ACPA, anti-
citrullinated protein antibodies; anti-CCP2, anti-cyclic citrullinated peptide 2; DMARD, disease-modifying 
antirheumatic drug; RA, rheumatoid arthritis; RF, rheumatoid factor.
Changes in RF IgM levels were larger in patients with sustained DMARD-free 
remission than in patients with persistent RA
Next, it was evaluated whether changes in autoantibody levels during the total 
follow-up period differed between patients. The change in anti-CCP2 IgG level per 
year was not associated with achievement of sustained DMARD-free remission 
(p=0.66). For RF IgM-positive patients, the change in RF level was associated with 
achievement of sustained DMARD-free remission; for every 10-unit decrease in 
RF IgM level per year the rate of sustained DMARD-free remission increased by 
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16% (p<0.001). Thus, seropositive RA patients who achieved sustained DMARD-
free remission did not have disappearance of autoantibodies; however, there was 
a significant decrease of RF IgM levels in patients who achieved sustained DMARD-
free remission compared with patients who did not.
Anti-CCP2 IgM seroreversion was not associated with sustained DMARD-free 
remission
Finally, the proportion of patients seroreverting from anti-CCP2 IgM positive to 
negative was studied as we hypothesised that if the ACPA immune response had 
changed in patients who achieved remission, this could be reflected by a decreased 
presence of anti-CCP2 IgM, since IgM is an indication of an ongoing immune 
response. Of anti-CCP2 IgG-positive patients, 25-29% were also positive for anti-
CCP2 IgM at disease presentation within the different groups. During follow-up, 
31% (4/13) of the anti-CCP2 IgG and IgM-positive patients who achieved DMARD-
free remission seroreverted from positive to negative anti-CCP2 IgM (Figure 9.5). 
For patients with a late flare and patients with persistent RA, this occurred in 
100% (3/3) and 60% (6/10), respectively. Thus, patients who achieved sustained 
DMARD-free remission and who were seropositive for anti-CCP2 IgM at disease 
presentation did not serorevert more frequently than patients who did not achieve 
remission.
Figure 9.5 Change in anti-CCP2 IgM status during follow-up in patients who achieved DMARD-free 
sustained remission, who had a flare and in patients with persistent RA
Data are shown for the subgroup of anti-CCP2 IgG+ patients at baseline. Number of patients in each group: 
DMARD-free sustained remission: n=47, flare: n=12, persistent RA: n=35. Anti-CCP2, anti-cyclic citrullinated 
peptide 2; DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis.
 173
AUTOANTIBODY LEVELS AND SUSTAINED DMARD-FREE REMISSION
9
Sensitivity analyses
To investigate whether our results were driven by patients with autoantibody 
levels fluctuating around the cut-off, analyses were performed in patients with 
baseline autoantibody levels above the median which showed that none of the 
anti-CCP2 IgG-positive patients had seroreverted. For RF IgM, 8% of patients who 
achieved sustained DMARD-free remission, none of the patients with a late flare 
and 10% of patients with persistent disease had seroreverted.
To study the hypothesis that early treatment might be associated with higher rates 
of seroreversion, analyses were repeated in patients with short symptom duration 
before treatment start (<12 weeks) and with long symptom duration (≥12 weeks). 
Of anti-CCP2 IgG-positive patients who achieved remission, 10% of the patients 
with a short symptom duration had reverted to seronegativity; this was 15% of 
patients with a long symptom duration (p=1.00). For RF IgM, these percentages 
were 25% and 18%, respectively (p=0.54). Thus, seroreversion rates were not 
higher in patients with earlier treatment initiation.
Next, it was assessed whether single autoantibody positivity was associated with 
higher seroreversion rates. Of ACPA-positive patients, 7% of ACPA+ RF+ and 23% 
of ACPA+ RF- patients had reverted from anti-CCP2 IgG positivity to negativity 
(p=0.12). Of RF-positive patients, 6% of ACPA+ RF+ and 34% of ACPA- RF+ patients 
had reverted to RF IgM negativity (p<0.001). 
In addition, analyses were stratified for different autoantibody combinations, 
since patients with sustained DMARD-free remission were less frequently positive 
for both ACPA and RF than the other studied groups. Similar to our main analysis, 
seroreversion rates for ACPA and RF were not significantly different between 
patients with and without sustained remission (Supplementary table 9.2). Thus, 
single RF-positive patients seroreverted more often (when cut-off of 8 was used) 
than ACPA+ RF+ patients, but the frequency of seroreversion was not higher in the 
group that achieved sustained remission group compared with the group that did 
not.
Analyses were also repeated in patients who had a follow-up duration of ≥4.2 years 
after achievement of sustained DMARD-free remission (i.e., within 50% of patients 
with the longest follow-up after DMARD cessation). This analysis was performed 
to verify if patients with shorter follow-up after DMARD cessation influenced 
the results, as these patients could be at risk of developing a late flare. Of anti-
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CCP2 IgG-positive RA patients who achieved sustained DMARD-free remission, 
6% had reverted to anti-CCP2 negativity around the time of remission, which was 
not different from patients with a late flare and with persistent disease, who had 
seroreversion in 8% and 6%, respectively (p=1.00). Of RF IgM-positive RA patients 
who achieved sustained DMARD-free remission, 16% had reverted to RF IgM 
negativity. Of patients with a late flare and with persistent disease this occurred in 
6% and 15%, respectively (p=0.78).
Finally, seroreversion for RF was also studied when the cut-off for positivity was 
set at 33. Also then no differences in seroreversion rates were observed between 
the three different groups (p=0.86, Figure 9.4C). When the different autoantibody 
combinations were studied with this cut-off, 6% of ACPA+ RF+ and 16% of ACPA+ 
RF- patients had reverted to anti-CCP2 negativity (p=0.27). Of RF-positive patients, 
37% of ACPA+ RF+ and 35% of ACPA- RF+ patients had reverted to RF IgM negativity 
(p=1.00). Thus, also when a different cut-off for RF positivity was used, patients 
who achieved sustained DMARD-free remission did not serorevert more often 
than patients with a late flare or with persistent disease.
Discussion
Currently, a sustained DMARD-free status is the best possible clinical outcome as, 
per definition, clinically apparent synovitis is persistently absent and patients in 
this status also have resolution of symptoms and normalised functional status.1 
This outcome is achievable in autoantibody-positive RA, although with a lower 
frequency than in autoantibody-negative RA. The biological nature underlying 
this type of persistent remission is unknown. It was recently suggested that it is 
characterised by disappearance of autoantibodies.14 The present large observational 
study with a unique, long follow-up period and with samples measured at the time 
of remission, explored this hypothesis. No association between remission and 
reversion to autoantibody negativity was demonstrated. Hence, although it has 
been suggested that immunological remission is characterised by disappearance 
of autoantibodies,14 we studied patients in the deepest form of clinical remission 
and observed no increased frequency of reversion to seronegativity in this group.
To our knowledge, this is the first study in which seroreversion rates in patients 
with long-standing DMARD-free status were investigated. Importantly, for both 
ACPA and RF seroreversion was infrequent and not related to clinical outcome. In 
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previous studies in patients with established RA who were treated with DMARDs 
and thus had persistent disease, similar seroreversion rates were observed.18,25-27 
Thus, seroreversion rates observed here are in line with previous findings in RA 
and are not increased in patients with sustained DMARD-free status.
When analyses were repeated in patients with high autoantibody levels (above the 
median) at baseline, seroreversion for anti-CCP2 IgG was not observed anymore, 
and seroreversion for RF IgM was less frequent than in the whole group of 
autoantibody-positive patients. This suggests that the observed seroreversion rates 
were mainly the result of patients who fluctuated around the cut-off level, and 
therefore that true seroreversion of ACPA and RF is only sporadically observed.
Although no association between remission and seroreversion was observed, 
patients who achieved a DMARD-free status had a larger decrease in RF levels 
during follow-up than patients who did not achieve this outcome. The slopes of 
the levels along follow-up are relevant to appreciate the immunological evolution, 
which was different for RF and ACPA. Several studies have shown that improvement 
in disease activity is accompanied by decrease in RF levels,27-31 although some other 
studies did not observe this.18,19,32 A unique feature of this study is that a prolonged 
period of absence of clinical synovitis is observed, which is a much more stringent 
outcome than improvement in disease activity scores. Previous studies showed no 
relation between ACPA levels and disease activity and our data also demonstrated 
no relation with sustained DMARD-free status.27-31
Previously, it was shown that anti-CCP2 IgM remains present in RA patients 
during treatment in a persistent disease phase, suggesting that the anti-CCP 
immune response is continuously reactivated.33 Interestingly, we have shown 
here that anti-CCP2 IgM also remained persistently present in patients who 
achieved sustained DMARD-free remission. This suggests that even in patients 
who are clinically cured, the anti-CCP response is persistently activated. ACPA 
characteristics other than level and IgM and IgG isotypes were not investigated. 
However, it is known that ACPA-level is highly associated with ACPA fine specificity 
and the number of ACPA isotypes.34 Based on this, it can be presumed that these 
characteristics were also not different between patients who did or did not achieve 
a sustained DMARD-free status. Nonetheless, we do not rule out that these, or other 
characteristics of the autoantibody response in RA correlate with the induction 
of sustained DMARD-free remission. Altogether, disappearance of clinical disease 
is not accompanied by changes in the humoral ACPA response in serum. Thus, 
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whereas for RA development it is not yet elucidated whether ACPA play a role 
in the pathophysiology or act as bystander, the present data suggest that the 
ACPA response does not explain the maintained resolution of clinical disease. 
Whether other immunological markers, for instance, changes in characteristics 
of autoantibody expressing B cells, associate with this phenotypic outcome, and 
therefore would be a better definition of immunological remission, is subject of 
further research.
A strength of this study is that patients had a long follow-up period also after 
DMARD cessation (median 4.2 years after achievement of sustained DMARD-free 
remission, thus median 5.2 years after DMARD stop). This follow-up time supports 
the validity of the outcome, as patients with an early flare after DMARD stop 
were never considered to be in remission, and also patients with a late flare were 
identified and excluded from the group of patients who achieved sustained DMARD-
free remission. Late flares generally occurred 2.2 years after DMARD cessation 
and the large majority of patients were followed for a longer period of time after 
DMARD stop. A subanalysis in the patients who were followed for >4 years after 
achieving remission showed similar results, showing the robustness of the data 
in this respect. Of course, we do not know if the autoantibody-positive patients 
will get a flare of disease after an even longer follow-up period; this is subject 
of future studies. Some of the patients have been discharged from the outpatient 
clinic because of prolonged absence of synovitis and symptoms. Importantly, it is 
plausible that if symptoms will recur patients will return to our clinic since the 
Leiden University Medical Center is the only referral centre in a healthcare region 
of ∼400,000 inhabitants and has very easy access services, allowing that patients 
with symptoms suspicious of RA are seen within 1 week.35
Treatment was not protocolised and the applied treatments changed over time. 
This resulted in heterogeneity of treatments received by patients. Nonetheless, 
when stratifying patients in groups according to medications ever used during 
follow-up, results remained similar.
Another limitation might be that not of all patients with sustained DMARD-free 
remission serum samples were available after medication was stopped. However, 
when analyses were repeated in this subgroup of patients, similar results were 
obtained (data not shown).
Previously, it was suggested that remission can be defined according to different 
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conditions and presence of immunological remission, defined as the disappearance 
of autoantibodies, was suggested to be the deepest form of remission. In this long-
term study, we were able to analyse a large number of ACPA-positive patients who 
achieved sustained DMARD-free remission. In this unique dataset, we observed 
that disappearance of autoantibodies rarely occurred, and that patients who 
achieved the best possible outcome of RA did not become more often seronegative 
than patients with persistent disease. Therefore, in our view, this definition of 
immunological remission should not be a long-term treatment target.
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Supplementary table 9.1 Comparison of seroreversion rates between patients with sustained 


















































0 (0) 0 (0) 2 (13) 0.63
Patients were stratified for medication use during follow-up. The duration of treatment and combination 
therapy is not indicated here. Numbers indicate the number of patients with CCP2 IgG or RF IgM 
seroreversion within patients who where ACPA-positive or RF-positive at disease presentation, and who 
used the indicated medication during follow-up. ACPA, anti-citrullinated protein antibodies; anti-CCP anti-
cyclic citrullinated peptide 2; DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; 
RF, rheumatoid factor; TNF, tumor necrosis factor.
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Supplementary table 9.2 Comparison of seroreversion rates between patients with sustained 










anti-CCP2 IgG reversion to negative, n(%) 4 (11) 2 (5) 0.41
anti-CCP2 stable positive, n(%) 34 (89) 41 (95)
RF IgM reversion to negative, n(%) 4 (11) 1 (2) 0.18
RF IgM stable positive, n(%) 34 (89) 42 (98)
ACPA+RF-
anti-CCP2 IgG reversion to negative, n(%) 2 (22) 1 (25) 1.00
anti-CCP2 stable positive, n(%) 7 (78) 3 (75)
ACPA-RF+
RF IgM reversion to negative, n(%) 10 (30) 6 (43) 0.51
RF IgM stable positive, n(%) 23 (70) 8 (57)
B ACPA+RF+
anti-CCP2 IgG reversion to negative, n(%) 2 (7) 2 (6) 1.00
anti-CCP2 stable positive, n(%) 28 (93) 30 (94)
RF IgM reversion to negative, n(%) 11 (37) 12 (37.5) 1.00
RF IgM stable positive, n(%) 19 (63) 20 (62.5)
ACPA+RF-
anti-CCP2 IgG reversion to negative, n(%) 4 (24) 1 (7) 0.34
anti-CCP2 stable positive, n(%) 13 (76) 14 (93)
ACPA-RF+
RF IgM reversion to negative, n(%) 4 (29) 3 (50) 0.61
RF IgM stable positive, n(%) 10 (71) 3 (50)
Patients were stratified for autoantibody status at baseline. In part A the cut-off for RF positivity was 8 
IU/ml, in part B this was 33 IU/ml to arrive at a specificity of 98%, comparable to the ACPA test. Numbers 
indicate the number of patients with CCP2 IgG or RF IgM seroreversion within patients who where ACPA-
positive or RF-positive at disease presentation. ACPA, anti-citrullinated protein antibodies; anti-CCP anti-
cyclic citrullinated peptide 2; DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; 
RF, rheumatoid factor.
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RA: patients with high 
likelihood of achieving 
sustained DMARD-free 
remission are characterized 
by a combination of 
serological markers at 
disease presentation









Disease-modifying antirheumatic drug (DMARD)-free remission, the sustained 
absence of synovitis after DMARD cessation, is increasingly achievable, especially 
in autoantibody-negative rheumatoid arthritis (RA). However, underlying 
mechanisms are unknown and patient subgroups that achieve this outcome are 
insufficiently characterized. We  ev aluated wh ether se rological biomarkers at 
disease onset, as measured within the multibiomarker disease activity (MBDA) 
score, are differently expressed in RA patients who achieve sustained DMARD-free 
remission.
Methods
Two hundred ninety-nine RA patients were evaluated for achievement of sustained 
DMARD-free remission during a median follow-up of 4.3 years. Twelve biomarkers, 
as included in the MBDA score, were determined from the serum obtained at 
disease onset. Patients were categorized as having a low (<30), moderate (30-44) or 
high (>44) score. Analyses were stratified for anti-citrullinated protein antibodies 
(ACPA) based under the assumption that ACPA-positive and ACPA-negative RA are 
different disease entities.
Results
Twenty percent achieved sustained DMARD-free remission. Overall, high MBDA 
scores were associated with achieving DMARD-free remission (high vs. low HR 
3.8, 95% CI 1.2-12.2). Among ACPA-negative RA patients, moderate or high scores 
associated strongly with DMARD-free remission (moderate vs. low HR 9.4, 95% 
CI 1.2-72.9; high vs. low HR 9.7, 95% CI 1.3-71.1). This association was 
independent of age and other clinical factors (high vs. low HR 8.2, 95% CI 
1.1-61.8). For ACPA-negative RA patients, the biomarkers C-reactive protein, 
serum amyloid A and matrix metalloproteinase-3 were individually associated 
with sustained DMARD-free remission. Among ACPA-positive RA patients, scores 
were not associated with DMARD-free remission.
Conclusions
ACPA-negative RA patients who achieved sustained DMARD-free remission after 
treatment withdrawal were characterized by moderate to high MBDA scores at 
diagnosis. This is the first evidence that ACPA-negative RA can be subdivided in 
clinically relevant subsets at disease onset using a protein profile.
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Background
Rheumatoid arthritis (RA) is a syndrome which presumably consists of several 
disease entities. Most data have focused on differences in RA characterized by the 
presence and absence of autoantibodies, in particular anti-citrullinated protein 
antibodies (ACPA). ACPA-positive patients have in general a more persistent 
and destructive disease course than ACPA-negative patients. The generation of 
different disease subsets in seronegative patients that have a clinical diagnosis of 
RA and fulfil respective classification criteria is unsuccessful thus far.1 Therefore, 
we investigated if we could identify patients in the ACPA-negative subgroup that 
have the best clinical outcome, which currently is the achievement of sustained 
disease-modifying antirheumatic drug (DMARD)-free remission.
The biological mechanisms underlying the achievement of sustained DMARD-
free remission are unknown. Additionally, it is undefined whether this outcome is 
potentially achievable by all RA patients or whether the ability to permanently stop 
DMARDs is restricted to a set of RA patients with certain biological characteristics. 
Several studies have shown that a shorter symptom duration, which is a disease 
phase characteristic rather than a ‘patient characteristic’, is associated with a 
greater probability of achieving sustained DMARD-free remission.2-6 The second 
important factor is the absence of ACPA.1,2,6 This suggests that patients who can 
achieve remission are inherently different. However, the absence of autoantibodies 
only explains part of the variability in outcome, since a proportion of ACPA-
positive patients can achieve sustained DMARD-free remission and the majority 
of ACPA-negative patients do not achieve it.7 We assumed that patients who are 
able to achieve sustained DMARD-free remission are intrinsically different from 
patients who are unable to do so. If this hypothesis is true, these patients might 
be identifiable by biomarkers present at disease presentation. With respect to 
systemically measurable markers, C-reactive protein (CRP) has been studied 
and decreased levels were associated with sustained DMARD-free remission 
in one study,2 while in another study no association was observed.8 Other 
inflammatory proteins have not been studied in relation to sustained DMARD-
free remission.
Several serological biomarkers are combined in the multi-biomarker 
disease activity (MBDA) score, which is developed to measure RA disease 
activity.9,10 The level of the 12 biomarkers which are combined in the MBDA 
score might indicate relevant pathways involved in RA disease activity, and the 





rate (ESR) or CRP alone. Several studies have shown that higher MBDA scores 
measured during the disease course are predictive of radiographic progression in 
the next years,11-13 although there are also studies showing no association.14-16 It is 
unexplored if the serological biomarkers included in the score are associated with 
an opposite, favourable outcome, i.e. achieving sustained DMARD-free remission.
Our ultimate aim was to identify subgroups of RA patients that are identifiable at 
disease presentation, for which sustained DMARD-free remission is an achievable 
outcome. We hypothesized that individual serological markers or a combination 
of these is helpful to characterize these subgroups. Therefore, we investigated the 
association between the MBDA score and its component serological markers at first 
presentation with RA and the achievement of sustained DMARD-free remission. 
We observed that the subgroup of ACPA-negative RA patients with a high chance 
of achieving sustained DMARD-free remission can already be identified at the time 
of diagnosis by the presence of a combination of proteins.
Methods
Patients
The Leiden Early Arthritis Clinic cohort is an inception cohort that enrolls patients 
with clinically confirmed arthritis of recent onset and symptom duration <2 years. 
At baseline, questionnaires were administered, joint counts and blood samples 
were collected and patients were evaluated annually thereafter.1 Baseline serum 
samples were tested for CRP level, ESR, IgG ACPA (EliA CCP (anti-CCP2), Phadia, 
Nieuwegein, the Netherlands) and IgM rheumatoid factor (RF; in-house ELISA, as 
described previously).17 Patients did not use DMARDs or glucocorticoids before 
inclusion.
For this study, RA patients included between 2010 and 2015 were evaluated, since 
this is the most recent inclusion period and since we have shown that sustained 
DMARD-free remission is increasingly achievable with current treatment 
strategies.8 RA was stringently defined by a clinical diagnosis of RA by an 
experienced rheumatologist. Besides a clinical diagnosis, patients needed to fulfil 
the 1987 or 2010 classification criteria during the first year.18,19 Both classification 
criteria were considered since ACPA-negative patients can be misclassified by the 
2010 criteria because they need >10 involved joints to achieve 6 points. Thus, all 
included RA patients had a clinical diagnosis of RA and in addition fulfilled RA 
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classification criteria. Patients diagnosed with conditions other than RA during the 
follow-up were not included in this study. In the period mentioned, 321 patients 
were eligible. Thirteen patients were excluded because they did not use DMARDs 
during the follow-up and 9 because measurement of an MBDA biomarker had 
failed. Thus, in total, 299 patients were studied.
The initial treatment of RA consisted of methotrexate, which could be combined 
with low-dose prednisone bridging therapy at DMARD start. Typically, when the 
first treatment failed, another conventional DMARD was initiated or added. A 
biological DMARD was allowed in patients that failed on ≥2 conventional DMARDs. 
During the full observation period, 91% of patients ever used methotrexate, 85% 
ever used other conventional DMARDs (systemic glucocorticoids, sulfasalazine, 
hydroxychloroquine, leflunomide or azathioprine) and 20% ever used biologicals. 
ACPA-positive patients more frequently used biologicals; further details are shown 
in Supplementary table 10.1. According to local and international guidelines, 
treatment was DAS44 guided with DMARD tapering in case of a DAS <2.4 and 
intensifying in case of a DAS ≥2.4.20 Subsequent to DMARD tapering, DMARDs were 
stopped in case the DAS44 remained <2.4 and synovitis was absent at clinical joint 
examination. Thereafter, patients were followed on the recurrence of synovitis 
or persistence of DMARD-free remission. The study was approved by the local 
medical ethics committee, and all patients signed informed consent.
Sustained DMARD-free remission 
Medical files were reviewed for all patients until April 2017 to identify the occurrence 
of sustained DMARD-free remission, which was defined as the absence of synovitis 
(by physical examination) that sustained after discontinuation of all DMARD 
therapy (including biologics and systemic and intra-articular corticosteroids) for 
the entire follow-up period and must have extended to at least 1 year after DMARD 
withdrawal. The date of sustained DMARD-free remission was defined as the date 
1 year after DMARDs were stopped. Patients who did not achieve remission were 
censored at the date when the medical file was explored or when they were lost 
to follow-up. One patient achieved sustained DMARD-free remission but relapsed 
during follow-up and was considered as not in remission.
The MBDA score 
Serum samples were collected at disease presentation, before any DMARD treatment 
(including glucocorticoids) was started, and stored at -80 °C. Crescendo Bioscience 




three separate multiplex, sandwich immunoassays: CRP, IL-6 (interleukin-6), SAA 
(serum amyloid A), TNFR1 (tumor necrosis factor receptor superfamily member 
1A), EGF (epidermal growth factor), VEGF-A (vascular endothelial growth factor-A), 
VCAM-1 (vascular cell adhesion molecule-1), MMP-1 (matrix metalloproteinase-1), 
MMP-3 (matrix metalloproteinase-3), YKL-40 (human cartilage glycoprotein-39), 
resistin and leptin. Measurements were performed blinded to clinical data and 
outcome. The biomarkers were studied individually and in combination by using 
a previously specified algorithm to calculate the MBDA score, ranging on a scale 
from 1 to 100.9,10,21 This MBDA algorithm was developed to measure disease activity 
with DAS28-CRP as reference. For analyses, patients were categorized according to 
previously established thresholds in categories of low (<30), moderate (30-44) and 
high (>44) MBDA score.10 Although we used the MBDA score for a purpose different 
than measuring disease activity, we used the same cut-off points for categorization.
Statistical analyses 
Kaplan-Meier analysis was used to estimate rates of achieving sustained DMARD-
free remission with MBDA category and the 12 individual biomarkers as grouping 
factors. For the latter analyses, patients were categorized into tertiles based on the 
biomarker levels to create three groups of equal size. Univariable Cox proportional 
hazards regression analyses were used to assess the association between baseline 
characteristics and the achievement of sustained DMARD-free remission. Baseline 
variables with a p-value <0.10 were included in a multivariable analysis to assess 
the independent relation between the serological markers and the achievement 
of sustained DMARD-free remission. Because achieving sustained DMARD-free 
remission is mostly confined to ACPA-negative RA and since we aimed to search for 
subgroups within ACPA-negative and ACPA-positive RA, analyses were stratified 




Baseline characteristics of the 299 RA patients are presented in Table 10.1. The 
median symptom duration at first presentation was 15 weeks (interquartile range 
(IQR) 8-32) and, similar to other early arthritis cohorts, 53% of patients were ACPA-
positive.22,23
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Age in years, mean (SD) 57 (14) 54 (14) 60 (14)
Female, n (%) 198 (66) 105 (66) 93 (66)
Symptom duration in weeks, median (IQR) 15 (8-32) 18 (9-38) 12 (5-26)
(Sub)acute symptom onset, n(%) 95 (34) 39 (27) 56 (43)
66-SJC, median (IQR) 6 (3-11) 5 (2-8) 8 (3-12)
68-TJC, median (IQR) 9 (4-15) 7 (4-13) 10 (4-18)
RF positivity, n (%) 183 (61) 134 (85) 49 (35)
ESR (mm/h), median (IQR) 28 (14-41) 28 (14-41) 28 (11-41)
CRP (µg/ml), median (IQR) 10 (3-23) 8 (3-18) 12 (3-30)
PTGA (0-100), median (IQR) 70 (50-80) 70 (45-80) 70 (60-80)
DAS44, median (IQR) 2.9 (2.4-3.4) 2.8 (2.3-3.3) 3.0 (2.5-3.7)
MBDA category
low (<30), n (%) 43 (14) 26 (16) 17 (12)
moderate (30-44), n (%) 64 (21) 35 (22) 29 (21)
high (>44), n (%) 192 (64) 97 (61) 95 (67)
Some data were missing as follows: symptom duration n=4, (sub)acute symptom onset n=23, 66-SJC n=19, 
68-TJC n=17, ESR n=3, PTGA n=50 , DAS44 n=20 and CRP n=1. ACPA, anti-citrullinated protein antibodies; 
CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; IQR, interquartile 
range; MBDA, multibiomarker disease activity; PTGA, patient global assessment; RA, rheumatoid arthritis; 
RF, rheumatoid factor; SD, standard deviation; (sub)acute symptom onset, prompt onset of symptoms 
(<1 week); SJC, 66-swollen joint count; symptom duration, time between symptom onset and inclusion in 
cohort; TJC, 68-tender joint count.
Development of sustained DMARD-free remission and distribution of MBDA 
scores 
The median follow-up duration was 4.3 years (IQR 4.0-4.7). Sustained DMARD-free 
remission was achieved in 20% (59/299) of RA patients after a median follow-up 
of 2.9 years (IQR 2.2-4.0). Sustained DMARD-free remission was achieved by 7% 
(11/158) of ACPA-positive patients and 34% (48/141) of ACPA-negative patients.
A combination of serological markers as reflected by MBDA scores associated 
with sustained DMARD-free remission within ACPA-negative RA
First, the association between the achievement of sustained DMARD-free remission 
during follow-up and the MBDA score at disease onset was evaluated in all RA 
patients (Figure 10.1A). With patients with low MBDA scores as reference, patients 
with moderate MBDA scores had an increased probability on the development of 
sustained DMARD-free remission (HR 3.42, 95% CI 0.97-12.02). A similar increased 
probability was observed for patients with high MBDA scores (HR 3.79, 95% CI 1.18-




ACPA-positive RA patients, the baseline MBDA category was not associated with 
achieving sustained DMARD-free remission (moderate vs. low HR 0.75, 95% CI 0.10-
8.19; high vs. low HR 0.89, 95% CI 0.19-4.31). By contrast, among ACPA-negative RA 
patients, moderate or high MBDA scores were strongly associated with achieving 
sustained DMARD-free remission (moderate vs. low HR 9.40, 95% CI 1.21-72.85; high 
vs. low HR 9.73 95% CI 1.33-71.10). Sustained DMARD-free remission was almost 
absent in the ACPA-negative group with low MBDA scores (only one patient in this 
group achieved remission after 6 years follow-up), whereas sustained DMARD-free 
remission was achieved by 38% of the ACPA-negative patients with moderate or 
high MBDA scores. The HR for achieving remission was 9.65 (95% CI 1.33-70.04) 
when ACPA-negative RA patients with either moderate or high MBDA scores were 
compared with patients with low MBDA scores. Thus, only for ACPA-negative RA 
patients, a combination of serological markers at diagnosis, reflected by the MBDA 
score, was associated with achievement of sustained DMARD-free remission.
A combination of serological markers associated with sustained DMARD-free 
remission, independent of clinical factors 
Next, we investigated whether the association between baseline MBDA score 
and sustained DMARD-free remission within ACPA-negative patients was 
independent of clinical characteristics. Of the clinical baseline characteristics, 
age at disease onset, the 66-swollen joint count and the presence of RF associated 
with sustained DMARD-free remission, with a p-value <0.10 in ACPA-negative 
RA; these characteristics were included in a multivariable analysis (Table 10.2). 
In this analysis, the MBDA category was associated with sustained DMARD-free 
remission, independent of these three factors, with moderate vs. low HR 6.96 (95% 
CI 0.88-55.31) and high vs. low HR 8.19 (95% CI 1.09-61.78) (Table 10.2).
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Figure 10.1 Kaplan-Meier plot showing achievement of sustained DMARD-free remission by category 
of MBDA score for all RA patients (A), ACPA-positive RA patients (B) and ACPA-negative RA patients 
(C)
Vertical lines indicate that a patient is censored. The numbers below the figures denote the number of 
patients at risk in each group. Visual representation of the data was restricted to 5 years follow-up since 
thereafter the number of patients was small. ACPA, anti-citrullinated protein antibodies; DMARD, disease-
modifying antirheumatic drug; MBDA, multi-biomarker disease activity; RA, rheumatoid arthritis.
Among ACPA-negative RA patients, higher CRP, SAA and MMP-3 levels 
associated with achieving sustained DMARD-free remission
Next, it was studied whether the observed association for ACPA-negative RA patients 
was driven by a subset of markers of the MBDA score. Therefore, the association 
between the level of the 12 individual biomarkers included in the MBDA score and 
the achievement of sustained DMARD-free remission was determined for ACPA-
negative RA patients (Supplementary figure 10.1). Of the individual biomarkers, 
higher CRP, SAA and MMP-3 levels at disease onset were associated with achieving 




7-39 μg/mL (second tertile) had a significantly increased probability on achieving 
sustained DMARD-free remission compared with patients with CRP levels <7 μg/
mL (lowest tertile) (HR 3.43, 95% CI 1.62-7.27), and for patients with CRP levels ≥39 
μg/mL (highest tertile), a similar trend was observed (HR 2.12, 95% CI 0.96-4.70). In 
addition, patients with MMP-3 levels ≥60 ng/mL (highest tertile) had a significantly 
increased probability on the development of sustained DMARD-free remission 
compared with patients with MMP-3 levels ≤28 ng/mL (lowest tertile) (HR 2.18, 
95% CI 1.06-4.48). SAA levels were also associated with achieving DMARD-free 
sustained remission. Patients with SAA levels ≥26 μg/mL (highest tertile) or 3-26 μg/
mL (second tertile) had a significantly increased probability on the development 
of sustained DMARD-free remission compared with patients with SAA levels ≤3 
μg/mL (lowest tertile) (HR 2.87, 95% CI 1.28-6.43 and HR 3.03, 95% CI 1.39-6.63, 
respectively). The other biomarkers were not individually associated with the 
achievement of sustained DMARD-free remission.
Table 10.2 Association between the MBDA score and achieving sustained DMARD-free remission 
over time within ACPA-negative RA patients
ACPA-negative RA patients




HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
MBDA score
low reference reference
moderate 9.40 (1.21-72.85) 0.032 6.96 (0.88-55.31) 0.067
high 9.73 (1.33-71.10) 0.025 8.19 (1.09-61.78) 0.041
Age at disease onset, per year 1.04 (1.02-1.07) 0.001 1.03 (1.01-1.06) 0.006 1.03 (1.00-1.06) 0.036
Female 1.43 (0.80-2.55) 0.23
Symptom duration >12 weeks 0.96 (0.54-1.70) 0.89
(Sub)acute symptom onset 0.93 (0.51-1.69) 0.81
66-SJC, per joint 1.04 (0.99-1.08) 0.099 1.03 (0.99-1.08) 0.15 1.02 (0.98-1.06) 0.40
68-TJC, per joint 0.99 (0.96-1.02) 0.56
ESR, per mm/h 1.01 (1.00-1.02) 0.17
CRP, per mg/L 1.00 (1.00-1.01) 0.36
RF positivity 0.57 (0.29-1.09) 0.088 0.84 (0.42-1.66) 0.61 0.78 (0.39-1.58) 0.50
Of the 141 ACPA-negative RA patients, 48 achieved sustained DMARD-free remission. Baseline variables 
with a p-value <0.10 in univariable analyses were included in a multivariable analysis to assess the 
independent relation between baseline variables and sustained DMARD-free remission. ACPA, anti-
citrullinated protein antibodies; CI, confidence interval; CRP, C-reactive protein; DMARD, disease-
modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HR, hazard ratio; MBDA, multi-
biomarker disease activity; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, 66-swollen joint count; 
(sub)acute symptom onset, prompt onset of symptoms (<1 week); symptom duration, time between 
symptom onset and inclusion in cohort; TJC, 68-tender joint count.
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Clinical characteristics at disease presentation of ACPA-negative RA patients 
with an elevated MBDA score 
Finally, as ACPA-negative RA patients with a high probability on achieving sustained 
DMARD-free remission were identifiable by a protein profile that reflected high 
disease activity at the time of diagnosis, we evaluated whether these patients also 
had differences in clinical characteristics compared with those presenting with 
low MBDA scores. ACPA-negative patients with a high MBDA score more often 
had a subacute onset of symptoms (vs. gradual or intermittent onset) (Table 10.3). 
ACPA-negative patients with a moderate or high MBDA score were approximately 
10 years older and had higher acute phase reactants at the first presentation, 
compared with ACPA-negative patients with a low MBDA score (Table 10.3). These 
associations with clinical characteristics at diagnosis suggest that subgroups of 
ACPA-negative RA, differentiated based on serological biomarkers, not only have 
differences in long-term outcome but also differ already at disease presentation.
Table 10.3 Baseline characteristics of ACPA-negative RA patients per MBDA category
MBDA category p-value
<30 (n=17) 30-44 (n=29) >44 (n=95)
Age in years, mean (SD) 48 (16) 60 (13) 62 (14) <0.001
Female, n(%) 13 (76) 22 (76) 58 (61) 0.21
Symptom duration in weeks, median (IQR) 26 (8-41) 12 (4-25) 12 (5-22) 0.13
(Sub)acute symptom onset, n(%) 3 (20) 7 (26) 46 (52) 0.01
66-SJC, median (IQR) 3 (2-7) 6 (3-13) 9 (3-13) 0.08
68-TJC, median (IQR) 12 (9-19) 11 (5-21) 9 (4-17) 0.23
RF positivity, n(%) 7 (41) 9 (31) 33 (35) 0.78
ESR (mm/h), median (IQR) 9 (4-14) 14 (6-33) 33 (19-48) <0.001
CRP (mg/L), median (IQR) 3 (3-3) 3 (3-4) 22 (11-44) <0.001
Characteristics of ACPA-negative RA patients with low, moderate or high MBDA score were compared with 
one-way ANOVA, chi-square test and Kruskal-Wallis test, as appropriate. ACPA, anti-citrullinated protein 
antibodies; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquartile range; MBDA, 
multi-biomarker disease activity; RA, rheumatoid arthritis; RF, rheumatoid factor; SD, standard deviation; 
SJC, 66-swollen joint count; (sub)acute symptom onset, prompt onset of symptoms (<1 week); symptom 
duration, time between symptom onset and inclusion in cohort; TJC, 68-tender joint count.
Discussion 
This is the first study showing that ACPA-negative RA patients with a high 
likelihood of achieving sustained DMARD-free remission during follow-up were 
identifiable at baseline by a combination of serological markers. This association 




characteristics. Furthermore, the ACPA-negative subgroup with a high likelihood 
of achieving sustained DMARD-free remission showed some differences in clinical 
characteristics as they were older (mean ≥60 years) and more often had a (sub)
acute symptom onset. Together, this suggests that a combination of serological 
biomarkers is helpful in identifying subgroups of ACPA-negative RA patients at 
disease presentation that differ in baseline characteristics and in their ability to 
maintain clinical remission after DMARD withdrawal.
Based on differences in genetic and environmental risk factors and in outcome, 
it is generally accepted that ACPA-positive and ACPA-negative RA are different RA 
subsets. In the past, we attempted to distinguish subgroups within the group of 
ACPA-negative RA patients based on only clinical characteristics at disease onset; 
this did not result in clinically distinguishable subgroups.24 The current data suggest 
that a subdivision is possible with serological markers and that, starting from 
this subdivision, the identified subgroups had some slight differences in clinical 
characteristics as ACPA-negative RA patients with moderate or high serologic 
scores at disease onset were older, had more often a (sub)acute onset of symptoms 
and appeared to have greater inflammatory burden (reflected by higher levels of 
inflammatory proteins and a tendency towards more swollen joints). Thirty-eight 
percent of these patients were able to permanently stop DMARDs after a relatively 
short period of treatment, since DMARD-free remission was achieved after a 
median disease duration of 2.9 years, which means that DMARDs were stopped 
after median 1.9 years. Thus, the identified subgroup of ACPA-negative patients 
was older at disease onset and had more often a prompt onset of symptoms with 
more severe inflammation but a relative short-term necessity of DMARD treatment. 
Further studies are needed to confirm these findings.
It is unlikely that ACPA-negative RA patients were misclassified as having RA 
because patients that during the first year of follow-up were diagnosed with 
conditions other than RA (e.g. inflammatory osteoarthritis and reactive arthritis) 
were not included in this study. Also, patients that achieved spontaneous remission, 
i.e. without the use of DMARDs, were excluded. Patients studied here had a clinical 
diagnosis of RA and fulfilled classification criteria. In the current taxonomy, 
these patients are called RA patients. However, our data support the notion that 
subgroups can be identified within ACPA-negative RA.
A study of established RA patients with a median disease duration of 5 years, 
who were in sustained remission, showed that high MBDA scores during DMARD 
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treatment and prior to treatment reduction were associated with increased risk 
of relapses in patients who reduced, and in some cases, stopped, all their DMARD 
treatments.25 This might be reflective of subclinical disease activity despite 
treatment and is conceptually very different from our data. In this study, the 
MBDA score was used to monitor disease activity, the aim for which the score 
was derived. In our data, we had a different aim for which measurements were 
performed in RA patients with very short symptom duration and before any 
DMARDs were initiated.
High MBDA scores have been associated with radiographic progression in several 
studies (although most did adjust but not stratify for ACPA).11-13,26 In our study, 
performed at disease presentation, high MBDA scores strongly associated with 
a favourable outcome in ACPA-negative RA. This contrasts with the previous 
findings, but measurements in these studies were done in patients with a disease 
duration of several years and the studied outcomes were also different.
Our study was focused on achieving sustained DMARD-free remission. Within the 
group of ACPA-negative RA patients, patients with low MBDA score infrequently 
achieved this favourable outcome. Numerically, this group was relatively small 
(12% of ACPA-negative RA patients). Furthermore, this group resembled the 
ACPA-positive group of RA patients that also infrequently achieved DMARD-free 
remission. This ACPA-negative subgroup may be interesting for studies on (novel) 
autoantibody reactivities, as it is speculated that a ‘serological gap’ exists, meaning 
that part of ACPA-negative patients harbour unmeasured autoantibodies.27 
Moreover, our data revealed that sustained DMARD-free remission is a feasible 
outcome in about half of the ACPA-negative patients with moderate or high MBDA 
score.
A limitation is that although rheumatologists at our outpatient clinic are 
encouraged to try to taper and stop DMARDs in case of DAS remission, patients 
and rheumatologists were not forced to stop DMARDs if this was felt inappropriate 
and we did not record how often DMARD tapering was not done despite the 
presence of DAS remission and the absence of swollen joints. Consequently, the 
proportion of patients able to achieve sustained DMARD-free remission might be 
underestimated. It is particularly conceivable that either physicians or patients 





Another limitation is that the follow-up duration of some patients might have 
been insufficient to detect flares occurring years after the absence of synovitis, as 
this may occur after discharge from the outpatient clinic. For this study, patients 
needed to be in sustained DMARD-free remission for at least 1 year and patients 
were instructed to return to the outpatient clinic when symptoms recurred, an 
instruction that is facilitated by the presence of early arthritis recognition clinics 
and the fact that we are the only referral center in the region.28 A final limitation 
is that the number of seronegative patients with low MBDA score was relatively 
small and therefore (multivariable) analyses within the ACPA-negative subgroup 
were of limited power resulting in wide confidence intervals of estimated hazard 
ratios. In addition, resampling methods to show robustness of the data were not 
performed. Therefore, validation of our results in another early RA cohort is 
needed.
Remission in this study was defined as the persistent absence of synovitis after 
DMARD cessation and thus was physician centred. Since synovitis needed to 
be persistently absent over time, this outcome is different from frequently 
used remission definitions that are used on single time points. Importantly, we 
have shown that patients who achieve sustained DMARD-free remission have 
normalization of functional status and of patient-reported outcomes, underlining 
that it is the best possible long-term outcome.1
The MBDA test comprised of serum levels of 12 proteins which were also evaluated 
separately. Of the different markers, CRP, SAA and MMP-3 were associated with 
achieving sustained DMARD-free remission. SAA is a protein linked to the acute 
phase response and is a sensitive indicator of RA disease activity.29,30 MMP-3 is a 
proteinase considered to contribute to cartilage degradation in RA. Its levels have 
been associated with radiographic progression and also with disease activity and 
inflammation.31-36 As the MBDA score was not designed to assess which patients 
might achieve DMARD-free remission, it is presumable that proteins other than 
the 12 that were studied here are also differently expressed in subgroups of ACPA-
negative RA. Further studies are needed to better characterize this subgroup 
serologically. Additionally, biologic studies are needed to identify pathways that 
are relevant for the development of this subgroup of RA patients.
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Conclusions 
In conclusion, ACPA-negative RA patients who achieved sustained DMARD-
free remission during follow-up were characterized by differences in protein 
expression at disease presentation. This is the first evidence that ACPA-negative 
RA can be subdivided at disease onset in clinically relevant subgroups with 
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Supplementary material
Supplementary table 10.1 Overview of medication used by all RA patients and by the subgroups of 
ACPA-positive and ACPA-negative RA patients during the total follow-up duration
All RA patients 
(n=299)
Subgroup of ACPA-positive 
RA patients (n=158)
Subgroup of ACPA-negative 
RA patients (n=141)
Methotrexate, n(%) 271 (91) 152 (96) 119 (84)
Other conventional DMARDs, n(%) 254 (85) 140 (89) 114 (81)
Systemic glucocorticoids, n(%) 228 (76) 127 (80) 101 (72)
Sulfasalazine, n(%) 102 (34) 61 (39) 41 (29)
Hydroxychloroquine, n(%) 131 (44) 88 (56) 43 (30)
Leflunomide, n(%) 56 (19) 46 (29) 10 (7)
Azathioprine, n(%) 6 (2) 3 (2) 3 (2)
Biological DMARD, n(%) 60 (20) 48 (30) 12 (9)
TNF-inhibitor, n(%) 48 (16) 39 (25) 9 (6)
Rituximab, n(%) 3 (1) 2 (1) 1 (0.7)
Abatacept, n(%) 5 (2) 5 (3) 0 (0)
Tocilizumab, n(%) 16 (5) 14 (9) 2 (1)
Omalizumab, n(%) 5 (2) 5 (3) 0 (0)
Baricitinib, n(%) 1 (0.3) 1 (0.6) 0 (0)
Numbers indicate the number of patients that used the indicated medication at any time during follow-
up. The number of patients using combination therapy, or of patients using several medications during 
follow-up is not specified here. ACPA, anti-citrullinated protein antibodies; DMARD, disease-modifying 




Supplementary figure 10.1 Kaplan-Meier plots showing achievement of sustained DMARD-free 
remission by ACPA-negative RA patients (n=141) grouped by tertiles of 12 serum biomarkers 
measured at disease presentation
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Supplementary figure 10.1 continued 
Higher CRP, SAA and MMP-3 levels were associated with achieving sustained DMARD-free remission. The 
other biomarkers were not associated with remission. Patients were categorized into tertiles based on 
the biomarker levels to create three groups of equal size. Vertical lines indicate that a patient is censored. 
CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; EGF, epidermal growth factor; 
IL-6, interleukin 6; MBDA, multi-biomarker disease activity; MMP-1, matrix metalloproteinase 1; MMP-
3, matrix metalloproteinase 3; RA, rheumatoid arthritis; SAA, serum amyloid A; TNFR1, tumor necrosis 
factor receptor superfamily member 1A; VCAM-1, vascular cell adhesion molecule 1; VEGF-A, vascular 







In this thesis, we aimed to get more insight into the earliest phases of rheumatoid 
arthritis (RA). It is clear that early treatment of RA patients is important to prevent 
joint damage progression and functional disability and to increase the chance 
of achieving remission. Although much research has focused on identifying RA 
patients as early as possible, risk stratification remains difficult. In Part I of 
this thesis we focused on the early recognition of RA patients. Different disease 
phases were studied. First, current knowledge about disease progression in 
patients with CSA (clinically suspect arthralgia) is explicated. Then, the phase of 
undifferentiated arthritis (UA) was studied in which the added value of different 
tools (antibodies, magnetic resonance imaging (MRI)) to early identification of RA 
patients was determined. In Part II the association between clinical and imaging 
features and the autoantibody response was investigated to get more insight into 
the mechanisms underlying RA. 
Besides the fact that it is difficult to identify patients with imminent RA, it is also 
challenging to differentiate RA patients who will suffer from severe progression 
of their disease from patients who will have a slowly progressive disease. RA is 
considered to be a heterogeneous disease with the most common subdivision 
into anti-citrullinated protein antibodies (ACPA)-positive and ACPA-negative RA. 
In general, ACPA-positive RA patients have a worse prognosis with more erosive 
progression and lower chances of achieving a sustained disease-modifying 
antirheumatic drug (DMARD)-free status, which is the sustained absence of clinical 
synovitis after cessation of all DMARD therapy. However, not all ACPA-positive 
patients have a fast progressive disease, and there are also ACPA-positive patients 
who are able to achieve sustained DMARD-free remission. In Part III of this thesis 
the aim was to improve the understanding of mechanisms underlying sustained 
DMARD-free remission. 
PART I 
Early recognition of RA patients
RA is considered to consist of a preclinical phase in which patients first have no 
symptoms, but carry certain genetic and environmental risk factors and they can 
have different circulating autoantibodies.1 Thereafter, symptoms of arthralgia 
might develop which eventually might progress to arthritis. The first phase 
in which patients with imminent RA can be identified is the phase of Clinically 




clinically detectable arthritis that is by the rheumatologist considered as at risk of 
progression to RA.2 
In Chapter 2, a literature review was performed on the preclinical phase 
of RA. First of all, the relevance of adequate prediction making is discussed. 
Musculoskeletal symptoms are very prevalent and only 7% of the patients 
presenting with arthralgia at the rheumatologist, were identified as clinically 
suspect to progress to RA.3 Furthermore, only 20% of these patients with CSA will 
develop arthritis, and only this subgroup might benefit from treatment to prevent 
disease progression.4 Therefore, preventive trials in individuals with arthralgia 
should only include patients with a high risk of progression because otherwise the 
treatment effect is diluted and it might be falsely concluded that treatment in the 
phase of arthralgia has no beneficial value. To improve accurate risk prediction 
in this group of individuals, different biomarkers are needed. In the review, the 
predictive accuracy of autoantibodies, other serological markers and imaging 
markers for progression to arthritis in patients with arthralgia was assessed. 
Although numerous predictors for progression from arthralgia to RA are studied, 
only the presence of ACPA is validated as independent risk factor in various 
studies.4-8 Several major issues remain unexplored and therefore further research 
is warranted. One of the issues is that the majority of the studies included 
patients based on the presence of either ACPA or rheumatoid factor (RF), and 
therefore a seronegative patient group is frequently lacking. The predictive value 
of autoantibodies with autoantibody-negative RA patients as a reference group 
subsequently needs to be assessed. Other serological markers, such as C-reactive 
protein (CRP), were studied, but were shown to be of limited value. Again, the 
predictive value was mainly assessed in autoantibody-positive patients. Future 
studies, stratified for ACPA-positive and ACPA-negative arthralgia should be 
performed to determine the predictive value of serological markers in patients 
with ACPA-negative arthralgia. Since ACPA-positive and APCA-negative RA are 
considered separate disease entities, it is conceivable that predictors of disease 
progression are different between both patient groups. 
Besides serological markers, the predictive accuracy of imaging markers 
detecting subclinical inflammation was reviewed in patients with arthralgia. Of 
the different imaging modalities, ultrasound (US) and MRI were most frequently 
studied. Unfortunately, performed studies differed in studied patient populations, 




the predictive value of US and MRI in patients with arthralgia for development 
of arthritis remains unclarified. Currently, it is debatable how an abnormal US 
or MRI should be defined. Previously, studies performed in healthy individuals 
showed that MRI-detected inflammation in metacarpophalangeal (MCP), wrist 
and metatarsophalangeal (MTP) joints is frequently observed and consideration 
of these findings when defining an abnormal MRI leads to an increased predictive 
accuracy.9,10 Therefore, it seems reasonable to define a threshold at which MRI 
features should be regarded as abnormal. Whether it is also important to consider 
US-detected inflammation as present in healthy individuals when defining an 
abnormal US should be clarified. In addition, it is unresolved what joint features 
and which joints are most predictive and whether there is an additional value of 
assessing MTP joints next to MCP joints. When it appears that imaging of the foot 
can be omitted than the scanning time can be reduced. 
Finally, in most cohort studies where the predictive value of several biomarkers 
was investigated, heterogeneous patient populations were included, e.g. arthralgia, 
seropositive arthralgia and ACPA-positive persons with non-specific musculoskeletal 
symptoms. Previously, a EULAR task force has defined a combination of symptoms 
and signs that characterize patients at risk of developing RA to enable inclusion of 
homogeneous sets of patients in studies.2 This definition might be used in future 
studies to enhance comparability between studies and thereby, assess the predictive 
accuracy of biomarkers in a homogeneous group of patients with arthralgia. Thus, 
the predictive accuracy of most studied predictors is limited and most predictors 
were not evaluated relative to each other. Furthermore, other biomarkers than the 
ones studied are probably needed to arrive at optimal risk prediction in patients 
with CSA. 
Early identification of RA patients is important because early treatment initiation 
is associated with an improved disease outcome, both in autoantibody-positive and 
autoantibody-negative RA.11-14 To facilitate the early identification of RA patients, 
the 2010 ACR/EULAR criteria have been developed, which indeed have shown to 
be more specific than the previously used 1987 ACR criteria.15-17 However, it was 
undetermined if the 2010 criteria identify both ACPA-positive and ACPA-negative 
patients earlier in time; this was subject of the study performed in Chapter 3. 
Patients from two different early arthritis cohorts were studied. For this study, 
patients were selected who fulfilled the 1987 criteria after one year follow-up, but 
not at the time of inclusion. When using the 1987 criteria these patients were thus 




already fulfilled the 2010 criteria at disease presentation, and thus were identified 
earlier when using the 2010 criteria. Of the autoantibody-positive patients, 92-
93% was identified earlier with the 2010 criteria within the two different cohorts. 
However, of the autoantibody-negative patients only 25-51% was identified earlier. 
This clearly indicates that ACPA-negative RA patients are still frequently missed by 
the 2010 criteria. Partly, this can be explained by the high weight that is given to 
the presence of ACPA and RF in the 2010 criteria. Although the 2010 criteria are 
classification criteria and were not developed for diagnosis, in clinical practise 
they can sometimes be used as such. To also diagnose ACPA-negative RA patients 
early in the disease process other diagnostics are therefore required. 
One of the options to improve early identification is to search for novel 
autoantibodies. ACPA and RF are the most well-known autoantibodies and 
are considered a hallmark of RA but recently other autoantibodies have been 
identified, such as anti-peptidylarginine deiminase antibodies, anti-acetylated 
antibodies and anti-carbamylated protein (anti-CarP) antibodies.18-20 Nonetheless, 
the clinical additional value of these autoantibodies was undetermined as the 
majority of the studies performed thus far did not stratify for the presence of 
ACPA and RF. This is important, since novel autoantibodies should have additional 
value to ACPA and RF to become clinically useful. Therefore we studied the 
additional diagnostic value of novel autoantibodies in Chapter 4. As an example 
the additional value of anti-CarP antibodies in predicting progression to RA for 
patients with UA was studied. It appeared that the additional value was dependent 
on the different classification criteria that are used. For patients with UA according 
to the 1987 criteria, anti-CarP antibodies were associated with progression to RA, 
independent of ACPA and RF (OR 1.7 95% CI 1.2-2.4). After stratification for ACPA 
and RF, anti-CarP antibodies were only associated with progression to RA within 
the ACPA- and RF-negative patient group (OR 2.1 95% CI 1.3-3.7). For patients with 
UA according to the 2010 criteria, anti-CarP antibodies were not associated with 
RA when analyses were corrected for ACPA and RF (OR 0.8, 95% CI 0.3-2.1). This 
observation is probably due to the fact that autoantibodies are heavily weighted 
in the 2010 criteria. Autoantibodies frequently occur together, thus patients who 
are positive for the novel autoantibody, are probably also positive for ACPA and/or 
RF and therefore the additional value of novel autoantibodies is limited. Perhaps 
other biomarkers such as other immunological markers present in the serum, or 
imaging markers might contribute to the early identification of RA. Finally, it is 
important to mention that this finding does not suggest that novel autoantibodies 




of future studies. 
Since the additional value of novel autoantibodies appeared to be limited in 
the early identification of RA patients, it was studied whether imaging markers 
contribute to earlier identification of RA. To this end, the presence of MRI-detected 
erosions was studied. The use of MRI to detect damage at an earlier time point 
in RA than conventional radiographs is recommended.21 It is already clear that 
MRI is more sensitive than radiography in detecting erosions.22-29 However, it 
was undetermined whether the earlier identification of MRI-detected erosions 
contributes to the earlier identification of RA patients. This was studied in Chapter 
5 and Chapter 6. First, in Chapter 5 the specificity of MRI-detected erosions for 
RA was determined. This was needed as MRI-detected erosions are also frequently 
observed in healthy individuals and in patients with other forms of arthritis.9,30-34 
Several characteristics of erosions present in MCP and MTP joints were compared 
between early RA patients, patients with other arthritides and symptom-free 
controls. This study revealed that total erosion scores, which are a combination of 
number and size of erosions, were comparable between the three groups. A few 
erosion characteristics were identified that were specific for RA when compared 
to symptom-free controls, which were grade ≥2 erosions, meaning that >20% of the 
bone was eroded, erosions in MTP5, erosions in MTP1 in patients aged <40 years at 
time of diagnosis and erosions with local inflammation in patients aged <60 years. 
When RA patients were compared with patients with other arthritides instead of 
symptom-free controls, erosions combined with inflammation were not specific 
for RA anymore since these were also frequently observed in patients with other 
arthritides. Grade ≥2 erosions, erosions in MTP5 and erosions in MTP1 in patients 
aged <40 years remained specific for RA but these were present in a minority 
(21%) of RA patients. 
The specificity of MRI-detected erosions was determined in patients who already 
received a clinical diagnosis. A subsequently and clinically relevant question is 
whether the identified RA-specific MRI-detected erosions are valuable in predicting 
progression in patients with UA, because they are at risk of developing RA and 
must be identified as early as possible. This was studied in Chapter 6. Besides 
development of RA, also the start of DMARDs within the first year of follow-up 
was studied, since autoantibody-negative RA patients require involvement of >10 
joints to fulfil the 2010 classification criteria and because progression to RA might 




the outcome (2010-RA and/or DMARD start) within the first year. The previously 
identified RA-specific erosions were present in only 7% of the 2010-UA patients 
and were not associated with development of RA (OR 0.6, 95% CI 0.2-1.5, PPV 
33%). Together these data demonstrate that although MRI is very sensitive in the 
detection of erosions, the value of MRI-detected erosions in the diagnostic process 
should not be overestimated. 
PART II 
Clinical and imaging features and the ACPA response
In this part, the association between clinical and imaging features and the 
autoantibody response was investigated to get more insight into the mechanisms 
underlying RA. In clinical practice conventional radiography is the most common 
used imaging modality but in research MRI and US are increasingly performed 
because with these modalities also inflammatory soft tissue changes can be 
visualized. A unique feature of MRI is the capability to detect bone marrow 
edema (BME). In RA patients these BME lesions consist of inflammatory cell 
infiltrates.35-37 Several studies have shown that BME is a strong predictor of erosive 
progression.38-46 Besides BME, also the presence of ACPA is strongly associated with 
erosive progression.47-55 The association between ACPA and other autoantibodies, 
and BME had not been extensively studied before and was subject of Chapter 
7. Intriguingly, we observed that the presence of ACPA alone was not associated 
with BME. However, the combined presence of ACPA with RF and/or anti-CarP 
antibodies was associated with more BME, suggesting an interactive effect between 
the different autoantibody systems. 
Several studies have evaluated the interaction between ACPA and RF. Using in vitro 
assays in which macrophages were incubated with ACPA immune complexes in 
the presence or absence of monoclonal RF IgM, it was observed that the combined 
presence of ACPA and RF induced a higher production of pro-inflammatory 
cytokines by macrophages than the presence of ACPA alone.56,57 Another study 
showed that the interaction between ACPA and citrullinated peptide targets was 
enhanced by the presence of RF, suggesting that the pathogenic effect of the 
combined presence of ACPA and RF might be explained by crosslinking immune 
complexes and thereby forming higher avidity immune complexes.58 Surprisingly, 
the binding of RF to ACPA IgGs was similar to that of non-ACPA IgGs and RF binding 




was suggested that RF-ACPA IgG complexes may still preferentially be formed over 
RF-non-ACPA IgG complexes due to the abundance of ACPA.59 Further fundamental 
studies should be performed to get more insight into the interaction between ACPA 
and RF. 
In Chapter 8, the association between clinical characteristics and the autoantibody 
response (ACPA, RF and anti-CarP antibodies) was investigated in five different 
early arthritis cohorts. This revealed that at older age of disease onset, patients are 
more frequently ACPA-negative. In addition, several clinical parameters at disease 
onset in RA patients were different in patients with an older age at disease onset: 
patients were more often male, did not smoke, had higher acute phase reactants 
and had more often a (sub)acute onset of their symptoms. These data suggest 
that part of the ACPA-positive and ACPA-negative RA patients diagnosed at older 
age are comparable to patients of younger age, but there might also be a distinct 
subgroup of ACPA-negative patients preferentially presenting at older age with 
slight differences in clinical presentation and probably in underlying pathogenic 
mechanism. All patients in this study were diagnosed with RA which makes 
phenotypic misclassification of this ACPA-negative patient group very unlikely. 
In a recent study, it was observed that part of the RA patients diagnosed at older 
age were initially diagnosed with polymyalgia rheumatica (PMR).60 Male patients 
with PMR in this study had a higher risk to develop RA than female patients 
which is contradictory to RA development at younger age where the risk of RA 
is much higher for female patients. Interestingly, although the presence of ACPA 
was associated with progression to RA in patients with PMR, the majority of these 
patients were ACPA-negative. Although this study had a different design than our 
study, these data might also point towards a subgroup of RA patients at older age 
with some differences in clinical characteristics and outcome. 
Together these data support the hypothesis that ACPA-negative RA at older age of 
onset has a different pathogenesis than ACPA-negative RA at younger age. A next 
step is to further validate this observation in other cohort studies. In addition, 
fundamental studies are required to evaluate whether the pathogenesis of ACPA-





Resolution of rheumatoid arthritis
In part III, the focus was on the long-term outcome of RA patients. While 
traditionally joint damage was the most important outcome, this has become 
less relevant since damage can be prevented with current treatment strategies. 
Therefore, other long-term disease outcomes will become more important. One of 
these outcomes is the achievement of sustained DMARD-free remission, which is 
defined as the absence of clinical synovitis for at least one year that is sustained 
during the complete follow-up. Sustained DMARD-free remission is an increasingly 
achievable outcome and can be considered as the closest proxy of cure of RA.61 The 
studies performed in part III of this thesis aimed to improve the understanding of 
mechanisms underlying a sustained DMARD-free status. 
Recently, it was suggested that patients who are in immunological remission, 
defined as the disappearance of ACPA and RF, have the highest likelihood of 
achieving sustained DMARD-free remission.62 However, this was all hypothesis 
based and therefore the association between ACPA and RF seroreversion and 
achievement of sustained DMARD-free remission was studied in Chapter 9. Of the 
anti-CCP2 IgG positive RA patients who achieved sustained DMARD-free remission, 
12.8% had seroreverted when remission was achieved. However, in RA patients 
who had recurrence of synovitis after initially being in DMARD-free remission 
and in RA patients with persistent disease, seroreversion was observed in 8.3% 
and 5.7%, respectively, which was not significantly different from the patients who 
achieved sustained DMARD-free remission. Similar results were obtained for RF 
IgM. 
The ACPA immune response has been shown to consist of various isotypes, which 
differ in their ability to mediate effector mechanisms. A typical immune response 
is characterized by the emergence of IgM antibodies after first antigen exposure, 
followed by the presence of IgG antibodies. After repeated antigen exposure, there 
is an increase in IgG antibodies while the IgM response disappears or lowers as 
compared to the primary response. In RA, it was shown that indeed IgM anti-CCP 
antibodies are present early in the disease course, however also after several years 
of follow-up, IgM antibodies remained present in the majority of patients who were 
positive for anti-CCP IgM at disease presentation, suggesting that there is continuous 
reactivation of the anti-CCP response.63 We hypothesized that if dampening of the 




CCP IgM antibodies would disappear. Therefore, in addition to anti-CCP2 IgG, also 
seroreversion rates for anti-CCP2 IgM were determined. However, patients who 
achieved sustained DMARD-free remission did not serorevert more frequently 
than patients who did not achieve remission, suggesting that the ACPA immune 
response is not underlying the maintained resolution of disease or that other 
characteristics of the ACPA response should be investigated. 
As regards characteristics of the ACPA response, it is known that ACPA level is 
highly associated with the ACPA fine specificity repertoire and the number of 
ACPA isotypes, and therefore we anticipated that these characteristics were also 
not different between patients who did and did not achieve sustained DMARD-
free remission.64 Further studies are needed to elucidate whether these ACPA 
characteristics indeed remain unchanged as well. Another characteristic of the 
ACPA response which might be relevant to study with this respect is glycosylation 
of the constant (Fc) and variable (Fab) domain of ACPA IgG. Glycosylation is a 
reaction in which carbohydrates are attached to other molecules, in this case, 
autoantibodies. Previously, it was shown that ACPA IgG in RA patients have a 
changed Fc glycosylation pattern with reduced galactosylation and sialylation 
compared to that of total serum IgG.65 This might have a proinflammatory effect 
by facilitating the formation of immune complexes and favoring the binding of 
IgG to activating FcγRs.66 In addition, the Fab fragment of ACPA IgG is shown to 
be extensively glycosylated which might affect several antibody properties and B 
cell survival.67-69 Thus, both changes in Fc and Fab glycans can have considerable 
impact on effector mechanisms of the autoimmune response and therefore it 
would be interesting to investigate whether the glycosylation profile of ACPA of 
patients who are in a sustained DMARD-free status has normalized by comparing 
it with that of non-ACPA IgG. 
Another possibility is that not characteristics of ACPA itself, but of the ACPA 
producing B cells are associated with achievement of sustained DMARD-free 
remission. Recently, a technology was developed to identify and isolate citrullinated 
antigen-specific B cells from peripheral blood of RA patients.70 This technology 
was used to compare the phenotype of citrullinated antigen specific B cells with 
tetanus-toxoid specific B cells of the same patient. The majority of the isolated cells 
had a memory phenotype and it appeared that citrullinated antigen specific B cells 
overexpress co-stimulatory molecules and proliferation markers, indicating the 
presence of an active immune response.71 It would be very exciting to measure 





Besides B cells, T cells could be the driving force underlying disease persistence. 
Several changes in the composition and characteristics of the T cell compartment 
have been described in patients in remission under DMARD treatment.72,73 Thus 
far, no studies have looked into the T cell compartment of patients in sustained 
DMARD-free remission. Overall, future studies are needed to define which 
immunological marker is the best reflection of disease persistence, and thus to 
determine the optimal definition of immunological remission. 
Although sustained DMARD-free remission is an increasingly achievable outcome, 
still only a minority of RA patients is able to achieve this outcome. In Chapter 10 the 
aim was to get more insight into this subgroup of patients. Clinical characteristics 
and autoantibodies alone are insufficient to assess which patients have a favorable 
outcome of their disease. We hypothesized that other serological markers than 
autoantibodies might contribute to the differentiation of subgroups of patients 
who have different chances of achieving sustained DMARD-free remission during 
follow-up. To this end, twelve different biomarkers (CRP, IL-6, SAA, TNFR1, EGF, 
VEGF-A, VCAM-1, MMP-1, MMP-3, YKL-40, resistin and leptin) were measured 
in serum samples of RA patients, collected at disease presentation. We started 
by measuring these biomarkers because these were already selected from a 
larger pool of markers by a company and were already shown to be associated 
with RA disease activity. 299 RA patients were followed for median 4.3 years of 
which 20% achieved sustained DMARD-free remission. Among ACPA-positive RA 
patients, biomarker scores were not associated with achieving sustained DMARD-
free remission, while among ACPA-negative RA patients, moderate or high scores 
associated strongly with DMARD-free remission (moderate vs. low HR 9.4, 95% CI 
1.2-72.9, high vs. low HR 9.7 95% CI 1.3-71.1). This association was independent of 
clinical characteristics (high vs. low HR 8.2 95% CI 1.1-61.8), showing the additive 
value of the serological markers. To get more insight into the markers driving this 
finding, the association with sustained DMARD-free remission was evaluated for 
each biomarker separately, revealing the largest associations for CRP, SAA and 
MMP-3 in ACPA-negative patients. This was the first time that ACPA-negative RA 
patients could be divided into subgroups with differences in long-term outcome 
using a protein profile. 
Intriguingly, ACPA-negative RA patients with higher serological scores, indicating 




and with more swollen joints, had the highest chance of achieving sustained 
DMARD-free remission during follow-up. Previously these clinical characteristics 
were insufficient in subdividing ACPA-negative RA, but here we show that when 
combined with serological markers, differentiation of ACPA-negative patients was 
improved.74 Although our findings are promising and may open possibilities for 
personalized treatment aiming at disease resolution in ACPA-negative RA, results 
should be validated in another early arthritis cohort. Furthermore, in the future 
certainly also other biomarkers should be investigated to further characterize this 
ACPA-negative subgroup. Eventually this will contribute to the identification of 
pathways that are relevant for the development of this subgroup of RA patients. 
Final considerations
Since it has become clear that early treatment of RA patients is needed to improve 
disease outcome, research has shifted towards identification of patients as early 
as possible. Part of the studies described in this thesis focused on the early 
identification of RA. Overall it can be concluded that more research is needed to 
arrive at adequate risk prediction for progression to RA in both patients with CSA 
and in patients with UA. One of the difficulties is that RA is a heterogeneous disease 
probably consisting of separate disease subsets besides ACPA-positive and ACPA-
negative RA. ACPA-negative RA in particular is considered to be a heterogeneous 
group and especially for the ACPA-negative group more predictors are needed. 
Adequate risk stratification is crucial, especially for interpretation of results from 
trials in which at-risk patients are treated to prevent progression to RA. When 
patients with low risk of progression are included in these trials it may be falsely 
concluded that preventive treatment has no beneficial effect. Therefore, further 
research in observational longitudinal studies should be performed and probably 
a combination of different markers (clinical, serological and imaging) is needed. 
Sustained DMARD-free remission is a very intriguing long-term outcome as it 
is the best approximation of cure of RA, nonetheless, it is infrequently studied. 
Partly, this can be explained by differences in treatment strategies in different 
countries. In the LUMC it is common practice to try to taper and stop DMARD 
therapy when patients have persistent low disease activity, while in outpatient 
clinics in other countries rheumatologists might be more reluctant with stopping 
DMARD therapy. This difference in treatment strategy might be due to the fact that 




medication without recurrence of arthritis.62,75 Another important notion is that 
sustained DMARD-free remission is a rather subjective outcome. When patients 
have a persistent low disease activity, the rheumatologist and the patient together 
decide whether or not to stop treatment. Presumably, rheumatologists are more 
reluctant to stop medication when patients are ACPA-positive. Furthermore, it is 
unknown what happens with patients after achievement of sustained DMARD-free 
remission. In the LUMC, RA patients who are in sustained DMARD-free remission 
are referred to their general practitioner and are instructed to return when 
symptoms recur. In addition, there are early access clinics to promote early access 
to rheumatologic care.76 Therefore it can be presumed that patients who do not 
return to the outpatient clinic remain in a sustained DMARD-free status.
Biological mechanisms underlying achievement of a sustained DMARD-free 
status remain unknown. Disappearance of autoantibodies was not associated 
with sustained DMARD-free remission, suggesting that absence of autoantibodies 
is not important for the maintained resolution of disease. Future studies should 
reveal whether changes in other immunological markers (e.g. B cell or T cell 
characteristics) are relevant. Besides understanding the underlying mechanisms 
of extinguishment of disease it is also important to identify patients who have 
the highest chance of a favorable outcome and who profit the most from DMARD 
cessation because DMARDs are expensive and have side-effects. Currently, absence 
of ACPA is the most important predictor for achievement of sustained DMARD-free 
remission, but more predictors are needed. One of the difficulties when studying 
the value of serological biomarkers in predicting sustained DMARD-free remission 
is that the moment when medication is attempted to stop is rather subjective. 
Therefore the moment of stopping medication does not necessarily indicate 
similar disease states between different patients. Some patients might have cure 
of their disease for a long period (although they use medication), while other 
patients have just recently become in disease remission. Although these patients 
might be considered as being in the same disease state when they are in sustained 
DMARD-free remission, biomarker profiles might be completely different. Another 
challenge is to find biomarkers that not merely reflect and coincide with disease 
activity, as it was observed for example for IP-10, but change before disease has 
been extinguished.77 Results from observational cohort studies and randomized 
controlled trials should clarify in which patient group DMARD tapering and 
stopping is worthwhile to consider. Eventually, a combination of biomarkers is 
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Reumatoïde artritis (RA) is een chronische ziekte die vooral wordt gekenmerkt 
door gewrichtsontsteking (artritis) van de kleine hand- en voetgewrichten. Met 
een prevalentie van 0.5-1% is het de meest voorkomende reumatische ziekte in 
de westerse bevolking. De ziekte komt drie keer vaker voor bij vrouwen dan bij 
mannen en de incidentie neemt toe met de leeftijd. 
De gewrichtsontstekingen gaan gepaard met pijn, zwelling en ochtendstijfheid 
wat zonder adequate behandeling kan leiden tot destructie van de gewrichten. 
Naast ontsteking van de gewrichten, kunnen ook ontstekingen van de inwendige 
organen optreden, zoals de longen, hart, nieren en bloedvaten. RA is een complexe, 
multifactoriële ziekte en wordt beschouwd als een auto-immuunziekte omdat bij 
ruim tweederde van de patiënten autoantistoffen in het bloed aanwezig zijn. De 
meest voorkomende autoantistoffen zijn reumafactor (RF) en antistoffen tegen 
gecitrullineerde eiwitten (ACPA). Met name ACPA zijn kenmerkend voor RA waarbij 
ACPA-positieve en ACPA-negatieve RA worden gezien als verschillende subsets van 
RA met verschillende onderliggende pathogenese en genetische risicofactoren. 
Daarnaast zijn zowel ACPA als RF geassocieerd met relevante uitkomstmaten zoals 
radiografische schade en het behalen van remissie. 
De laatste decennia is de behandeling van RA sterk verbeterd door de ontwikkeling 
van nieuwe effectieve medicatie, waaronder ‘disease-modifying antirheumatic 
drugs’ (DMARDs) en ‘biologicals’. Daarnaast heeft het vroeg starten van behandeling 
en het gebruik van ziekteactiviteit scores bijgedragen aan de verbeterde 
behandeling van RA. Omdat vroege behandeling belangrijk is om progressie van 
gewrichtsschade en functionele achteruitgang te voorkomen, richt veel onderzoek 
zich op het zo vroeg mogelijk identificeren van RA patiënten. De ontwikkeling 
van RA kan worden verdeeld in verschillende ziekte fasen. Voordat symptomen 
ontstaan, kunnen er al genetische risicofactoren of omgevingsrisicofactoren 
aanwezig zijn. Daarnaast kunnen autoantistoffen ook al jaren voor het ontstaan 
van RA aanwezig zijn. In de fase van ‘clinically suspect arthralgia’ (CSA) hebben 
patiënten recent ontstane gewrichtsklachten die volgens klinisch expertise van 
de reumatoloog verdacht zijn voor het ontwikkelen van RA. In deze fase hebben 
patiënten wel al symptomen maar heeft er zich nog geen klinische artritis 
ontwikkeld. Maar een klein deel van deze CSA patiënten ontwikkelt artritis tijdens 
follow-up. Onderzoek in deze groep patiënten is van belang om uiteindelijk 
beter te kunnen voorspellen welke CSA patiënten progressie naar artritis zullen 
hebben, en mogelijk baat hebben bij vroege behandeling, en bij welke patiënten 




ontwikkelen. De fase waar klinische artritis kan worden vastgesteld is de fase van 
ongedifferentieerde artritis (UA). Van de patiënten met UA zal ongeveer de helft 
spontane remissie behalen, terwijl ongeveer een derde RA zal ontwikkelen. Van 
de patiënten met RA zal de meerderheid persisterende ziekte hebben. Echter voor 
een deel van de patiënten is het mogelijk om blijvende DMARD-vrije remissie te 
behalen. Dit houdt in dat na het staken van alle medicatie er geen klinische artritis 
meer wordt vastgesteld en er dus genezing van de ziekte lijkt te zijn ontstaan. 
Bovengenoemde ziektefasen zijn weergegeven in Figuur 12.1. De verschillende 
ziektefasen worden niet door alle patiënten doorlopen en volgen elkaar ook niet 
noodzakelijk in dezelfde volgorde op.
Figuur 12.1 Verschillende fasen van RA ontwikkeling 
Identificatie van de patiënten met CSA met uiteindelijk progressie naar RA is 
een uitdaging omdat de meeste patiënten nooit RA zullen ontwikkelen. Een 
aantal factoren zijn geassocieerd met het ontwikkelen van RA in patiënten met 
CSA, waaronder de aanwezigheid van autoantistoffen en de aanwezigheid 
van subklinische ontsteking van de gewrichten, zoals vastgesteld op magnetic 
resonance imaging (MRI). Hoofdstuk 2 van dit proefschrift geeft een overzicht 
van de literatuur over de preklinische fase van RA. Hoewel er veel verschillende 
voorspellers voor progressie van artralgie naar RA zijn onderzocht, zijn alleen ACPA 
aangetoond als onafhankelijke risicofactor in meerdere studies. De toegevoegde 
waarde van andere markers in het bloed is nog niet aangetoond. Ook de waarde 
van echografie en MRI om gewrichtsontsteking in een vroege fase vast te stellen, 
is nog onduidelijk. Er is dus meer onderzoek nodig om tot adequate risicopredictie 
te komen binnen patiënten met CSA. 
In de klinische praktijk wordt de diagnose RA gesteld door de reumatoloog 
op basis van een combinatie van klinische symptomen en bevindingen bij 
lichamelijk en aanvullend onderzoek. De diagnose RA is dus in feite gebaseerd op 




wat resulteert in een heterogene groep van patiënten. Om de resultaten van studies 
met RA patiënten met elkaar te kunnen vergelijken, is het echter belangrijk om een 
relatief homogene groep van RA patiënten te hebben. Om dit te bereiken zijn in 
de loop der jaren verschillende classificatiecriteria ontwikkeld. In huidige studies 
worden zowel de 1987 ACR criteria als de 2010 ACR/EULAR criteria gebruikt. De 
1987 criteria zijn ontwikkeld om de specificiteit te verhogen ten opzichte van de 
oudere criteria, dus om het onderscheid tussen patiënten met RA en patiënten met 
artritis door een andere ziekte te verbeteren. Een nadeel van de 1987 criteria is 
dat patiënten in de vroege fase van RA minder goed worden geïdentificeerd dan 
patiënten met gevorderde RA. Om de identificatie van patiënten in de vroege fase 
van RA te verbeteren, zijn de 2010 criteria ontwikkeld. Het grootste verschil tussen 
de 2010 en 1987 criteria is dat de 2010 criteria zijn gericht op kenmerken van vroege 
artritis die geassocieerd zijn met persisterende ziekte en met de ontwikkeling van 
schade. Daarom zijn de aanwezigheid van acute fase eiwitten (CRP en BSE) en 
ACPA toegevoegd aan de criteria. Kenmerken die passen bij gevorderde ziekte, 
zoals de aanwezigheid van reuma noduli en radiografische erosies werden niet 
meer in de 2010 criteria meegenomen. Meerdere studies hebben laten zien dat 
de 2010 criteria inderdaad beter zijn in het identificeren van vroege RA patiënten 
dan de 1987 criteria, dus de sensitiviteit is hoger. Dit gaat echter ten koste van een 
lagere specificiteit wat inhoudt dat er ook patiënten zijn die aan de 2010 criteria 
voldoen die geen RA hebben maar artritis door een andere ziekte. Het was tot nu 
toe echter nog onduidelijk of met de 2010 criteria zowel ACPA-positieve als ACPA-
negatieve patiënten in een vroegere fase van de ziekte worden geïdentificeerd. 
Dit is onderzocht in hoofdstuk 3 van dit proefschrift. In deze studie werden 
patiënten van twee verschillende vroege artritis cohorten onderzocht. Patiënten 
die voldeden aan de 1987 criteria na een jaar follow-up, maar niet op het moment 
van inclusie, werden geselecteerd. Deze RA patiënten werden dus met de 1987 
criteria niet op het moment van presentatie geïdentificeerd, maar pas later tijdens 
follow-up. Van deze patiënten is bekeken of zij al wel voldeden aan de 2010 criteria 
op het moment van presentatie met klachten. Indien dit het geval zou zijn dan 
zouden deze patiënten dus met de 2010 criteria eerder worden geclassificeerd als 
RA dan met de 1987 criteria. Van de autoantistof positieve RA patiënten werd 92-
93% van de patiënten eerder geïdentificeerd met de 2010 criteria binnen de twee 
verschillende cohorten. Van de autoantistof negatieve RA patiënten werd echter 
maar 25-51% eerder geïdentificeerd. Dit laat duidelijk zien dat de 2010 criteria met 
name goed zijn in het zo vroeg mogelijk identificeren van autoantistof positieve 
patiënten maar dat autoantistof negatieve patiënten nog steeds frequent worden 




RF zwaar worden gewogen in de 2010 criteria. Patiënten die deze autoantistoffen 
niet hebben, moeten veel meer aangedane gewrichten hebben om alsnog aan 
de 2010 criteria te kunnen voldoen. Deze bevinding is belangrijk aangezien het 
bekend is dat vroege behandeling, zowel van ACPA-positieve als ACPA-negatieve 
RA, belangrijk is om de ziekte uitkomst te verbeteren.
Ondanks dat de classificatie criteria zijn ontwikkeld voor wetenschappelijk 
onderzoek en niet voor het stellen van de diagnose RA, worden ze in de klinische 
praktijk soms wel zo gebruikt. Ongeveer een derde van de patiënten met RA zijn 
negatief voor zowel ACPA als RF. Om ook deze autoantistof negatieve patiënten 
eerder te diagnosticeren zijn andere diagnostische tools nodig. Huidig onderzoek 
richt zich onder andere op het ontdekken van andere, nieuwe autoantistoffen, 
om ook deze groep patiënten zo vroeg mogelijk te identificeren. In hoofdstuk 4 
is gekeken naar de toegevoegde waarde van een van die nieuwe autoantistoffen, 
namelijk naar antistoffen tegen gecarbamyleerde eiwitten (anti-CarP antistoffen). 
Dit is onderzocht binnen patiënten met UA. Dit zijn patiënten met klinische artritis 
maar zij voldoen nog niet aan RA classificatiecriteria. Het bleek dat de toegevoegde 
waarde van anti-CarP antistoffen afhankelijk is van de classificatiecriteria die 
worden gebruikt. Binnen ACPA en RF negatieve UA patiënten volgens de 1987 
criteria was de aanwezigheid van anti-CarP antistoffen geassocieerd met de 
ontwikkeling van RA. In deze groep steeg het risico op ontwikkeling van RA van 
21% naar 35% wanneer anti-CarP antistoffen aanwezig waren. Echter wanneer RA 
werd gedefinieerd volgens de 2010 criteria was er geen toegevoegde waarde van 
anti-CarP antistoffen. Deze bevinding kan worden verklaard door het grote gewicht 
dat aan ACPA en RF wordt gegeven binnen de 2010 criteria. Als gevolg hiervan zijn 
de meeste UA patiënten ACPA en RF negatief. Het is bekend dat autoantistoffen 
vaak samen voorkomen waardoor patiënten die positief zijn voor ACPA en RF 
ook vaker positief zullen zijn voor een andere antistof; andersom zijn patiënten 
die negatief zijn voor ACPA en RF ook vaker negatief voor een andere antistof. 
Dit is belangrijk omdat nieuwe autoantistoffen alleen van klinisch toegevoegde 
waarde zullen zijn wanneer zij iets toevoegen aan ACPA en RF. Voor anti-CarP 
antistoffen lijkt de toegevoegde diagnostische waarde beperkt te zijn. Gezien 
het frequent samen voorkomen van autoantistoffen zal dit voor andere nieuwe 
autoantistoffen wellicht ook het geval zijn. Om de vroege identificatie van RA te 
verbeteren, kan daarom misschien beter gezocht worden naar andere markers, 
zoals immunologische markers die aanwezig zijn in het serum, of naar markers 





In hoofdstuk 5 en 6 is de aanwezigheid van erosies bestudeerd met behulp van MRI. 
Het gebruik van MRI wordt al aangeraden om schade eerder in het ziekteproces aan 
te tonen dan met conventionele röntgenfoto’s. Het is echter nog onbekend of het 
vroeger aantonen van MRI-gedetecteerde erosies leidt tot eerdere identificatie van 
RA patiënten. In hoofdstuk 5 is onderzocht of MRI-gedetecteerde erosies in hand 
(MCP) en voet (MTP) gewrichten specifiek zijn voor RA of dat ze ook vaak worden 
gezien in gezonde mensen of patiënten met andere vormen van artritis. Hiervoor 
is gekeken naar verschillende erosie karakteristieken. Wanneer RA patiënten 
werden vergeleken met gezonde mensen waren een aantal erosie karakteristieken 
specifiek voor RA. Dit waren grote erosies (>20% van het bot aangedaan), erosies 
in MTP5, erosies in MTP1 in patiënten jonger dan 40 jaar op het moment van 
diagnose, en erosies met lokale ontsteking in hetzelfde bot in patiënten jonger dan 
60 jaar. Erosies met lokale ontsteking waren niet meer specifiek voor RA wanneer 
RA patiënten werden vergeleken met patiënten met andere vormen van artritis in 
plaats van met gezonde mensen. Dit komt omdat erosies samen met ontsteking ook 
veel bij andere vormen van artritis wordt gezien. Grote erosies, erosies in MTP5 en 
erosies in MTP1 in patiënten jonger dan 40 jaar op het moment van diagnose bleven 
specifiek voor RA maar deze waren aanwezig in maar 21% van de RA patiënten. 
Een klinisch relevante vervolgvraag is of de aanwezigheid van RA specifieke 
erosies bijdraagt aan het voorspellen van het ontwikkelen van RA in patiënten 
met een verhoogd risico op RA. Dit is onderzocht in hoofdstuk 6. Hiertoe is gekeken 
binnen UA patiënten. Het bleek dat de eerder gevonden RA specifieke erosies maar 
aanwezig waren in 7% van de UA patiënten. Daarnaast was de aanwezigheid van 
deze erosies niet geassocieerd met het ontwikkelen van RA. Samenvattend, laat dit 
onderzoek zien dat MRI erg sensitief is in het vaststellen van erosies, maar dat de 
waarde van MRI-gedetecteerde erosies in het diagnostisch proces niet overschat 
moet worden aangezien erosies ook in gezonde mensen en patiënten met andere 
vormen van artritis aanwezig zijn. 
Het is bekend dat de aanwezigheid van autoantistoffen is geassocieerd met het 
ontstaan van RA, echter de precieze rol van autoantistoffen in de ziekte is nog 
onbekend. Onderzoek beschreven in hoofdstuk 7 en 8 is verricht om hier meer 
inzicht in te krijgen. In hoofdstuk 7 is de relatie tussen inflammatie zoals gezien op 
MRI en de aanwezigheid van autoantistoffen onderzocht. Een unieke eigenschap 
van MRI is dat beenmergoedeem kan worden afgebeeld. Beenmerg oedeem laesies 
zijn afwijkingen die ontstaan door de vervanging van beenmerg vet door een 
ontstekingsinfiltraat. Verschillende studies hebben laten zien dat de aanwezigheid 




in het bot. Naast beenmergoedeem, zijn ACPA een sterke voorspeller voor het 
ontstaan van erosies. De associatie tussen ACPA en andere autoantistoffen, en 
het ontstaan van beenmergoedeem was nog niet bekend. Verrassend genoeg 
bleek uit ons onderzoek dat de aanwezigheid van ACPA alleen niet geassocieerd 
is met beenmergoedeem. Echter, de combinatie van ACPA met RF of anti-CarP 
antistoffen was wel geassocieerd met aanwezigheid van meer beenmergoedeem. 
Dit suggereert dat er een interactief effect is tussen de verschillende autoantistof 
systemen. Meer onderzoek zal moeten worden verricht om hier meer inzicht in te 
krijgen.
In hoofdstuk 8 is de associatie tussen klinische karakteristieken en de autoantistof 
respons onderzocht. Hieruit bleek dat patiënten die pas op oudere leeftijd RA 
krijgen, vaker ACPA-negatief zijn dan patiënten op jonge leeftijd. Daarnaast 
waren een aantal klinische parameters bij presentatie met RA verschillend tussen 
jonge en oude patiënten. Oudere RA patiënten waren vaker man, rookten niet, 
hadden meer acute fase eiwitten in het bloed en vaker een (sub)acute presentatie 
van hun symptomen. Deze data suggereren dat een deel van de ACPA-positieve 
en ACPA-negatieve patiënten die worden gediagnosticeerd op oudere leeftijd 
vergelijkbaar zijn met patiënten op jongere leeftijd, maar ook dat er mogelijk een 
ACPA-negatieve subgroep van patiënten bestaat op oudere leeftijd die een andere 
klinische presentatie heeft met mogelijk een andere onderliggend mechanisme van 
ontstaan dan ACPA-negatieve patiënten op jongere leeftijd. Verder fundamenteel 
onderzoek is nodig om te zien of dit inderdaad het geval is.
In het laatste deel van dit proefschrift is de lange termijn uitkomst van RA 
patiënten onderzocht. Hiertoe is het behalen van blijvende DMARD-vrije remissie 
bestudeerd. Maar een klein deel van de RA patiënten kan deze uitkomst behalen 
en biologische processen die ten grondslag liggen aan het uitdoven van de ziekte 
zijn nog onduidelijk. Het is gesuggereerd dat autoantistoffen de drijvende kracht 
zijn voor persisterende inflammatie in RA en dat daarom het verdwijnen van 
autoantistoffen mogelijk is geassocieerd met een grote kans op het behalen van 
blijvende DMARD-vrije remissie. Echter, de associatie tussen het verdwijnen van 
ACPA en RF en blijvende remissie is nog onvoldoende verduidelijkt en was daarom 
onderzocht in hoofdstuk 9. Het bleek dat van de ACPA-positieve RA patiënten 
die blijvende DMARD-vrije remissie haalden, 13% geen ACPA meer hadden 
op het moment dat zij in remissie waren. Van de ACPA-positieve patiënten met 
persisterend RA, waarbij het niet mogelijk was om medicatie te stoppen, werd 




verschillend. Vergelijkbare resultaten warden gezien voor RF. Dit suggereert dat 
de autoantistof respons niet ten grondslag ligt aan het behalen van blijvende 
DMARD-vrije remissie. Het sluit echter niet uit dat andere karakteristieken van de 
autoantistof respons een rol spelen. 
Blijvende DMARD-vrije remissie wordt maar door een klein deel van de RA patiënten 
behaald. Klinische kenmerken en autoantistoffen alleen zijn onvoldoende om te 
voorspellen voor welke patiënten het mogelijk is om deze uitkomst te behalen. In 
hoofdstuk 10 is onderzocht of serologische markers, anders dan autoantistoffen, 
bijdragen aan het differentiëren van subgroepen binnen RA met een verschillende 
kans op het behalen van DMARD-vrije remissie tijdens follow-up. Twaalf 
verschillende biomarkers (CRP, IL-6, SAA, TNFR1, EGF, VEGF-A, VCAM-1, MMP-
1, MMP-3, YKL-40, resistin and leptin) zijn gemeten in serum samples van RA 
patiënten op het moment van presentatie met RA. Onder ACPA-positieve patiënten 
was de combinatie van deze biomarkers niet geassocieerd met het behalen van 
blijvende DMARD-vrije remissie. Onder ACPA-negatieve patiënten daarentegen, 
waren de biomarkers wel geassocieerd met het behalen van remissie. Deze 
associatie was onafhankelijk van klinische kenmerken wat betekent dat er een 
toegevoegde waarde is van de gemeten biomarkers. Dit is de eerste keer dat de 
groep van ACPA-negatieve RA patiënten kan worden onderverdeeld in subgroepen 
met verschillen in lange termijn uitkomst. Het is opvallend dat ACPA-negatieve 
patiënten met hogere serologische scores, wijzend op hoge ziekte activiteit 
op moment van presentatie met RA, een grotere kans hadden om blijvende 
DMARD-vrije remissie te behalen. Resultaten van deze studie kunnen uiteindelijk 
bijdragen aan gepersonaliseerde behandeling van RA patiënten, echter eerst zal 
het onderzoek gevalideerd moeten worden in andere studies. 
Conclusie
Om de ziekte uitkomst van RA patiënten te verbeteren, is het belangrijk om de 
diagnose zo vroeg mogelijk te stellen zodat behandeling vroeg in het ziekteproces 
gestart kan worden. Klinische kenmerken van de patiënt zijn hierbij belangrijk, 
maar bijvoorbeeld ook de aanwezigheid van autoantistoffen of van subklinische 
inflammatie zoals gezien met behulp van echo of MRI. Echter de combinatie van deze 
verschillende biomarkers voorspelt vooralsnog onvoldoende welke patiënten met 
gewrichtsklachten progressie van hun ziekte zullen hebben. Ook het voorspellen 




een rol speelt is dat RA een heterogene ziekte is die meest waarschijnlijk bestaat 
uit verschillende ziekte subsets, naast het onderscheid tussen ACPA-positieve en 
ACPA-negatieve RA. 
De meest klinisch relevante uitkomst onder RA patiënten is het bereiken van 
blijvende DMARD-vrije remissie. Uit onderzoek beschreven in dit proefschrift 
blijkt dat een subgroep van ACPA-negatieve RA patiënten een grote kans heeft op 
het behalen van deze uitkomst. Onderliggende mechanismen voor het behalen 
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